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Chapter 1 
General introduction 
1.1 Antineoplastic agents 
Antineoplastic agents1 are widely used in the treatment of cancer and some 
non-neoplastic diseases [Black et al., 1990ab]. The cytotoxic activity may 
differ among the several antineoplastic agents. Depending on their mechanism 
of (anti-cancer) action, these drugs are subdivided in several categories such 
as alkylating agents, antibiotics, antimetabolites, and mitotic inhibitors (Table 
1) [Black et al., 1990ab; Sorsa et al., 1985]. Alkylating agents express their 
activity by alkylating the DNA of tumor cells. Antibiotics interfere with the 
transcription of DNA. Antimetabolites block the synthesis of DNA and RNA. 
Mitotic inhibitors act on the mitotic mechanism necessary for karyokinesis. In 
therapy, antineoplastic agents are often used in a combination of drugs having 
different actions. The mechanism of action of some antineoplastic agents is 
still under investigation. Many antineoplastic agents interfere with DNA or 
DNA synthesis of tumor cells. Consequently, the proliferation of these cells is 
decreased. Antineoplastic agents are extremely active biological compounds. 
However, due to their in general non-selective mode of action, normal (non-
tumor) cells may also be damaged resulting in toxic side-effects. Hence, 
workers handling these drugs, such as pharmacists, pharmacy technicians and 
nurses involved in the preparation and administration, and workers employed 
in the synthesis and production, may face certain health-risks. 
Acute toxic side-effects of many antineoplastic agents such as irritation of 
skin, eyes and mucuous membranes, alopecia, nausea, vomiting and diarrhoea 
have frequently been observed in patients treated with these drugs. More 
severe toxic side-effects may occur in several organs and tissues such as bone 
marrow (leucopenia, anaemia, trombocytopenia), liver, bladder, kidney and 
lung [Black et al, 1990ab; Ladik et al., 1980; McDiarmid et al., 1988]. 
However, during occupational activities such as preparation and administration 
of these drugs, acute toxic side-effects have not been observed except for 
accidents in the course of which workers have been exposed to large amounts 
of spilled drugs. 
Synonyms: anticancer agents/drugs, antineoplastics drugs, antineoplastics, cytostat ic agents/ 
drugs, cytostat ics, cytotoxic agents/drugs. In this thesis the synonyms are used interchangeably. 
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Apart from acute effects, special attention is given to the delayed toxic side-
effects of antineoplastic agents such as mutagenicity, teratogenicity, and 
carcinogenicity [Sorsa et al., 1985]. 
Mutagenic effects have been observed in mammalian systems in vitro (animal 
and human cells) and in vivo (animals and humans) for almost all (alkylating) 
antineoplastic agents [IARC, 1981, 1986, 1987]. 
Teratogenic effects have been found in experimental animal studies for 
several, also non-alkylating, antineoplastic agents [IARC, 1981, 1986, 1987]. 
In some epidemiological studies, it is suggested that the increase in the 
number of spontaneous abortions and malformations in the offspring of nurses 
is caused by occupational exposure to antineoplastic agents [Hemminki et al., 
1985; Selevan et al., 1985]. However, in a recent study no increased risks 
were found for miscarriages, malformations, low birth weight, or preterm birth 
among the offspring of nurses handling antineoplastic agents during pregnancy 
[Skov et al., 1992]. In one study liver damage in nurses is associated with 
occupational exposure to antineoplastic agents [Sotaniemi et al., 1983]. 
According to the International Agency for Research on Cancer, there is 
sufficient evidence for carcinogenicity of eight (alkylating) antineoplastic 
agents to humans (group 1) (Table 1) [IARC 1981, 1986, 1987]. These 
conclusions are based on epidemiological studies showing secondary tumors in 
cancer patients treated with these drugs and primary tumors in non-cancer 
patients treated with these drugs for other purposes [Baker et al., 1987; 
Greene et al., 1986]. In addition, several antineoplastic agents are 
carcinogenic in animal studies. They are qualified by the International Agency 
for Research on Cancer as probably or possibly carcinogenic to humans (group 
2A and group 2B, respectively) (Table 1). A few antineoplastic agents 
(antimetabolites and mitotic inhibitors) are not classifiable to their 
carcinogenicity to humans by the International Agency for Research on Cancer 
(group 3) (Table 1). 
A quantitative risk assessment of a toxic side-effect in relation to occupational 
exposure to antineoplastic agents has not been published (yet). Based on 
current scientific knowledge upon the mechanism of action of genotoxic 
carcinogens, among which almost all alkylating antineoplastic agents, the 
absence of a no-adverse-effect level is supposed. Therefore, exposure to these 
compounds should be avoided, and safety guidelines and protective measures 
such as wearing masks, gloves, gowns and special clothes and the use of 
vertical laminar airflow safety hoods were introduced to protect the workers 
when handling these drugs [ASHP, 1990; VIK, 1992; Skov, 1993]. For such 
compounds, an exposure corresponding to an acceptable small risk is strived 
for [Arboraad, 1992]. 
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Table 1. Carcinogenicity of antineoplastic 
mechanism of anti-cancer action3. 
agents in relation to their 
antineoplastic agent (abbreviation/synonym) CAS reg.no. IARC evaluation' 
alkylating agents 
/V,/V-bis(2-chloroethyl) 2-naphtylamine (chlornaphazine) 
bischloroethyl nitrosourea (BCNU, carmustine) 
1,4-butanediol dimethanesulphonate (busulfan) 
chlorambucil 
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine) 
1 -(2-chloroethyl)-3-(4-methylcyclohexyl)-1 -nitrosourea 
(methyl-CCNU, semustine) 
cisplatm 
cyclophosphamide 
dacarbazine 
iphosphamide 
melphalan 
nitrogen mustard (chlormethine, mustine) 
nitrogen mustard /V-oxide 
streptozotocin 
treosulphan 
tns(1-azindinyl)phosphine sulphide (thiotepa) 
antibiotics 
adriamycin (doxorubicin) 
bleomycin 
daunomycin (daunorubicin) 
mitomycin С 
an urne taboh tes 
azathiopnne 
5-fluorouracil 
6-mercaptopunn 
methotrexate 
mitotic inhibitors 
vinblastine 
vincristine 
miscellaneous agent 
procarbazine 
494-03-1 
154-93-8 
55-98-1 
305-03-3 
13010-47-4 
13909-09-6 
15663-27-1 
50-18-0 
4342-03-4 
3778-73-2 
148-82-3 
51-75-2 
126 85-2 
18883-66-4 
299-75-2 
52-24-4 
23214-92-8 
11056-06-7 
20830-81-3 
50-07-7 
446-86-6 
51-21-8 
50-44-2 
59-05-2 
143-67-9 
2068-78-2 
366-70-1 
1 
2A 
1 
1 
2A 
1 
2A 
1 
2B 
3 
1 
2A 
2B 
2B 
1 
2A 
2A 
2B 
2B 
2B 
1 
3 
3 
3 
3 
3 
2A 
evaluation according to the IARC IIARC, 1 9 8 1 , 1 9 8 6 , 1 9 8 7 ] 
1 : carcinogenic to humans 2A: probably carcinogenic to humans 
2B: possibly carcinogenic to humans 3: not classifiable as to its carcinogenicity to humans 
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Occupational exposure to antineoplastic agents 
In Dutch hospitals most antineoplastic agents are administered by infusion 
[IMS, 1989]. During the preparation and administration of the drugs needles 
and broken ampules may result in pricks en cuts giving rise to a potential 
exposure. Contaminated vials and ampules are also a source of exposure. 
Contamination already present on the vials and ampules before preparation has 
started, will finally result in spreading out of the contamination, especially 
when the cleaning procedures are ineffective and inefficient. Besides, several 
studies have shown that the gloves used during preparation were permeated 
by the drugs, finally resulting in possible uptake of the drugs. During the 
preparation and administration of the drugs, some overpressure will result in 
the release of aerosols. In addition, urine, faeces, vomit, sweat and bedding 
and clothes of the patient may be contaminated with the drugs. This means 
not only a potential risk for the nursing staff but also for the workers in the 
laundry and internal transportservices and for family and friends of the patient. 
In addition, nurses prefer not to use protective measures such as special 
clothes, masks and gloves in order to treat the patient in a friendly way. 
About fifteen years ago, it was shown that compared to the use of a 
horizontal flow hood, the use of a vertical-flow safety cabinet resulted in a 
decreased mutagenicity in the urine of the technicians preparing antineoplastic 
agents [Anderson et al., 1982]. Thereafter, several publications have shown 
the possible risks of hospital workers involved in the preparation and 
administration of antineoplastic agents. Consequently, protective measures 
were taken and safety guidelines were developed to protect the workers 
handling these drugs. Special attention was given to the effective use of 
protective clothes, masks and gloves. In addition procedures were improved 
and the vertical laminar airflow hood was introduced. In The Netherlands, the 
safety guidelines were introduced in 1986, amended in 1992 [IKN/IKO, 1986; 
VIK, 1992] and are reamended in 1996. 
1.2 Methods for monitoring of occupational exposure to antineo-
plastic agents 
In the previous section it is shown that antineoplastic agents not only destroy 
tumor cells but may also harm normal cells. This is inherent to the therapy 
with these drugs. For workers handling antineoplastic agents, exposure should 
be prevented because replacement of these agents by other less harmful drugs 
is not possible. A second way to reduce exposure is the use of closed 
systems. For several moments during drug handling this may be appropriate. 
However, total protection is not possible during treatment and care of 
patients. Finally, there is only one way to reduce exposure by using personal 
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protective measures combined with the application of guidelines. Despite the 
use of protective measures, one has to check whether there is still exposure in 
a qualitative and a quantitative manner. In occupational health several 
techniques are available to monitor exposure, dose or effect. Environmental 
monitoring (EM) and biological monitoring (BM) are used to measure 
environmental exposure and uptake (dose), respectively. Effects of drugs are 
assessed by biological effect monitoring (BEM) or health surveillance. Next, 
methods for monitoring of occupational exposure to antineoplastic agents 
hitherto used are briefly reviewed. 
Environmental monitoring 
Determination of air concentrations of antineoplastic agents (aerosols) is used 
for the quantification of external exposure to these drugs. After environmental 
air is sucked through a filter, the filters are extracted and analysed for the 
presence of antineoplastic agents. 
Following this procedure and using high volume samplers, 5-fluorouracil (5FU) 
and cyclophosphamide (CP) were detected in the environment of pharmacy 
technicians and nurses involved in the preparation of antineoplastic agents 
[DeWerk Neal et al., 1983]. The samples were taken from three drug-
preparation sites. 5FU was detected in nine samples (0.12-82.26 ng/m3) and 
CP was present in one sample (370 ng/m3). Methotrexate (MTX) and 
doxorubicine were not detected. 
Release of 5FU from a horizontal air-flow hood was found by mimicking the 
preparation and administration of this drug [Kleinberg et al., 1981]. The mean 
concentration was 30 //g/m3 (range: 0-70 //g/m3). 
No release of CP was found either in or outside of a vertical laminar flow hood 
or in a ward of a hospital during CP preparation and administration, 
respectively (detection limit: 0.05 //g/m3) [Pyy et al. 1988; Sorsa et al., 1988, 
1990]. However, a one year old HEPA filter of the hood was contaminated 
with CP (510 //g/m2), showing release of CP. 
In a comparable study no airborne 5FU was detected during drug preparation 
in the preparation area adjacent to the biological safety cabinet [McDiarmid et 
al., 1986]. 
High concentrations of CP were found in the air during the manufacturing 
process and drug production of CP in a pharmaceutical plant in Finland 
(stationary sampling: 0.1-810 //g/m3; personal sampling: 0.6-190 //g/m3) [Pyy 
et al., 1988; Sorsa et al., 1988, 1990]. The workers wore protective clothing, 
and gloves, and were supplied with air-respirators and encapsulating suits 
during all phases of potential high exposure. Besides, the workers were 
working in ventilated rooms and laminar flow hoods. 
MTX has been determined in personal air samples of nurses involved in the 
preparation of CP, MTX, 5FU, adriamycin and cisplatin without any protection 
such as gloves, masks or a vertical laminar airflow hood [Friederich et al., 
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1986]. MTX was detected in none of these samples (detection limit: 20 
pmol/m3. 
Biological monitoring 
Methods for biological monitoring can be divided in two groups: compound-
selective methods and non-selective methods. For compound-selective 
methods, the amount or the concentration of a particular compound or its 
metabolites is determined by using sensitive chemico-analytical methods. For 
non-selective methods common properties of a group of chemicals are 
measured such as mutagenicity or electrophilicity. For biological monitoring of 
occupational exposure to antineoplastic agents the non-selective methods 
have been used very frequently. Some of the methods are discussed below. 
Urinary mutagenicity assay 
Some antineoplastic agents are alkylating compounds and express their 
cytotoxic activity by interaction with DNA resulting in a covalent bond. This 
interaction may result in the formation of mutations. These agents are 
mutagenic in several bacterial and eukaryotic test systems. An assay 
frequently used to detect mutagenic properties of chemical compounds is the 
so-called Ames-assay. Application of the Ames-assay on urine extracts of 
workers exposed to mutagenic compounds may indicate exposure to such 
compounds. However, no increase in mutagenicity does not mean no uptake 
of these compounds at all [Tuffnell et al., 1986]. Therefore, this approach 
should be considered as a signal test. In Table 2 an overview of studies is 
presented in which urinary mutagenicity is used as an indicator of exposure to 
antineoplastic agents. In several studies, an increase in urinary mutagenicity 
was observed. Other studies didn't show an increase. This assay is a 
compound non-selective method of biological monitoring which means that 
also other factors in addition to the exposure to antineoplastic agents may 
influence the results. In several studies an influence of smoking was observed 
[Barale et al., 1985; Bos et al., 1982; Breed et al., 1986; Courtois et al., 
1987; Everson et al., 1985; ]. The influence of smoking can be eliminated by 
the use of bacterial strains sensitive to antineoplastic agents but not to urinary 
mutagens due to smoking. However, it was also found that other factors are 
of influence such as diet and exposure to other environmental mutagens 
[Ames, 1983; Baker et al., 1982; Sasson et al., 1983]. Together, these 
factors cause a variation in background levels and it is questionable whether 
current exposure levels to antineoplastic agents will result in a significant 
increase in urinary mutagenicity [Friederich et al., 1986; Gibson et al., 1984]. 
This might be a possible explanation for the negative results in some studies. 
However, the urinary mutagenicity assay was suitable in a few studies to 
show the effect of protective measures such as masks and gloves. After 
introduction of these measures, the urinary mutagenicity was significantly 
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decreased [Falck et al., 1982]. It was also shown that exposure to 
antineoplastic agents could be significantly decreased if a horizontal laminar-
flow hood is replaced by a vertical-flow biological safety cabinet [Anderson et 
al., 1982]. Horizontal laminar-flow hoods are normally used to protect the 
product while vertical-flow biological safety cabinets also protect the worker. 
In 1985, a large investigation was started in three Dutch hospitals to study the 
mutagenicity in urine of health care workers handling antineoplastic agents 
[Fransman et al., 1986]. No increase in urinary mutagenicity was found in the 
exposed group when compared to the control group. However, in 1981 and 
1985 an increase in urinary mutagenicity was observed in nurses and 
pharmacy technicians working in Dutch hospitals [Bos et al., 1982; Breed et 
al., 1986]. The introduction of protective measures and safety guidelines are 
possibly the reason that in this study exposure to antineoplastic agents could 
no longer be detected. 
Thioether assay 
The determination of thioethers in urine is just like the urinary mutagenicity 
assay a non-selective method for biological monitoring. The assay is used as 
an indicator for exposure to (potential) electrophilic compounds. As mentioned 
before, some antineoplastic agents obtain electrophilic (alkylating) properties 
and may react with glutathione. Finally, mercapturic acids or thioethers can be 
formed and excreted in urine. Thus, an increase in thioether excretion is 
associated with exposure to (potential) alkylating compounds. Three papers 
have been published in which the thioether assay was applied to study 
occupational exposure to antineoplastic agents. In two studies an increase in 
thioethers was observed in the urine of nurses handling antineoplastic agents 
[Fransman et al., 1986; Jagun et al., 1982]. No safety measures were taken in 
one of these studies [Jagun et al., 1982]. In another study no increase in 
thioethers was observed in the urine of nurses. Most of them did not wear 
gloves and masks [Burgaz et al., 1988]. In summary, the thioether assay is a 
rather non sensitive method and the presence of background levels is strongly 
influenced by smoking. Hence, the thioether assay is less appropriate for BM 
of occupational exposure to antineoplastic agents. 
Chemico-analytical methods 
Determination of (metabolites of) antineoplastic agents in blood or urine due to 
occupational exposure belongs to the compound-selective methods of BM. 
Due to its chemical reactivity, the rather complex biotransformation pattern 
and an expected low exposure level, it is reasonable to assume low 
concentrations of (metabolites of) antineoplastic agents in urine or blood. 
Hence, sensitive methods are necessary. A few studies have been published. 
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Table 2. A literature overview of studies in which urinary mutagenicity has 
been used as a marker of exposure to antineoplastic agents. 
reference exposed group result" 
Falck et al. (1979) 
Staiano et al. (1981) 
Wilson é t a l . (1981) 
Anderson et al. (1982) 
Bos et al. (1982) 
Nguyen et al. (1982) 
Theiss et al. (1982) 
Hoffman et al. (1983) 
Kolmodin-Hedman et al. (1983) 
Gibson et al. (1984) 
Veni« et al. (1984) 
Barale et al. (1985) 
Cloak et al. (1985) 
Everson et al. (1985) 
Benhamou et al. (1986) 
Breed et al. (1986) 
Connor et al. (1986) 
Fransman et al. (1986) 
Friederich et al. (1986) 
Pohlová et al. (1986) 
Stucker et al. (1986) 
Courtois et al. (1987) 
Caudell et al. (1988) 
Poyen et al. (1988a) 
Poyen et al. (1988b) 
Sorsa et al. (1988 , 1990) 
Krepinsky et al. (1990) 
Thinnger et al. (1991) 
DeMeo et al. (1995) 
nurses 
pharmacists 
pharmacy technicians 
pharmacy personnel 
(smoking) nurses 
pharmacy technicians 
pharmacists 
nurses 
nurses 
pharmacy technicians 
nurses 
nurses/pharmacists 
nurses 
nurses 
nurses/pharmacists/pharmacy technicians 
nurses 
(smoking) nurses/pharmacy technicians 
pharmacy technicians 
nurses/pharmacy technicians 
nurses 
pilot plant workers, chemists, laboratory assistants 
nurses 
(non smoking) nurses 
nurses 
nurses 
nurses/oncology personnel 
nurses/pharmacists 
process/production workers, laboratory technicians 
nurses 
nurses 
mainly nurses and doctors 
urinary mutagenicity was significantly higher in the exposed group than in the control group 
there was no significant difference in urine mutagenicity between the exposed group and the 
control group 
In one study, CP was detected in the urine of two nurses involved in the 
preparation of CP for administration to patients during a 6-week test period 
[Hirst et al., 1984]. They did not take safety measures. Gas chromatography 
nitrogen-phosphorus detection (GC-NPD) and gas chromatography mass-
selective detection (GC-MSD) was used for detection of CP. The mean 
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excretion of CP was 3.35 /yg/day (range: 0.35-9.08 //g/day) in samples 
collected within 1-5 h after drug handling. In order to establish the route of 
exposure, the excretion of CP was studied after application of the compound 
on the skin of volunteers. It appeared that CP was excreted earlier in the urine 
of the nurses than in urine of the volunteers (18-24 h after drug application). It 
was concluded that the assumed uptake of CP in the nurses by inhalation 
occurs faster than dermal uptake in the volunteers. 
Another study showed the excretion of CP in the urine of hospital workers 
despite the use of masks, gloves and a laminar air-flow hood. Once again CP 
was detected through the use of GC-MSD. The mean excretion of CP over 24 
hrs was 1.6 μQ (range: 0.7-2.5 //g) [Evelo et al., 1986]. 
Despite safety precautions platinum was found in the urine of exposed nurses 
and pharmacists handling cisplatin. Atomic-absorption spectrophotometry 
(AAS) was used as detection method. The mean excretion was 10.22 ng 
platinum/ml urine (range: 0.6-23.1 ng platinum/ml urine) [Venitt et al., 1984]. 
However, also in the urine of the control group of office workers platinum was 
found in equal amounts (mean: 8.9 ng platinum/ml urine; range: 2.6-15.0 ng 
platinum/ml urine). 
Urine and blood samples have been taken from nurses involved in the 
preparation of CP, MTX, 5FU, adriamycin and cisplatin [Friederich et al., 
1986]. None of the urine samples contained measurable amounts of cisplatin 
(detection limit: 2 μg/\). No MTX was detected in the nurses blood samples 
(detection limit: 2 nmol/l). 
During the studies presented in this thesis other methods have been published. 
MTX has also been determined in the urine of nurses preparing MTX infusions 
and involved in care of patients [Mader et al., 1993]. The samples were 
determined by high performance liquid chromatography (HPLC) and ultraviolet 
(UV)-detection. The highest cumulative urinary excretion was observed in 
nurses preparing the MTX infusion, but traces of MTX were also detected in 
the urine of nurses engaged exclusively in the care of patients. The limit of 
detection was 4 ng MTX. 
CP and iphosphamide (IP) were determined in urine samples of nurses and 
pharmacy personnel from eight hospitals [Ensslin et al., 1994b]. The analyses 
were performed by gas chromatography electron-capture detection (GC-ECD), 
detection limit 2.5 //g/24h urine. Despite standard safety precautions, 
including a vertical laminar airflow safety cabinet and gloves, CP and IP were 
detected in amounts ranging from 3.5 to 38 /jg/24h (mean 11.4 /vg/24h) and 
from 5 to 12.7 //g/24h (mean 9 //g/24h), respectively. 
The platinum levels of nurses and hospital pharmacy personnel exposed to 
platinum containing antineoplastic agents were determined in 24h urine by 
voltametric analysis after UV photolysis [Ensslin et al., 1994a]. All study 
participants applied standard safety measures, including a vertical laminar 
airflow cabinet and gloves. Urinary platinum was significantly increased in a 
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few urine samples of a pharmacist and a pharmacy technician compared to a 
non-exposed control group. The limit of detection was 4 ng/l. 
Biological effect monitoring 
During the last 10 years, a quick development of new methods has taken 
place to detect so-called early, possibly reversible, biological effects of 
mutagenic and carcinogenic compounds (BEM parameters). Among these 
assays are the cytogenetic methods such as the analysis of chromosomal 
aberrations (CA), sister-chromatid exchanges (SCE) and micronuclei (MN) 
proliferation in blood lymphocytes. Cytogenetic methods are frequently used 
as marker of occupational exposure to antineoplastic agents. 
Cytogenetic methods 
CA in blood lymphocytes are made visible by cultivation of the lymphocytes 
followed by microscopic observation. Abnormalities are registered. SCE are 
observed if exchanges have taken place between sister-chromatids of 
chromosomes. The exchanges are only visible if both sister-chromatids can be 
distinguished from one another. A chromatid-break is supposed to be 
necessary for the formation of SCE. In the MN-test, lymphocytes are 
microscopically observed and scored on the presence of micronuclei. MN 
proliferation is seen as a direct result of damage to chromosomes. Table 3 
shows an overview of studies performed with cytogenetic methods among 
hospital workers handling antineoplastic agents. In most studies no increase in 
cytogenetic effects was observed. Analogous to the mutagenicity assay, 
cytogenetic methods belong to the compound non-selective methods of BEM. 
This means that the effects found could also be caused by other factors. By 
using SCE and CA one should take into account that the effects measured are 
cumulative effects. So the effect measured at a particular moment is merely 
due to exposure in the past. Age is a confounder when using MN proliferation. 
MN are increased by age [Sorsa et al., 1988]. The causal relationship between 
cytogenetic effects and adverse health-effects is unknown. The usefulness of 
the cytogenetic methods is limited by a large variable background level. 
Besides, these methods are highly time consuming. 
Pointmutations 
Another technique is the assessment of mutation frequencies (HGPRT-locus) in 
lymphocytes as indicator of exposure to genotoxic compounds. Despite the 
use of gloves, masks and a vertical-flow safety cabinet, the number of 
pointmutations was increased in a group of nurses and pharmacists handling 
antineoplastic drugs when compared to their controls [Chrysostomou et al., 
1984]. Mutation frequencies were also increased in a group of industrial 
workers employed in CP manufacturing and drug production compared to a 
non-exposed population [Hüttner et al., 1990]. 
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Table 3. A literature overview of studies in which chromosomal aberrations 
(CA), sister-chromatid exchanges (SCE) and micronuclei (MN) 
proliferation in blood lymphocytes of hospital workers have been 
used as markers of occupational exposure to antineoplastic agents. 
reference parameter result' 
Norppa et al. (1980) 
Waksvik et al. (1981) 
Szigeti et al. (1982) 
Kolmodin-Hedman et al. (1983) 
Stiller et al. (1983) 
Nikulaetal . (1984) 
Barale et al. (1985) 
Jordan et al. (1986) 
Pohlová et al." (1986) 
Stucker et al. (1986) 
Benhamou et al. (1988) 
Sorsa et al.c (1988, 1990) 
Oestreicher et al. (1990) 
Sarto et al. (1990) 
Krepinsky et al. (1990) 
Milkovic-Kraus et al. (1991) 
Cooke et al. (1991) 
Sardas et al. (1991) 
Thirmger et al. (1991) 
Grummt et al. (1993) 
SCE 
CA and SCE 
SCE 
SCE 
CA and SCE 
CA 
SCE 
SCE 
CA and SCE 
CA and SCE 
CA and SCE 
CA and SCE 
MN 
CA 
SCE 
CA and SCE 
CA and SCE 
CA and SCE 
CA 
SCE 
SCE 
CA 
+ 
+ 
-
-
-
+ 
-
-
+ 
-
-
-
•>•> 
+ 
-
-
-
+ 
-
+ 
+ 
+ 
" + : the parameter in question was significantly higher in the exposed group compared to the 
control group 
- : there was no significant difference in the parameter in question between the exposed group 
and the control group 
b
 only pilot plant workers, chemists and laboratory assistants 
" pharmacists, nurses, process and production workers and laboratory technicians 
d
 the results are inconclusive 
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Immunological effects 
Many antineoplastic agents are immunosuppressive drugs. In one study 
immune functions were used as markers of exposure of nurses handling 
antineoplastic agents. No differences were observed between nurses and 
controls in respect of immune functions. It is supposed that the parameters are 
not sensitive [Lassila et al., 1980]. 
Conclusion 
To assess occupational exposure to antineoplastic agents several methods 
have been developed and applied. Most studies concern compound non-
selective methods for BM and BEM such as the urinary mutagenicity assay and 
the analysis of CA and SCE in peripheral blood lymphocytes. The disadvantage 
of these methods is that one can not prove beyond any doubt that the results 
found were caused by occupational exposure to antineoplastic agents. In 
addition, the sensitivity of these methods is low. In one study, no correlation 
was found between mutagenicity and CP concentration in urine [Evelo et al., 
1986]. For occupational health services it is important to have the disposal of 
sensitive methods for BM of antineoplastic agents. In addition, these methods 
should also be specific for antineoplastic agents. In fact, methods should be 
developed for the determination of (metabolites of) antineoplastic agents in 
urine. 
1.3 Objectives 
The main question nowadays asked by many health care workers is: "Is there 
exposure and if so, what are the corresponding risks?" To answer the last 
question, it is necessary to measure the exposure to these drugs first. Second, 
exposure data are extrapolated by using dose-response relationships to 
establish risks in a qualitative and a quantitative manner. Till now, no 
quantitative risk asessments have been published to answer the last question. 
The problem is how to translate increases in non-specific parameters such as 
urinary mutagenicity, SCE and CA in peripheral blood lymphocytes into a 
quantitative risk. The results of the several studies show that the monitoring 
methods used nowadays are not sensitive and specific enough for the detec-
tion of the current exposure to antineoplastic drugs. Actually, at this moment 
adequate methods to determine occupational exposure to antineoplastic agents 
are lacking. The aim of the studies in this thesis is the development and 
validation of methods for monitoring of occupational exposure to antineo-
plastic agents. In this context, the following questions have to be answered: 
1 ) Which (groups of) antineoplastic agent(s) should be selected for monitoring? 
2) Are the developed methods applicable in situations in which hospital and 
other workers are exposed to antineoplastic agents? 
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1.4 Strategy 
Selection of antineoplastic agents to be monitored 
The aim of this study is to develop a small battery of compound selective EM 
and BM methods for the detection of exposure to antineoplastic agents. One 
of the first tasks is the selection of antineoplastic agents. Secondly, it is 
important to look at the pharmacokinetics of these drugs. Thirdly, it is 
necessary to look at the analytical possibilities to determine these 
antineoplastic agents or their metabolites in low concentrations in combination 
with their chemical stability. 
Amount of antineoplastic agents used in The Netherlands 
There are now approximately 50 antineoplastic agents commercially available 
for the treatment of cancer. Nitrogen mustard, the first drug used in cancer 
therapy was introduced in the late 40's. Recently taxol and taxotere have been 
introduced. It is expected that new drugs will be developed in the future 
because chemotherapy, in addition to surgery and radiotherapy, will remain an 
important approach in the treatment of (non)-neoplastic diseases. Moreover, 
new (immuno)chemotherapies will be developed based on further clarification 
of the mechanism of carcinogenesis. 
Data on the use of antineoplastic agents in The Netherlands over 1986-1988, 
the starting period of the investigations presented in this thesis, showed a 
large difference between the use in hospitals and outside hospitals [IMS, 
1989]. In hospitals, antineoplastic agents are mostly prepared for parenteral 
administration (infusion). Outside the hospitals, antineoplastic agents are 
mostly prescribed as tablets (oral administration). In Dutch hospitals, 5FU, CP 
and IP contributed to about 40% of the parenterally applied antineoplastic 
agents (wt basis) (Table 4). 
The large number of clinically applied (combinations of) antineoplastic agents 
makes it necessary to look for one or more markers to be representative for 
the total group of antineoplastic agents. Based on the above information, 5FU, 
CP and IP were selected as antineoplastic agents to be monitored in the 
studies presented in this thesis. During several studies it was found that the 
amount of MTX was large enough to add this compound to the list of drugs to 
be monitored. The chemical structures of these compounds are presented in 
Figure 1 . 
Pharmacokinetics 
Much information is available in literature about the biotransformation of CP, 
IP, 5FU and MTX in both man and animal in therapeutic doses [IARC, 1981; 
Sladek, 1985; Black et al., 1990a]. Except for MTX, the biotransformation 
pattern is rather complex. No studies are available using the relatively low 
doses to be expected during occupational exposure. The drugs or their 
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metabolites are mainly excreted in urine. 
Chemico-analytical possibilities and stability 
Most analytical methods are based on the determination of the parent 
compound in blood of treated patients and animals. Less attention is given to 
the determination of the parent compound or their metabolites in urine. 
Compounds or their metabolites in urine should be concentrated to obtain 
enough compound for detection. A careful and selective clean-up procedure 
may finally influence the results positively. 
GC analysis in combination with ECD, NPD and MSD (SIM) is frequently used 
for the determination of CP and IP [Ensslin et al., 1994b]. Before analysis the 
parent drugs are denvatized with tnfluoracetic anhydride (TFAA). The highest 
sensitivity is expected from GC-MS(D). 
Analysis of 5FU is more problematic because hardly any 5FU is excreted in 
urine of 5FU-treated patients [Bernadou et al., 1985; lARC, 1981]. Therefore 
the metabolite σ-fluoro-ß-alanine (FBAL), an ammo acid, was choosen which 
appeared to be excreted in the urine of a 5FU-treated patient in relatively large 
amounts [Bernadou et al., 1985]. A routine denvatization method, frequently 
used for GC determination of amino acids was used [Schallenberg et al., 
1955]. 
Table 4. Amounts of 5FU, CP, and IP parenterally administered (infusion) in 
Dutch hospitals over 1986-1988 [IMS, 1989]. 
1988 antineoplastic 
agent 
5 FU 
CP 
IP 
kg 
22 2 
13 8 
12 0 
1986 
units 
72 ,400 
25 ,600 
14 ,500 
%' 
17 
10 
9 
kg 
1 7 9 
16 8 
12 6 
1987 
units 
68 ,500 
2 5 , 6 0 0 
12 ,200 
%' 
16 
10 
9 
kg 
28 8 114,500 20 
14 9 26,200 10 
12.3 9,300 8 
total 48 0 112,500 36 47.3 106,300 35 56.0 150,000 38 
' as percentage of the total amount of parenterally administered drugs 
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Analysis of MTX in blood is frequently used in patients to prevent toxic side-
effects after high-dose administration of this drug. HPLC with UV detection, 
fluorescence polarization immunoassay (FPIA) and enzyme-multiplied 
immunoassay technique (EMIT) are most frequently used as methods for 
monitoring [Tjaden et al., 1990]. Preference is given to FPIA and EMIT 
because of less interference with other compounds and consequently high 
sensitivity [Pesce et al., 1986]. Solid-phase extraction is an appropriate 
technique for concentration of MTX out of urine. 
Fig. 1. Chemical structures of CP, IP, 5FU and MTX. 
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Environmental monitoring 
Several approximations are available to estimate concentrations or amounts of 
antineoplastic agents in the work environment. In this thesis the following 
aspects are presented and discussed. 
1) Development and validation of methods for the determination of 
concentrations of antineoplastic agents in the air (aerosols and particles). 
2) Development and validation of wipe-tests for the determination of 
environmental contamination and possible skin exposure and uptake. 
3) Quantification of antineoplastic agents on the skin by skin contamination 
tests with gloves. 
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Biological monitoring 
For the estimation of the internal dose, BM is choosen as approach and urine 
as matrix. Finally, the BM results in combination with toxicokinetic 
investigations in animals will be used to estimate the internal exposure (dose) 
in occupational^ exposed workers. Such information may play an important 
role in eventual risk assessment procedures. In addition, other information 
should be available such as dose-response relations in animals and in patients 
treated with antineoplastic agents [Baker et al., 1987; Greene et al., 1986; 
Schmähl et al., 1979]. Afterwards, the efficiency of the protective measures 
can be checked with the aid of the developed analytical methods. 
For BM, an analytical method developed by Evelo et al. for the determination 
of CP is considered to be most appropriate as starting point [Evelo et al., 
1986]. This method is further optimised to be suitable for BM. Several 
toxicokinetic aspects are of importance for adequate application of BM and 
should be further investigated. Many studies have been undertaken to the 
kinetics of CP in the clinical setting. However, the question is how the kinetics 
of CP will be at low doses as expected during occupational activities. To 
answer this question, the uptake and the kinetics of low dose CP 
administration by other exposure routes are studied in experimental animals. 
1.5 Outline of the thesis 
This thesis describes the development and validation of methods for 
monitoring of occupational exposure to antineoplastic agents. 
In chapter 1 a general introduction to the subject is given. Attention is paid to 
the use of antineoplastic agents for the treatment of several diseases, their 
pharmacological activity, mechanism of action, toxicity, health risks and 
protective measures and safety precautions taken to protect the workers 
handling these drugs. Methods frequently used for monitoring of occupational 
exposure to antineoplastic agents are summarized and their usefulness is 
discussed. Finally the objectives of the thesis and the strategy is outlined and 
literature references are given. 
Chapter 2 shows some developed and applied methods for monitoring 
occupational exposure to antineoplastic agents in several occupational 
settings. All methods are based on CP, IP, 5FU and MTX, the four most 
frequently used antineoplastic agents for parenteral administration (infusion) in 
The Netherlands over 1986-1988. 
Some biological effects in workers exposed to antineoplastic agents are 
described in chapter 3. In a study, the analysis of CA in blood lymphocytes as 
BEM parameter is compared with the BM parameter CP in urine. In another 
study, the influence of antineoplastic agents upon renal effect parameters in 
workers exposed to antineoplastic agents is investigated. 
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Variation in uptake, biotransformation and excretion of CP, studied under 
several in vitro conditions (human and rat liver preparations) and in vivo 
conditions (rat), are presented in chapter 4. 
Finally, a quantitative cancer risk assessment for health care workers exposed 
to CP is presented in chapter 5. 
In chapter 6 the results of the research project are summarized and discussed. 
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Abstract 
The contamination with fluorouracil (5FU), cyclophosphamide (CP) and 
methotrexate (MTX) was studied in a hospital pharmacy department where 
these drugs were prepared. In the preparation room, air samples were taken 
before and during preparation of the drugs. MTX was detected in one sample 
which was collected during preparation (0.3 //g/m3). Spot samples were taken 
in the vertical laminar air-flow safety hood before and after preparation of the 
drugs and after cleaning of the hood. Contamination of the laminar air-flow 
hood was: CP: 1-160 ng/cm2; 5FU: 10-62 ng/cm2 and MTX 2-623 ng/cm2). 
Spot samples from the floor in front of and beneath the laminar air-flow hood 
showed contamination with especially 5FU (48-236 /yg/m2). The gloves used 
during preparation of the drugs were contaminated mainly with 5FU (5-980 
ng/cm2). Urine samples from two workers involved in the preparation of the 
drugs were analysed for unmetabolized CP; it was not detected. Although no 
uptake of CP was established, it is shown that the methods for measurement 
of CP, 5FU and MTX in the preparation room are applicable for the control of 
occupational exposure to these drugs. 
Introduction 
The toxic side-effects of antineoplastic agents have been described extensively 
[1]. Much attention has been paid to the carcinogenic, mutagenic and 
teratogenic properties of these compounds, which are related to the 
interaction of the drugs with DNA, RNA and proteins. 
Several investigators have studied occupational exposure to cytostatic drugs 
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by determining urinary thioethers [2,3], urinary mutagens [4-26], chromosomal 
abberations and sister chromatid exchanges in lymphocytes [14-16,24-32] or 
by measurement of cytostatic drugs like CP in urine [33,34]. In many cases 
the measurements demonstrated occupational exposure of hospital personnel 
[2,17-29,33-35]. 
To a lesser extent attention was paid to the question how the persons were 
exposed. It was suggested that during preparation antineoplastic drugs were 
absorbed by inhalation and dermal penetration [33,36,37]. 
To prevent occupational exposure to cytostatic drugs in the Netherlands, but 
also in other countries, special safety guidelines were introduced [38,39]. 
However, little is known about the effectiveness of the advised measures 
because methods to check these measures were not or scarcely developed. In 
addition, there is still great concern about the health risks due to exposure to 
cytostatic drugs among hospital workers [40]. 
For these reasons, it is important to be able to measure the spill and 
distribution of cytostatic drugs when handling these agents. Not only the 
contamination of the working environment but also the uptake of cytostatic 
drugs in hospital workers should be measured in order to identify risky actions 
and circumstances. Therefore, we have studied the contamination with 
cytostatic drugs of the pharmacy department of a Dutch hospital where these 
drugs were prepared. Because 5FU, CP and MTX were the most applied 
cytostatic drugs in this hospital, these substances were measured in air 
samples, and in spot samples taken in the laminar air-flow hood and from the 
floor in order to validate the applied methods and to study the efficiency of the 
guidelines and precautions used. Also contamination with cytostatic drugs of 
the gloves that were used was investigated. Finally, we have studied the 
uptake of CP by measurement of unmetabolized CP in urine. 
Methods 
Study design 
Air, wipe and urine samples were taken on four separate days during two 
weeks of preparation (twice on a Monday and twice on a Friday). 2 
Technicians were involved in the preparation; worker A on the first Monday 
(day M1) and Friday (day F1) and worker В on the second Monday (day M2) 
and Friday (day F2). The way of preparation of the drugs and the working 
methods of the two workers were observed and described. The drugs were 
prepared in a laminar air-flow hood (Class II, model DLF BSS 6, Clean Air, 
Woerden, the Netherlands). 
In Table 1 an overview of the amounts of CP, 5FU and MTX prepared during 
this study is given. CP, 5FU and MTX contributed 96% of the drugs prepared. 
Development and validation of monitoring methods 27 
Table 1. Amounts of CP, 5FU and MTX prepared during this study (mg). 
day worker 
M l A 
F1 A 
M 2 В 
F2 В 
total of 4 days 
CP" 
2 , 9 0 0 (60) 
1,500 (33) 
npc (-) 
np (-) 
4 , 4 0 0 (36) 
5FU' 
1 , 5 0 0 ( 3 1 ) 
2 , 7 5 0 (61) 
1,000 (90) 
1,750 (95) 
7 , 0 0 0 (57) 
MTX" 
6 4 ( 1 ) 
1 4 0 (3) 
8 0 ( 7 ) 
7 0 ( 4 ) 
3 5 4 (3) 
totalb 
9 2 
9 7 
9 7 
9 9 
9 6 
number in parentheses: as percentage (wt/wt) of all drugs prepared 
sum of CP, 5FU and M T X as percentage (wt/wt) of all drugs prepared 
np: no preparation 
Air sampling 
Before and during preparation of the drugs, air samples were taken 
approximately 50 cm from the worker and the laminar air-flow hood. The 
samples were collected on a glass microfibre filter with 150 mm diameter and 
1.6 //m pore size (Whatman GF/A, Maidstone, UK) using a high-volume 
sampler (type Gromoz, Department of Air Pollution, Wageningen Agriculture 
University, Wageningen, the Netherlands). The suction flow was about 900-
1,000 l/min. After sampling, the filters were packed in a glass pot and 50 ml 
of a sodium hydroxide solution (0.03 mol/l) was added. After sonification 
during 90 min, the extracts were centrifuged and analysed by high pressure 
liquid chromatography (HPLC) and gas chromatography (GC). 
Wipe tests in the laminar air-flow hood 
Before and after preparation of the drugs and after cleaning of the laminar air­
flow hood at the end of the day, spot samples (1-6) were taken from several 
places for the detection of contamination of the laminar air-flow hood with 
cytostatic drugs. Spot samples 7 and 8 were added on days F1, M2 and F2 
and spot samples 9 and 10 were added on days M2 and F2. A description of 
the spots is given in Table 2. 
Two tissues (Kleenex professional wipes, 20 χ 21 cm, Kimberly-Clark 
Corporation, Koblenz, Germany) were moisturized with 5 ml of a sodium 
hydroxide solution (0.03 mol/l) and the spots were swept clean. The tissues 
were put in a glass pot and 45 ml of a sodium hydroxide solution (0.03 mol/l) 
were added. After sonification during 90 min the extracts were centrifuged 
and analysed by HPLC and GC. Routine cleaning of the laminar air-flow hood 
occurred by using a gauze pad which was soaked in an alcohol solution. 
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Table 2. Description of the spots in the /aminar air-flow hood. 
spot description* 
1-4 working tray (100) 
5-6 top side aerofoil (100) 
7 top side aerofoil (300) 
8 front grill of the working tray (300) 
9 back side aerofoil (500) 
10 inside viewing screen (8500) 
* number in parentheses is the area swept clean (cm2) 
Wipe tests of the floor 
Spot samples of the floor were taken once before preparation on day F l . They 
were taken from the floor in front of and beneath the laminar air-flow hood 
(11-16), in the centre (17) and at the entrance (outside) of the preparation 
room (18). 
On each spot (approximately 0.5 m2), 10 ml of a sodium hydroxide solution 
(0.03 mol/l) were pipetted. The spots were swept clean with four tissues (see 
above). The tissues were put together in a glass pot and 90 ml of a sodium 
hydroxide solution (0.03 mol/l) were added. After sonification during 90 min 
the extracts were centrifuged and analysed by HPLC and GC. 
Glove contamination 
During preparation of the drugs gloves were worn (Ansell Gammex pre-
powdered sterile latex hypoallergenic surgical gloves, 0.52 mm thickness, 
Ansell Medical, Munich, Germany). Four pairs were used on day M1, three 
pairs on day F1, two pairs on day M2 and one pair on day F2. 
After preparation of the drugs, left and right glove were collected separately 
and put in glass pots with the possibly contaminated side outside. 100 ml Of a 
sodium hydroxide solution (0.03 mol/l) were added and the samples were 
shaken during 120 min. The extracts were centrifuged and analysed by HPLC 
and GC. 
Urine sampling 
Total urine was collected in several portions during the period of 24 h after 
preparation of the drugs. They were stored at -20°C until sample preparation. 
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Chemicals 
CP (Endoxan; purity >97%) and ¡phosphamide (IP) (Holoxan; purity >97%) 
were purchased from ASTA-Pharma (Bielefeld, Germany). Trifluoroacetic 
anhydride (purity >98%) was obtained from Johnson Mattey (Karlsruhe, 
Germany). 5FU (purity 99%) was purchased from Janssen Chimica (Beerse, 
Belgium) and MTX (purity 99.7%) was donated by Pharmachemie (Haarlem, 
the Netherlands). All other chemicals were of the highest purity obtainable. 
Distilled water was used. 
For preparation CP (Endoxan in vials of 100, 200, 500 and 1,000 mg) was 
purchased from ASTA-Pharma, 5FU (Fluorouracil in ampules of 250 mg/5 ml) 
from Hoffmann-La Roche (Mijdrecht, the Netherlands) and methotrexate 
(Ledertrexate in vials of 5 and 50 mg/2 ml) from Lederle (Etten-Leur, the 
Netherlands), respectively. 
HPLC analysis 
5FU and MTX analyses were conducted on a reversed-phase HPLC system 
(Pye Unicam LC3-XP, Pye Unicam Ltd., Cambridge, UK). Aliquots of 20 μ\ of 
the centrifuged extracts were injected onto a 1 50 χ 4.6 mm i.d., Nucleosil RP 
18 column with 5 μπ\ particles (Macherey-Nagel, Düren, Germany). The 
column temperature was 40°C. For 5FU a sodium acetate buffer (0.05 mol/l; 
pH 4.0) was used. MTX was eluted with a mixture of 72.5% sodium acetate 
buffer (0.05 mol/l; pH 4.0) and 27.5% methanol. The solvent flows were 1.0 
ml/min. The HPLC system was equipped with an ultraviolet spectrophotometer 
(Pye Unicam LC-UV detector, Pye Unicam Ltd.). 5FU and MTX were analysed 
at 260 and 300 nm with retention times of 3.5 and 4.5 min, respectively. The 
selectivity of the method was verified by the analysis of blank and spiked 
samples and by taking full UV spectra. 
Quantification (peak height) was carried out by reference to calibration curves 
constructed from the analysis of freshly prepared reference samples containing 
5FU or MTX dissolved in distilled water. Linearity was found until at least 15 
mg/l (r >0.99). The limits of detection for 5FU and MTX were approximately 
50 and 60 /yg/l sample, respectively. 
The recovery (±S.D.) of the wipe assay is 98 ±3% for 5FU and 81 ±25% for 
MTX (η = 5). For the gloves it is 1 0 3 ± 3 % for 5FU and 61 ± 2 0 % for MTX 
(n = 4). 
GC analysis 
Air samples, spot samples and gloves 
1 ml Tris buffer (0.2 mol/l; pH 4.5) and 100 μ\ internal standard (IP (5 //g/ml 
distilled water) were added to 1 ml centrifuged sample. The samples were 
extracted twice with 5 ml ethyl acetate and the ethyl acetate layers were 
combined in conical tubes with screw caps. The extracts were dried under 
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nitrogen at 40° С and shaken with 50 μ\ ethyl acetate until the residue was 
totally dissolved 50 μ\ Tnfluoroacetic anhydride were added and after shaking 
the tubes were closed for denvatization for 20 mm at 70°C [41] The samples 
were cooled down to room temperature and dried again under nitrogen at 
40° С 50 μ\ Toluene were added and after sonification during 3 mm vials were 
filled with sample and stored at -20°C until analysis The recovery (±S.D.) of 
CP is 95 ± 3 5 % for the wipe assay and 58+ 17% for the gloves (n = 6) 
Urine samples 
Instead of 1 ml centrifuged sample, 5 ml of urine sample were used The 
samples were extracted twice with 10 ml ethyl acetate. The ethyl acetate 
layers were combined in conical tubes with screw caps and washed 
successively with 5 ml of a 10% (wt/wt) sodium hydrogencarbonate solution 
and 5 ml of a hydrogen chloride solution (0 05 mol/l). The aqueous layers 
were discarded The organic phase was dried under nitrogen at 40° С The 
denvatization was performed in 100 μ\ ethyl acetate with 100 μ\ tnfluoroacetic 
anhydride 500 μ\ Of a saturated sodium chloride solution were added to the 
samples After shaking, the samples were extracted twice with 5 ml л-hexane 
The л-hexane layers were combined in conical tubes and dried under nitrogen 
at 40°C. Finally, the dried samples were dissolved in 100 μ\ toluene 
GC-MS conditions 
GC-MS analysis was performed on a Vanan Saturn GC-MS system which was 
controlled by a Compaq 386-20e personal computer (Vanan, Houten, the 
Netherlands) The 'on column injection' mode was used (SPI Septum 
equipped temperature Programmable Injector) A 30 m DB-5 column (J & W 
Scientific, Folsom, California, USA) was used with 0 25 mm i.d and 0.25 //m 
film thickness The column was connected with a deactivated fused silica 
retention gap (Chrompack, Middelburg, the Netherlands) with a length of 2 5 
m and 0 53 mm ι d The initial injector temperature was 100°C After 1 mm 
the temperature rose to 260°С (180°C/min) After 5 mm at 260°С the 
temperature was lowered to the initial temperature by cooling with liquid 
carbon dioxide. The initial oven temperature was 100°C. After 1 mm, the 
temperature rose to 280°C (15°C/mm) where it remained constant for 5 mm. 
Helium was used as carrier gas (column inlet pressure 100 kPa [14 psi]; 
column flow 0 8 ml/mm) The interface temperature was 280°С and electron 
impact was used as ionization mode Identification was carried out by the 
combination of full scan spectra (250-399 atomic mass units) and retention 
time of CP Retention times of denvatized IP and CP were 10.4 and 11 1 mm, 
respectively 
Quantification was performed on the selected ion fragment 307, which was 
abstracted from the full scan spectra By using a high background mass we 
eliminated the unwanted matrix ions For quantification the peak area ratio of 
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CP/IP was calculated. Quantification of the trifluoroacetyl derivatives was 
carried out by reference to calibration curves constructed from the analysis of 
freshly prepared reference (urine) samples containing CP dissolved in blank 
urine or distilled water (air samples, spot samples and gloves). 
Frozen reference urine samples containing CP were analysed during a period of 
three months. No significant loss of CP was observed. The limit of detection 
was approximately 1 /yg/l urine or distilled water. 
Results 
Air samples 
Different volumes were sucked during stationary air sampling (23-92 m3). Only 
on one filter (day F2, during preparation) MTX was found (0.3 //g/m3). CP and 
5FU were not detected. 
Contamination in the laminar air-flow hood 
The results of a wipe assay for the measurement of contamination with CP, 
5FU and MTX in the laminar air-flow hood are presented in the Table 3. The 
amounts are divided by the area swept clean. Contamination with CP, 5FU and 
MTX was measured before and after preparation of the drugs and even after 
cleaning of the hood. Surprisingly, after cleaning, the drugs were measured at 
many spots whereas after preparation no contamination was detected at the 
same spots. For CP and for MTX, contamination was found after preparation. 
5FU contamination was not found after preparation. Since many samples were 
positive before preparation and negative after preparation, the results suggest 
that CP, 5FU and MTX were removed from the surface very well during taking 
the first sample (before preparation). The overall degree of contamination per 
cm2 was: MTX > 5FU > СР. 
Contamination of the floor 
In Table 4 an overview of the contamination on the floor of the preparation 
room is given. Before preparation of the drugs on day F l , 5FU was detected at 
all spots. Relatively high amounts were found in front of and beneath the 
laminar air-flow hood (11-16) and in the centre of the preparation room (17). 
The presence of 5FU at the entrance (outside) of the preparation room (18) 
was remarkable. Incidentally, low amounts of CP were measured in front of 
the laminar air-flow hood. MTX was not detected at all. 
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Table 4. Contamination of the floor of the preparation room with CP, 5FU and 
MTX (μς/m2) before preparation of the drugs on day F1. 
position CP' 5FU MTX" 
11 - 122 
12 - 182 
13 - 88 
14 - 148 
15 2.6 236 
16 1.4 162 
17 - 126 
18 - 48 
" -: not detected 
Glove contamination 
The results of contamination of the gloves are shown in Table 5. It appeared 
that all gloves used, the left as well as the right ones, were contaminated with 
5FU. MTX contamination was found to a lesser degree and CP was detected 
at only one pair (day F1; pair 2). Nearly all amounts of CP, 5FU and MTX 
measured were between 10 and 100 μg for each glove. No difference in 5FU 
contamination was found between the two workers. For each pair of gloves 
there was no systematic difference between the contamination on the left and 
the right-hand. 
CP in urine 
CP was not detected in any of the urine samples (n = 29). The detection limit 
was approximately 1 /ig/l. 
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Table 5. Contamination with CP, 5FU and MTX of the gloves used during 
preparation of the drugs (pg/glove)*. 
day glove CP 5FU MTX 
left right left right left right 
hand hand hand hand hand hand 
1 
2 
3 
4 
1 
2 
3 
1 
2 
1 
-
-
-
-
-
17 
-
na 
na 
na 
-
-
-
-
-
20 
-
na 
na 
na 
22 
666 
5 
135 
980 
66 
77 
27 
22 
19 
27 
58 
11 
135 
60 
58 
44 
27 
14 
22 
105 
-
-
-
-
-
-
156 
19 
-
26 
-
40 
-
-
-
-
-
-
-
' -: not detectable; na: not analysed (no CP preparation) 
Discussion 
From the contamination of the gloves, the laminar air-flow hood, the floor and 
one positive air sample, it can be concluded that release of drugs during 
preparation did happen. 
On day M2 and day F2 preparation occurred while the viewing screen was not 
closed completely which might be responsible for the possitive air sample. 
Contamination of the laminar air-flow hood was found for 5FU as well as for 
CP and MTX. Although much more 5FU was used than MTX, higher amounts 
of MTX were found in the laminar air-flow hood. Many spot samples were 
negative after preparation of the drugs but were positive before preparation. 
This suggests that the drugs were removed completely during the first 
sampling and, therefore, taking the wipe samples must be rather adequate. It 
is remarkable that spot samples were negative after preparation of the drugs 
but positive after cleaning of the hood. An explanation for these findings might 
be that during routine cleaning of the laminar air-flow hood with a gauze pad 
soaked in an alcohol solution these spots became contaminated from other 
surfaces which were cleaned with the gauze pad. In fact, this means that the 
laminar air-flow hood was not cleaned but that the contamination was spread 
out. 
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It was found that during the preparation of the drugs the gloves were 
contaminated with CP, 5FU and MTX. Whether this was due to contamination 
of the outside of the vials/ampoules or occurred while opening was not 
established. 
It was striking that amounts of 5FU were found on the floor because a laminar 
air-flow hood was used and working procedures were performed according to 
special safety guidelines [38]. However, from observations of the working 
methods of the two workers it appeared that packing materials from 
disposables used for the preparation of the drugs were dropped on the floor in 
front of and beneath the laminar air-flow hood in order to maintain a good 
overview in the laminar air-flow hood. Because of the contamination of the 
gloves with 5FU, the packing materials could also be contaminated. The 
contamination might be transferred to the floor when the packing materials 
were dropped. Finally, it is possible that contamination was spread out 
unconsiously inside and outside the preparation room by the footwear of the 
workers or by cleaning the floor. The present study has demonstrated that 
when working procedures are not performed according to special safety 
guidelines, which do not allow to drop contaminated materials out of the 
laminar air-flow hood, contamination of the floor is possible. Contamination of 
the preparation room and spreading outside can possibly be reduced by 
dropping packing materials in a mini risk-container, which should be placed 
inside the laminar air-flow hood. 
Several investigators have suggested that cytostatic drugs, like CP, are 
absorbed by inhalation and dermal penetration during occupational activities 
[33,36,37]. In two studies the excretion of unchanged CP was detected in 
urine of nurses involved in the preparation of cytostatic drugs [33,34]. After 
application of CP on the skin of volunteers (1 mg in methanol) low 
concentrations of CP were found in the urine [33]. The excretion rate was 
lower when compared to the excretion rate of CP in the urine from nurses 
involved in the preparation of CP, suggesting another route of absorption 
(inhalation). Also in rats after dermal application a lower excretion rate was 
observed compared to intratracheal instillation of CP (1 mg/kg body weight) 
[42]. 
In the present study, no uptake of CP was found by determination of CP in the 
urine. This might be due to the special safety guidelines and the security 
precautions taken [38]. However, in spite of the use of protective clothing, 
gloves and surgery masks, we recently found CP in the urine (0.7 /vg/24 h) of 
an animal laboratory worker who was involved in the administration of CP to 
mice [43]. It is not clear to what extent the use of gloves by the hospital 
workers prevented the uptake of the drugs because only negative urine 
samples were found. The efficiency of protective gloves is discussed in 
literature [44-47]. Permeability of latex and polyvinyl chloride gloves to CP, 
5FU, MTX and other cytostatic drugs was established. In general, the degree 
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of permeability appearred to be small for both types of gloves but lower 
permeability seemed to correspond with higher thickness. Contradictory 
results concerning the permeability to CP were found. The intralot variability in 
permeation suggested that exposure of personnel could be variable. 
Another explanation for the absence of CP in the urine might be the complex 
metabolism of CP, which is found in patients but is unknown at low dose 
levels which might be expected after occupational exposure [48]. However, 
Hirst et al. and Evelo et al. did find CP in urine in similar circumstances 
[33,34]. Sensitive methods for the determination of CP metabolites and other 
cytostatic drugs or their metabolites are also necessary but unfortunately not 
available. 
Although the uptake of CP by determination of CP in urine was not 
established, it is shown that the other methods applied in this study can be 
used for controlling the exposure to CP, 5FU and MTX. 
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Summary 
The occupational exposure to cyclophosphamide (CP), iphosphamide (IP), 5-
fluorouracil (5FU), and methotrexate (MTX) of 25 pharmacy technicians and 
nurses from four departments of a hospital was investigated. Previously 
developed methods for the detection of exposure to some antineoplastic 
agents were validated. Exposure to CP, IP, 5FU, and MTX was measured by 
the analysis of these compounds in the environment (air samples and wipe 
samples from possible contaminated surfaces and objects). Contamination of 
the work environment was found not only on the working trays of the hoods 
and on the floors of the different rooms but also on other objects like tables, 
the sink unit, cleaned urinals and chamber pots, and drug vials and ampules 
used for preparation and packing of drugs. The gloves used during preparation 
of the drugs and during cleaning of the hoods were always contaminated. The 
uptake of CP or IP was determined by the analysis of both compounds in 
urine. CP or IP was detected in the urine of eight pharmacy technicians and 
nurses. The amounts ranged from <0.01 to 0.5 μg (median: 0.1 //g). CP and 
IP were found not only in the urine of pharmacy technicians and nurses 
actively handling these compounds (n = 2) but also in the urine of pharmacy 
technicians and nurses not directly involved in the preparation and 
administration of these two drugs (n = 6). CP and IP were excreted during 
different periods ranging from 1.40 to 24.15 h after the beginning of the 
working day, suggesting different times of exposure, different exposure 
routes, and/or interindividual differences in biotransformation and excretion 
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rate for these compounds. The urinary CP and IP determination method seems 
to be sensitive and suitable for monitoring the exposure to and measuring the 
uptake of these toxic compounds by pharmacy technicians and nurses during 
occupational activities. 
Introduction 
Chemotherapy with antineoplastic agents is often used in the treatment of 
cancer. In the Netherlands, the most frequently used antineoplastic agents for 
parenteral administration are cyclophosphamide (CP), iphosphamide (IP), 5-
fluorouracil (5FU), and methotrexate (MTX) [8]. CP and IP are alkylating 
agents. These compounds are genotoxic after biotransformation [9]. Clinical 
studies show an increase in secundary tumors in patients treated with CP 
[2,5,6,10,12]. This is one of the reasons why the International Agency for 
Research on Cancer has classified CP as a human carcinogen [9]. There is 
limited evidence for the carcinogenicity of IP in mice and rats [9]. However, 
because of the structural resemblance of this compound to CP and the 
similarity with respect to biotransformation pathways and short-term 
genotoxicity results, IP may be considered a suspected carcinogen [9]. There 
are no indications for a carcinogenic potential of 5FU [9]. MTX is not 
classifiable with regard to its carcinogenicity; however, it is a human teratogen 
[9]. 
For genotoxic carcinogenic agents the absence of a no-adverse-effect level is 
supposed. Therefore exposure to these compounds should be avoided, and 
safety guidelines and protective measures like wearing masks, gloves, and 
gowns and using laminar air-flow safety hoods were introduced to protect the 
workers handling antineoplastic agents [1,16]. In order to monitor exposure 
levels and to measure possible uptake of these drugs it is necessary to use 
sensitive and compound-specific detection methods [4]. 
In this study we have validated some recently developed methods for the 
detection of contamination of the work environment with antineoplastic agents 
and for the determination of some of these drugs in urine of exposed workers 
[13]. We describe the occupational exposure of 25 hospital workers involved 
in handling antineoplastic agents at four departments in which CP, IP, 5FU, 
and MTX were prepared or administered. Exposure to these compounds was 
measured by the analysis of air samples and wipe samples from possibly 
contaminated surfaces and objects. The uptake of CP and IP was determined 
by the analysis of the unmetabolized form of one of both compounds in urine. 
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Materials and methods 
Study design 
Twenty-five female pharmacy technicians and nurses of four different 
departments [clinical pharmacy department, outpatient department 
(preparation), outpatient department (administration) and oncology 
department] participated in this study. Preparation of the drugs occurred in the 
clinical pharmacy department and in the preparation room of the outpatient 
department. In the administration rooms of the outpatient department and in 
the oncology department the drugs were not prepared but only administered. 
In the oncology department other nursing activities also took place, such as 
washing of the patients, urine collection, and cleaning of the beds and rooms 
of the patients. 
The drugs were prepared in laminar air-flow safety hoods. The pharmacy 
technicians wore protective clothing, nurses caps, masks, and gloves. 
However, hardly any protective measures were taken by the nurses working in 
other departments. 
It should be noted that many antineoplastic agents were prepared and 
administered but that in this study attention was given only to CP, IP, 5FU, 
and MTX. In all departments but one, CP, IP, 5FU, and MTX were prepared or 
administered. In the oncology department IP was administered but practically 
no CP or 5FU administration took place. Therefore in this department IP was 
determined in the urine of the nurses, whereas in all other departments CP 
was measured in urine of the pharmacy technicians and nurses. 
Clinical pharmacy department 
On two successive days, one air sample was taken during preparation of the 
drugs. Sampling occurred 1.5 m from the floor and approximately 0.5 m from 
the two pharmacy technicians who were working in the two hoods. 
Contamination of the working tray of the two hoods (1.90 χ 0.80 m) was 
measured on 4 days. Wipe samples were taken before and after the 
preparation of the drugs and after the cleaning of the hoods with an alcohol 
solution at the end of each working day. 
Wipe samples were taken from the floor (0.70 χ 0.70 m) of the preparation 
room on 2 days: on day 1 (at the beginning and end of the working day) and 
on day 4 (at the end of the working day). The samples were taken from the 
floor in front of each hood and in the center and at the entrance (inside and 
outside) of the preparation room. The total area of the preparation room was 
about 50m2. 
Contamination of the gloves used during preparation of the drugs and cleaning 
of the hoods was investigated. Twenty pairs of gloves were analyzed for 
contamination. Fourteen pairs were used for preparation of the drugs and six 
for cleaning of the hoods. 
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Before use, 9 CP vials, 20 5FU ampules, and 15 MTX vials were checked for 
contamination on the outside by taking wipe samples. 
For each preparation, all necessary solutions and chemicals, needles, and 
syringes were put in a plastic box together with the preparation order. 
Contamination of nine of these boxes was measured by taking wipe samples 
from the inner surface. 
Seventy-six packings of prepared cytostatic drugs (infusion bags, medication 
cassettes, and syringes) were checked for contamination by taking wipe 
samples on the outside. 
Eleven pharmacy technicians were involved in the preparation of the drugs. 
Pharmacy technician 5 appeared twice in the research schedule. In addition to 
their work at the clinical pharmacy department, pharmacy technicians 4 and 9 
were also working at the outpatient department (preparation). Pharmacy 
technicians 2, 5, 10, and 11 were not actively involved in the preparation of 
the drugs but collected all necessary items, including the drug for the 
preparation, and put them together with the preparation order in the boxes. 
During this investigation 18 g CP, 29 g 5FU, and 15 g MTX were prepared. 
Outpatient department (preparation) 
From the working tray of the hood (1.90 χ 0.80 m) wipe samples were taken 
on 4 days before and after preparation of the drugs and after the cleaning of 
the hood with an alcoholic solution at the end of the working day. 
Wipe samples were taken from the floor of the preparation room (0.70 χ 0.70 
m) on two days: on day 1 (at the beginning and end of the working day) and 
on day 4 (at the end of the working day). The wipe samples were taken in 
front of the hood and at the entrance (inside and outside) of the preparation 
room. The total area of the preparation room was about 12m2. 
Contamination of the gloves used for preparation of the drugs and for cleaning 
of the hood was analyzed. Eleven pairs of gloves were used. 
The prepared drugs were packed ready to be transported and administrated in 
the administration rooms of the outpatient department. Nineteen packings 
(infusion bags, bottles, medication cassettes, and syringes) were checked for 
contamination by taking wipe samples from the outside. 
Six pharmacy technicians were involved in the preparation of the drugs. 
Pharmacy technicians 4 and 9 were also working at the clinical pharmacy 
department. The worker coded number 14 was involved in the study as a 
pharmacy technician at the outpatient department (preparation) and as a nurse 
at the outpatient department (administration). During the investigation 2 g CP, 
7 g 5FU, and 0.5 g MTX were prepared at this department. 
Outpatient department (administration) 
Five outpatient administration rooms (about 7-11 m2) were used for the 
administration of the drugs. In each room wipe samples were taken twice on 4 
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days (at the beginning and end of the working day). The samples were taken 
from the floor (0.70 χ 0.70 m) at the entrance (inside) of the administration 
rooms and from the area surrounding the beds and chairs used for the 
administration of the drugs. 
Wipe samples were taken from the tables (1.20 χ 0.70 m or 0.90 χ 0.60 m) in 
the administration rooms to check for possible contamination with the drugs. 
Four nurses were involved in the administration of the drugs. 
Oncology department 
In the so-called dirty room where urinals and chamber pots of the patients 
were collected and cleaned, samples were taken from the floor (0.70 χ 0.70 
m) on 4 days. Wipe samples were taken from the floor in front of the rinsing 
machine and at the entrance (inside) of the room. Wipe samples were also 
taken from the sink unit (0.80 χ 0.50 m) where the urinals and chamber pots 
were collected. 
The cleaning efficiency was checked for by taking wipe samples from the 
outside of 11 chamber pots and 9 urinals. Seven wipe samples were taken on 
two successive days from the floor (0.70 χ 0.70 m) of four patient rooms. 
Seven nurses were examined. Nurse 19 was involved twice. 
Air sampling 
Total airborne particulate matter was collected with a high volume sampler. 
The diameter of the cone was 20 mm and the suction flow was about 23.5 
l/min. Cellulose filters (50 mm diameter, pore size 0.45 pm, Schleicher & 
Schuell, type RC 45, 's-Hertogenbosch, The Netherlands) were used. On day 
1, 6.73 m3 air was sampled, and on day 2, 5.55 m3. The limits of detection for 
CP, 5FU, and MTX were 5, 30, and 300 ng/m3, respectively. 
Wipe sampling 
Tissues (Kleenex professional wipes, 20 χ 21 cm, Kimberly Clark Corp., 
Koblenz, Germany) were wetted with a sodium hydroxide solution (0.03 M) 
and the spots and objects were swept clean. 
For the packings, boxes, chamber pots and urinals, two tissues and 5 ml of 
the above-mentioned solution were used. The floors, working trays of the 
hoods, the tables, and the sink unit were cleaned with four tissues and 10 ml 
solution. For the wipe samples taken from the floor, the tissues were not 
wetted but the solution was pipetted on the floor. The detection limits for the 
wipe samples were: floors and tables (CP = 0.02, 5FU=0.1, MTX = 1 ng/cm2), 
working trays of the hoods (CP = 0.01, 5FU = 0.04, MTX = 0.4 ng/cm2), boxes 
and drug vials/ampules before and packings after preparation of the drugs 
(CP = 0.06, 5FU = 0.3, MTX = 3/yg). 
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Gloves 
Gloves were only worn during preparation of the drugs. Two types were used 
(Perry White Latex surgical gloves and Perry Dermaguard surgical gloves, 
Smith & Nephew Medical, Massillon, Ohio, USA). After preparation of the 
drugs, the left and the right glove were collected together. The limits of 
detection for CP, 5FU, and MTX were 0.1, 0.7, and 6 /yg/glove. 
Sample preparation 
After sampling, the filters, the tissues, and the gloves were put in a glass pot 
and a sodium hydroxide solution (0.03 M) was added (45 ml for the packings, 
boxes, chamber pots, and urinals, 90 ml for the floors, working trays of the 
hoods, tables, and sink unit). After sonif¡cation (90 min) and shaking (10 min), 
the extracts were centrifuged and the supernatant was analyzed by high-
performance liquid chromatography (HPLC) and gas chromatography (GC). The 
gloves were only shaken (120 min). 
Urine sampling 
Total urine was collected in portions during the period of about 24 h starting 
from the beginning of the working day. The amounts excreted and the 
excretion periods were registered. The urine samples were stored at -20°C 
until sample preparation. 
Chemicals 
CP (Endoxan; purity >97%) and IP (Holoxan; purity >97%) were obtained 
from ASTA-Pharma (Bielefeld, Germany). 5FU (purity >99%) was purchased 
from Janssen Chimica (Beerse, Belgium) and MTX (purity >99.7%) was kindly 
donated by Pharmachemie (Haarlem, The Netherlands). Trifluoroacetic 
anhydride (purity >99%) was purchased from Johnson Mattey (Karlsruhe, 
Germany). All other chemicals were of the highest purity obtainable. 
HPLC analysis (5FU and MTX) 
Analysis of 5FU and MTX was performed on a reversed-phase HPLC system 
(PU LC3-XP). Twenty-microliter aliquots of the centrifuged extracts were 
injected onto a 1 50 χ 4.6 mm Nucleosil RP 18 column with 5 μπ\ particles 
(Machery-Nagel, Duren, Germany). The column temperature was 40°C. For 
5FU a sodium acetate buffer (0.05 M; pH 4.0) was used. MTX was eluted 
with a mixture of 72.5% sodium acetate buffer (0.05 M; pH 4.0) and 27.5% 
methanol. The solvent flow rate was 1.0 ml/min in all cases. The apparatus 
was equipped with an ultraviolet spectrophotometer (PU LC-UV detector). 5FU 
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and MTX were analyzed at 260 and 300 nm with retention times of 3.5 and 
4.5 min, respectively. The selectivity of the method was verified by the 
analysis of blank and spiked samples and by taking full UV spectra. 
Quantification (peak height) was carried out by reference to calibration curves 
constructed from the analysis of freshly prepared reference samples containing 
5FU or MTX dissolved in distilled water. The limits of detection for 5FU and 
MTX were approximately 7 and 60 цдІ\ sample, respectively. 
GC analysis (CP and IP) 
Air samples, wipe samples, and gloves 
One milliliter TRIS buffer (0.2 M; pH 4.5) and 100 μ\ internal standard (5 mg 
IP/ml distilled water) were added to 1 ml centrifuged sample. After mixing, the 
samples were extracted twice with 5 ml ethylacetate and the ethyl acetate 
layers were combined in conical tubes with screw caps. The extracts were 
dried under nitrogen at 40°C and mixed with 50 μ\ ethyl acetate until the 
residue was totally dissolved. After addition of 50 μ\ trifluoroacetic anhydride 
and subsequent mixing, the tubes were closed for derivatization for 20 min at 
70°C. The samples were cooled to room temperature and dried again under 
nitrogen at 40°C. Thereafter 50 μ\ toluene was added, and following 
sonification for 3 min, vials were filled with sample and stored at -20°C until 
analysis. 
Urine samples 
Five milliliters of urine was used instead of a 1 ml centrifuged sample. The 
samples were extracted twice with 10 ml ethyl acetate. The ethyl acetate 
layers were combined and washed successively with 5 ml of a 10% (w/w) 
sodium hydrogen carbonate solution and 5 ml of a hydrochloric acid solution 
(0.05 M). The aqueous layers were discarded. The organic phase was dried 
under nitrogen at 40°C. The derivatization was performed in 100 μ\ ethyl 
acetate with 100 μ\ trifluoroacetic anhydride. Thereafter 500 μΙ of a saturated 
sodium chloride solution was added to the samples. After mixing, the samples 
were extracted twice with 5 ml n-hexane. The n-hexane layers were combined 
in conical tubes and dried under nitrogen at 40°C. Finally the dried samples 
were dissolved in 100//I toluene. 
When IP was analyzed, CP was used as internal standard (5 mg CP/ml distilled 
water). 
GC-MS conditions 
GC-MS (gas chromatography-mass spectrometry) analysis was performed on a 
Varían Saturn GC-MS system which was controlled by a Compaq 386-20e 
personal computer. The on column injection mode was used (SPI: septum 
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equipped temperature programmable injector). A 30-m DB-5 column (J & W 
Scientific, Folsom, California, USA) was used with 0.25 mm internal diameter 
and 0.25 μπι film thickness. The column was connected with a deactivated 
fused silica retention gap (Varían, Houten, The Netherlands) with a length of 5 
m and an internal diameter of 0.53 mm. The initial injector temperature was 
110°C. After 1 min the temperature was increased by 180°C/min to 280°C. 
After 8 min at 280°C the temperature was decreased to the initial temperature 
by cooling with liquid carbon dioxide. The initial oven temperature was 110°C. 
After 1 min, the temperature was increased by 15°C/min to 280°C, where it 
remained constant for 5 min. Helium was used as carrier gas (column inlet 
pressure 14 psi). The interface temperature was 280°С and electron impact 
was used as ionization mode. Identification was carried out by the combination 
of full scan spectra (250-399 amu) and retention times of CP and IP. Retention 
times of derivatized IP and CP were 10.4 and 11.1 min, respectively. 
Quantification was performed on the selected ¡on fragment 307 which was 
abstracted from the full scan spectra. By using a high background mass we 
eliminated the unwanted matrix ions. For quantification the peak area ratio of 
CP/IP was calculated. Quantification of the trifluoroacetyl derivatives was 
carried out by reference to calibration curves constructed from the analysis of 
freshly prepared reference (urine) samples containing CP and IP dissolved in 
blank urine or distilled water (air samples, wipe samples, and gloves). 
Frozen reference urine samples containing CP or IP were analyzed over a 
period of 3 months. No significant loss of CP was observed. The limit of 
detection for both compounds is about 0.1 /yg/l urine or distilled water. 
Results 
Clinical pharmacy department 
In the two air samples taken during preparation of the drugs no CP, 5FU, or 
MTX was detected. 
Contamination of the working tray with 5FU was detected once before 
preparation in both hood 1 and hood 2 (Table 1). CP was measured once after 
preparation in hood 2 (0.1 ng/cm2; data not shown). No MTX contamination 
was observed. 
Contamination of the floor with 5FU was found at all locations on at least one 
of the two days, except in front of hood 2, where no 5FU was detected (Table 
2). CP and MTX were not detected in any of the wipe samples taken from the 
floor. 
The gloves appeared to be contaminated during preparation of CP, 5FU, and 
MTX (Table 3). The gloves were found to be contaminated with 5FU and MTX 
not only during preparation of these two drugs but also during preparation of 
other drugs. CP contamination was found once during preparation of other 
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antineoplastic agents. No significant correlation was found between the 
contamination with 5FU and the amounts (total mass or number of ampules) 
of 5FU prepared. Many of the gloves used for cleaning the hoods were 
contaminated with CP, 5FU and/or MTX (Table 4). Contamination with 5FU 
was found most frequently. 
Some of the packings of the drugs were contaminated on the outside. One vial 
of CP was contaminated with 0.06 pg CP and one vial of MTX had 1 5 //g MTX 
on the outer surface. 
No contamination was observed on the boxes in use for the collection of the 
solutions and chemicals necessary for preparation of the drugs. 
On the outside of the packings of four prepared products (two 5FU cassettes 
and one 5FU and one IP infusion bag) 5FU was found (1.4, 3.1, 4.0, and 6.2 
//g, respectively). CP was detected once on a CP infusion bag (2.1 pg). 
Table 1. Contamination of the working tray of the hoods with 5FU in two 
departments (ng/cm2). 
day sampling clinical pharmacy department outpatient department 
time (preparation) 
hood 1 hood 2 
bp-
apb 
ac
c 
bp 
ap 
ac 
bp 
ap 
ac 
bp 
ap 
ac 
ndd 
nd 
nd 
0.5 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
0.2 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
1.4 
1.8 
0.6 
0.3 
0.6 
nd 
0.2 
0.5 
nd 
nd 
nd 
nd 
" bp: before preparation 
ь
 ap: after preparation 
c
 ac: after cleaning 
d
 nd: not detectable ( < 0 . 0 4 ng/cm2) 
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Outpatient department (preparation) 
Before as well as after preparation, 5FU contamination of the working tray of 
the hood was detected on the first 3 days (Table 1). Contamination with MTX 
was not found. CP was only detected on day 2 after preparation (12 ng/cm2). 
Contamination of the floor with 5FU was found on both days (Table 2). CP 
and MTX were not detected in any of the spot samples. 
During preparation of the drugs and during cleaning of the hood 11 pairs of 
gloves were used (seven and four pairs, respectively). On the gloves worn 
during preparation of the drugs only contamination with 5FU was found (Table 
3). 5FU was also present on gloves not used for the preparation of 5FU. A 
significant correlation was found between the contamination of the gloves 
with 5FU and the amount of 5FU prepared with them (Spearman's coefficient 
of rank correlation: rs = 0.78, P<0.05). Many of the gloves used for cleaning 
the hood were contaminated with 5FU and MTX but not with CP (Table 4). 
The outside of the packings of the prepared drugs was not contaminated with 
CP, 5FU, or MTX. 
Table 2. Contamination of the floor with 5FU (ng/cm2). 
department ' day 1 
beginning of 
working day 
clinical pharmacy department 
in front of hood 1 0.2 
in front of hood 2 nd 
center of the room 3.1 
inside the room 0.8 
outside the room 5.5 
outpatient clinical department (preparation) 
in front of the hood 1.2 
inside the room 2.6 
outside the room 2.1 
end of 
working day 
nd' 
nd 
1.1 
2.1 
3.3 
1.1 
3.1 
0.5 
day 4 
end of 
working day 
nd 
nd 
nd 
2.9 
10.7 
nd 
2.9 
2.5 
nd: not detectable (< 0.1 ng/cm2) 
Outpatient department (administration) 
Contamination of the floors of the administration rooms was detected during 
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all 4 days of the investigation (at the beginning and end of the working day). 
The amount of 5FU (n = 10) decreased from a median value of 1.8 ng/cm2 on 
day 1 (beginning of the working day) to a median value of 0.7 ng/cm2 on day 
4 (end of the working day) (data not shown). CP was only found on the floor 
at the beginning of the working days and mostly only around the beds and 
chairs (n = 5) used for the administration (< 0.02-4.5 //g/cm2) (data not 
shown). Contamination with MTX was not found. 
On the tables in the administration rooms, 5FU contamination was found once 
before administration (day 1: 22 pg) and twice after administration (day 1: 6.5 
pg; day 3: 4.9 pg). CP contamination was detected at the beginning of 
working day 1 on one table (4.5 pg) and on day 2 on three tables (0.2, 0.3, 
and 0.7 pg). 
Oncology department 
On the floor of the "dirty room", CP was detected once in front of the rinsing 
machine (0.9 ng/cm2). MTX contamination was not observed. MTX was 
measured in three wipe samples taken from the floor of two patient rooms 
(5.5, 5.5, and 5.9 ng/cm2). CP contamination of the floors was not observed. 
CP was detected on one urinal (8.3 pg). MTX was not found on the urinals or 
chamber pots. 
Table 3. Contamination of the gloves used during preparation of the drugs3 
(pg/glove). 
department CP + b 
clinical pharmacy department 
pairs used 2 
pairs contaminated 0 
range (//g) 
median (pg) 
outpatient department (preparation) 
pairs used 2 
pairs contaminated 0 
range (/;g) 
median (μφ 
СР-
Ь 
12 
1 
•CO.1-21 
< 0 . 1 
5 
0 
-
• 
5FU + 
6 
6 
2 3 - 6 2 
5 9 
4 
3 
•C0.7-140 
5 4 
5FU-
8 
8 
19-87 
36 
3 
2 
< 0.7-30 
18 
M T X + 
9 
2 
< 6 - 4 9 
< 6 
5 
0 
-
-
MTX-
5 
1 
< 6 - 3 1 
< 6 
2 
О 
-
" 
limits of detection: CP = 0 . 1 , 5 F U = 0 . 7 , and M T X = 6 //g/glove 
+ : gloves used for the preparation of the indicated drug 
- : gloves not used for the preparation of the indicated drug 
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Table 4. Contamination of the gloves used for cleaning the hoods3 (цд/діо е). 
department 
clinical pharmacy department 
pairs used 
pairs contaminated 
range (//g) 
median (¿ug) 
outpatient department (preparation! 
pairs used 
pairs contaminated 
range (pg) 
median (//g) 
" limits of detection: CP = 0 . 1 , 5FU = 
CP 
6 
1 
< 0 . 1 -
< 0 . 1 
4 
0 
-
-
11 
= 0 .7 , and MTX = 
5 FU 
6 
6 
25-59 
49 
4 
3 
< 0 . 7 - 1 8 
10 
 6 //g/glove 
MTX 
6 
2 
< 6 - 4 9 
< 6 
4 
2 
< 6 - 4 0 
18 
CP and IP in urine 
The urine analysis data for CP and IP obtained from the urine samples of the 
pharmacy technicians and nurses are given in Table 5. CP and IP were 
detected in the urine samples of 8 of 25 pharmacy technicians and nurses 
from all four departments. The amounts excreted ranged from 0.01 to 0.5 //g 
(median: 0.1 ¿/g). In urine of two of these workers CP or IP was identified but 
the amounts were too low for quantification (signal to noise ratio <3). In urine 
of 17 other workers neither CP nor IP was detected (<0.1 ¿/g/l). CP and IP 
were not only measured in urine of pharmacy technicians and nurses actively 
handing these compounds (n = 2) but also in urine of pharmacy technicians 
and nurses who were not directly involved in the preparation and 
administration of these drugs (n = 6). 
Since total 24-h urine was collected and the individual portions were analyzed, 
the excretion periods can be indicated with the time at zero at the beginning of 
the working day. In fact this is the time at which the exposure also might have 
started. The data in table 5 show different "excretion periods" for all pharmacy 
technicians and nurses. CP and IP excretion was complete within 24 h after 
the beginning of the working day. In all pharmacy technicians and nurses CP 
was measured in only one urine portion except for nurse 14. She excreted CP 
in two successive fractions. Nurse 19 took part in this study on two 
successive days. On both days IP was measured in her urine. On the first day, 
the "excretion period" was 5-8.5 h after the beginning of the working day. On 
the second day the "excretion period" was 18.25-24 h. 
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Table 5. Urinary CP or IP excretion3. 
51 
department 
clinical pharmacy 
department 
outpatient department 
(preparation) 
outpatient department 
(administration) 
oncology department' 
nurse/ 
pharmacy 
technician 
1 
2 
3 
4d 
5 
6 
7 
8 
5 ,9 -11" 
12 
13 
4d 
9" 
14°,15 
14 g h 
16 
17,18 
19 
19 
20 
21 
22-25 
CP or IP* 
preparation/ 
administration 
(mg) 
4 2 0 0 
-
-
1500 
4 2 0 0 
5700 
2600 
4 7 5 0 
-
-
-
600 
1750 
-
-
2 3 0 0 
-
-
-
4 8 0 0 
1000 
-
CP or IP in 
amount 
W 
0.1 
0.3 
0.5 
nd' 
nd 
nd 
nd 
nd 
nd 
0.07 
< 0 .01 ' 
nd 
nd 
nd 
0.07 
0.04 
0.1 
nd 
< 0 . 0 1 ' 
0.4 
nd 
nd 
nd 
urine 
excretion period' 
(h.min) 
12 .45 -13 .40 
22 .45 -24 .15 
12 .00 -13 .30 
-
-
-
-
-
-
2 .10-7 .00 
1.40-3.45 
-
-
-
8.20-10 .30 
10 .30 -19 .00 
10 .25 -11 .00 
-
5.00-8 .30 
18 .15 -24 .00 
-
-
-
at all departments except for the oncology department urine samples were analysed for the 
presence of CP 
at the oncology department the urine samples were analysed for the presence of IP 
-, neither CP nor IP preparation or administration 
"excretion period" is defined as follows: starting at the time of the previous urine production 
and ending at the time of the production of this particular urine sample, with the time at zero at 
the beginning of the working day 
pharmacy technician 4 and 9 were working at both departments 
nd, not detectable ( < 0 . 1 /yg/l urine) 
positively identified but not quantified (signal/noise ratio < 3) 
pharmacy technician/nurse 14 was working at both departments 
CP was detected in two successive urine portions 
52 Chapter 2 
No significant correlations were observed between the amounts of CP and IP 
excreted in urine and the amounts of CP and IP prepared or administered. Also 
no correlation was observed between the amounts of CP and IP excreted in 
urine and smoking habits, the use of alcohol, or the use of hormonal 
contraceptives. 
Discussion 
In the biomonitoring studies directed at the detection of occupational exposure 
to antineoplastic agents, hardly any data have until now been published about 
environmental contamination due to spillage during working procedures [15]. 
In two studies in hospital departments, air-contamination with cytostatic drugs 
was found, which suggested that inhalation was a potential absorption route 
[11,17]. 
Recently we published the results of an investigation in a pharmacy 
department of a hospital in which the occupational hygiene of preparing 
cytostatic drugs was studied [13]. Environmental contamination with CP, 5FU, 
and MTX was observed but no CP was detected in urine of the pharmacy 
technicians preparing these drugs. In the present investigation not only was 
environmental contamination found, but CP and IP were detected in the urine 
of pharmacy technicians and nurses whether or not they were directly 
involved in the preparation and administration of these drugs. 
In the present study, the preparation of the drugs occurred in the clinical 
pharmacy department and in the preparation room of the outpatient 
department. The working conditions and the operating procedures in both 
departments were essentially the same. Protective clothing, hair-nets, masks, 
and gloves were worn and the drugs were prepared in laminar air-flow safety 
hoods. Therefore, it is not suprising that the findings in these departments 
show comparable results. The results of our investigation demonstrated that 
handling of CP, 5FU, and MTX resulted in contamination of the environment. 
In the wipe samples taken from the floor only 5FU was found. It was 
remarkable that 5FU was also measured outside the preparation room. During 
preparation, contamination of the working trays of the hoods with CP and 5FU 
was found occasionally in the clinical pharmacy department. Frequent 
contamination with 5FU of the working tray of the hood in the preparation 
room of the outpatient department was observed and the amounts were higher 
than in the clinical pharmacy department. Not only preparation of the drugs 
but also cleaning of the hoods resulted in contamination of the gloves. Contact 
with these gloves may result in further contamination such as was found on 
the packings of the prepared products. The boxes, however, were not 
contaminated. Drugs on the outside of the vials and ampules may also be a 
source of contamination. 
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Administration of the drugs took place in the administration rooms of the 
outpatient department and in the patient room of the oncology department. 
Hardly any safety measures or precautions were taken by the nurses. It should 
be emphasized that in the outpatient department only administration of the 
drugs took place whereas in the oncology department also other activities 
were also carried out (washing of the patients, urine collection, and cleaning 
of the beds and rooms of the patients). This may have resulted in exposure to 
the drugs otherwise than during administration. In both departments 
environmental contamination was found. Not only on the floors of the 
administration rooms and the rooms of the patients, but also on the tables in 
the administration rooms, small quantities of cytostatic drugs were found. It is 
surprising that the floors of the administration rooms were contaminated with 
CP at the beginning of the working day although no CP was detected the day 
at the end of the previous working day. It should be mentioned that in the 
meantime the rooms had been cleaned. This finding suggests that the 
administration rooms were not cleaned efficiently and that the contamination 
may have been spread. Since the administration rooms of the outpatient 
department and the rooms of the patients in the oncology department were 
also accessible to people other than nurses (family and friends of the patients), 
these rooms may also be a source of exposure for these persons. 
In the so-called dirty room urinals and chamber pots were collected on the sink 
unit for registration. Thereafter, they were cleaned in the rinsing machine. 
These urinals and chamber pots may be potential sources of cytostatic drugs 
which could be responsible for the contamination of the sink unit and the floor 
in front of the rinsing machine. Although the chamber pots and urinals were 
cleaned in the rinsingmachine, the outside of some was still contaminated. 
CP and IP were detected in urine of eight pharmacy technicians and nurses 
working in all departments under investigation. It is remarkable that CP and IP 
were also measured in urine of pharmacy technicians and nurses not directly 
involved in the preparation or administration of these two drugs. This suggests 
exposure sources other than preparation or administration, e.g., contact with 
contaminated surfaces. In general, biological monitoring is applied in addition 
to environmental monitoring to procure maximum information about the 
exposure of the persons involved and to have possibilities to study the role of 
the various exposure routes. Measurements in urine do not per se reflect 
measurements in the environment. In many cases where dermal exposure may 
occur, like in this study, it is impossible to determine the total environmental 
exposure. For that purpose one would have to measure everything the workers 
touch or breathe. 
We were interested in a relation between the working period and the time of 
excretion of CP/IP. Therefore we have indicated the period of excretion of 
CP/IP in relation to the time from the beginning of the working day (Table 5). 
In all workers the excretion intervals started at different times. This might be 
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explained by different times of exposure, different exposure routes, and 
interindividual differences in biotransformation and/or excretion of CP and IP. 
Our results show different periods from the beginning of the working day until 
the time of urinary CP excretion, ranging from 2 to 24 h. In the case of nurse 
19 two rather different periods were found, suggesting different times or 
routes of absorption of IP since differences in biotransformation and excretion 
are less likely. 
For antineoplastic agents, dermal uptake and inhalation are suggested as 
routes of exposure. In two studies the excretion of unchanged CP was 
detected in urine of nurses involved in the preparation of CP [3,7]. In the study 
by Evelo et al. CP was measured in total 24-h urine samples [3]. In a study by 
Hirst et al. the times of handling CP and the periods of the collection of the 
urine samples were indicated with respect to the end of the working day [7]. 
After application of 1 mg CP on the skin of volunteers, low concentrations of 
CP were found in urine. The excretion rates were lower than the excretion 
rates of CP in urine from nurses involved in the preparation of CP, suggesting 
another route of absorption (inhalation). It was not possible to establish 
whether CP was excreted over a longer period, as might be caused by dermal 
uptake, since urine samples were collected from the nurses only at the end of 
the working day. Therefore the suggestion that CP was absorbed by inhalation 
could be premature. Evidence for a different excretion rate after dermal 
application in comparison to exposure via inhalation was obtained in a 
toxicokinetic study using rats. In this study lower urinary excretion rates were 
observed after dermal application than after intratracheal instillation of CP 
[14]. 
Conclusion 
Environmental contamination was found in all four departments, not only on 
the floors of the different rooms and on the working trays of the hoods but 
also on other objects (tables, sink unit, cleaned urinals and chamber pots, the 
packings of the prepared and unprepared drugs). In urine of pharmacy 
technicians as well as nurses, CP or IP was detected. Although safety 
precautions were taken during preparation of the drugs in the clinical 
pharmacy department and in the preparation room of the outpatient 
department, CP was measured in urine of some pharmacy technicians working 
in these departments. How this might have happened remains unclear and will 
be the subject of further study. It was also shown that preparing or 
administering CP or IP was not the only determining factor since CP or IP was 
detected in urine of pharmacy technicians and nurses not directly involved in 
these tasks. The urinary CP/IP determination method seems suitable for 
controlling the exposure to and measuring the uptake of these toxic 
compounds. 
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Abstract 
A sensitive gas chromatographic method for the determination of 
cyclophosphamide (CP) in urine is presented. After liquid-liquid extraction with 
diethyl ether and derivatization with trifluoroacetic anhydride, CP was 
identified and quantified with mass spectrometry. The method is suitable for 
the determination of CP at concentrations of more than 0.25 ng/ml, which 
enables the uptake of CP during occupational activities, such as the 
preparation and administration of antineoplastic agents in hospitals, to be 
measured. Simple preparation makes the method appropriate for routine 
analysis. 
Introduction 
Antineoplastic agents are widely used in cancer chemotherapy. When handling 
antineoplastic agents, pharmacy technicians and nursing personnel may face 
certain health risks. There is sufficient evidence that several antineoplastic 
agents are carcinogenic to humans, because secondary cancers are found in 
cancer patients treated with these drugs, and carcinogenic effects have been 
observed in non-cancer patients treated with these therapeutics for other 
purposes [1]. Special guidelines and extensive safety precautions were 
introduced in the Netherlands about ten years ago, to protect workers from 
contact with these toxic compounds [2]. Recently, these guidelines were 
amended [3]. 
In order to measure possible uptake of these compounds by workers, it is 
neccessary to use sensitive detection methods. Non-specific detection 
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methods, such as urinary mutagenicity, analysis of chromosome aberrations 
and sister chromatid exchanges in blood lymphocytes, have been used for the 
determination of occupational exposure to antineoplastic agents [4,5]. These 
methods are suitable in cases when hospital workers had a minimum or a lack 
of protective measures against possible exposure to cytostatic drugs. Sensitive 
methods have been scarcely developed. 
We have studied the amounts of drugs used in the Netherlands over the years 
1986 to 1988 [6]. We found that CP was prepared and administered in Dutch 
hospitals most frequently. Therefore and because of CP's carcinogenic 
potency, we chose to concentrate of this drug. 
A literature review showed that the most suitable method for the detection of 
CP was derivatization with trifluoroacetic anhydride followed by gas 
chromatography (GO with nitrogen-phosphorus, electron-capture, or mass-
selective detection [7-10]. Also, a method without derivatization using GC 
with electron-capture detection has been published [11]. Unfortunately, some 
of these methods are not sensitive enough for the detection of exposure to the 
low levels of CP in urine expected during occupational activities under the 
regimen of the present Dutch guidelines [7,8], and others are time-consuming 
and not suitable for routine analysis [9,10]. 
This paper describes a GC method with liquid-liquid extraction, derivatization 
with trifluoroacetic anhydride and mass spectrometric (MS) detection. The 
method is sensitive and simple in practice, which makes it suitable for routine 
analysis. 
Experimental 
Materials and reagents 
CP (Endoxan) and iphosphamide (IP) (Holoxan) were purchased from ASTA-
Pharma (Bielefeld, Germany). Trifluoroacetic anhydride was obtained from 
Johnson Mattey (Karlsruhe, Germany). All other chemicals were of the highest 
purity obtainable. 
Sample preparation 
A 0.5-ml volume of 1M Tris buffer (pH 8.0) and 100 μ\ of the internal standard 
IP (5 //g/ml in distilled water) were added to a 5-ml urine sample. After mixing, 
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the samples were extracted twice with 20 ml of diethyl ether1, a and the ether 
layers were combined and evaporated under nitrogen at 30°C until a residue 
of ca. 2 ml was obtained. The solution was transferred to conical tubes with 
screw caps and further evaporated to dryness. Then 100 μ\ of ethyl acetate 
were added, and the solution was mixed until the residue was totally 
dissolved. Trifluoroacetic anhydride (100 μ\) was added and, after mixing, the 
tubes were closed for derivatization for 20 min at 70°C. The samples were 
cooled to room temperature and evaporated to dryness under nitrogen at 
40°C. The dried samples were dissolved in 100 μΙ of toluene, mixed and 
sonificated for 5-10 min. Vials were filled with sample and stored at -20°C 
until analysis. 
Calibration 
Calibration curves were constructed from the analysis of standard urine 
samples, which were freshly prepared by adding CP to blank urine. The CP 
concentrations of the standard urine samples were 0, 2, 10, 20, 50, and 100 
ng/ml urine. 
A control urine sample was obtained by adding CP to pooled blank urine (11.7 
ng/ml). From this control urine sample, aliquots of ca. 10 ml were stored at -
20°C. These aliquots were analysed in duplicate on every occasion when urine 
samples were assayed. The results from these determinations were used to 
calculate the inter- and intra-assay precision. 
Gas chromatographic-mass spectrometric analysis 
The samples were analysed on a Varian Saturn GC-MS ion-trap system with a 
Varían 8100 autosampler, which was controlled by a Compaq 386-20e 
personal computer (software version B). The on-column injection mode was 
used (SPI: septum equipped temperature programmable injector). Separation 
was carried out on a fused-silica capillary column (DB-5, 30 m χ 0.25 mm I.D., 
film thickness 0.25 μτη). The column was connected to a deactivated fused-
silica retention gap (Varian, 5 m χ 0.53 mm I.D.). The initial injector 
temperature was 110°C. After 1 min, the temperature was increased by 
180°C/min to 280°C. After 8 min at 280°C, the temperature was decreased 
to the initial temperature by cooling with liquid carbon dioxide. The initial oven 
temperature was 110°C. After 1 min, the temperature was increased by 
15°C/min to 280°C, where it remained constant for 5 min. Helium was used 
Previously we used ethyl acetate with two clean-up steps. But greater amounts of solvents 
should be used and, after derivatization with trifluoroacetic anhydride, an additional extraction 
with n-hexane is needed to reach the same detection limit. 
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as carrier gas (column inlet pressure 96 kPa). The interface temperature was 
280°C. Electron impact (El) was used as ionization mode. Identification was 
carried out by the combination of full-scan spectra (m/z = 250-399) and 
retention times of CP and IP. Retention times of derivatized IP and CP were 
9.40 and 10.20 min, respectively. Quantification of the N-trifluoroacetyl 
derivatives was performed on the selected-ion fragment m/z 307, which was 
abstracted from the full-scan spectra. By using a high background mass, the 
unwanted matrix ions were eliminated. For quantification, the CP/IP peak area 
ratio was calculated. 
Results and discussion 
Mass spectra of N-trifluoroacetylated CP and IP are shown in Fig. 1. High 
relative intensity was found for m/z 307 (M + + 1-CH3CI) for both compounds, 
because the molecular fragment m/z 356 was not stable under El conditions 
[7,8]. Fig. 2 shows total and reconstructed (m/z 307) ion chromatograms of a 
blank urine sample spiked with CP and IP (A), a blank urine sample (B), and a 
urine sample from a CP-exposed pharmacy technician involved in the 
preparation of CP (C). CP and IP were completely separated, and no 
interference with other compounds was observed. When the selectivity was 
increased by the use of the reconstructed ion fragment (m/z 307) a higher 
sensitivity was Obtained (Fig. 2A). The use of chemical ionization instead of El 
did not result in a higher sensitivity. 
The clean-up and derivatization procedure sounds similar to already published 
methods. The difference is the use of an ion-trap mass spectrometer instead of 
a quadrupole device with selected-ion monitoring (SIM). In previous 
unpublished work we found that, in this particular case for the determination 
of CP in urine, the ion-trap spectrometer is more sensitive than a quadrupole 
device with SIM. 
Thirty frozen control urine samples containing 11.7 ng/ml CP were analysed in 
duplicate during a period of three months. No significant loss of CP was 
observed, which means that the medium-term stability is good. The mean CP 
concentration of these analyses was 9.9 ng/ml. The coefficient of variation 
(C.V.), as a measure of the inter-assay precision, was 18%. The intra-assay 
precision was 5 .1%. The calibration curves were linear, with a coefficient of 
correlation of at least 0.99. The limit of detection was ca. 0.25 ng/ml urine 
(12.5 pg on column) with a signal-to-noise ratio of more than 3. 
According to the International Agency for Research on Cancer, CP is a human 
genotoxic carcinogen (group 1). This means that exposure to this compounds 
should be avoided because any detectable level is considered to be a hazard. 
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This supports the need for a sensitive method for the determination of CP in 
urine. 
The method presented in this study is sensitive and suitable for the detection 
of CP in urine at the low ng/ml level. This is the level we have found in 
workers occupationally exposed to this carcinogenic drug [12-14]. 
Fig. 1. Mass spectral fragmentation of N-trifluoroacetylated CP and IP 
(internal standard). 
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Fig. 2. Total and reconstructed (m/z 307) ¡on chromatograms. Filament and 
multiplier were switched on at 9:20 min. (A) A blank urine sample 
spiked with 10 ng/ml CP and 100 ng/ml IP (internal standard). (В) A 
blank urine sample. (C) A urine sample of a pharmacy technician 
involved in the preparation of antineoplastic agents, including CP. The 
concentrations of CP and IP were 18 and 100 ng/ml. 
TOT-
387 
' I I I « I T 
I I I I | I f" 
8:28 9:18 
I ' ι 
' ! ' I ' — I • I • I · I • I < I > I < I ' 1 ^ 
ів:ва ia-.sa 1 1 : 4 8 RETENTION TIME 
3 8 7 -
B 
' 1 ' I I 1 1 1 ' 1 • Г • 1 • 1 ' 1 ' | • 1 ' 1 ' 1 ' 1 • 1 • 1 • 1 ' 1 • 1 • 1 • 1 • 
9:18 1 1 : 4 8 RETENTION TIME 
3 8 7 -
c 
1
 • • 1 • • 
IF 
J 
\ CP 
V )\_ 
I I I ' ι - · ι • ι *• τ—· T - > " V * - 1 ' Τ • 1 • I ' | '·Λ ' 1 
Development and validation of monitoring methods 63 
Appendix 
Introduction 
El ionisation with the reconstructed (m/z = 307) ion chromatogram is specific 
for CP and IP. However, specificity is increased by using MSMS. Thereto, the 
parent ion mass m/z = 307 is stored in the ion-trap and further split in a so-
called daughter ion with m/z = 212 which is very specific for CP and IP. This 
new application has resulted in some changes in the method which are briefly 
discussed below. 
Gas chromatographic-mass spectrometric analysis 
The samples were analysed on a Varían Saturn 4D GC/MS/MS ion-trap system 
with a Varian 8200 autosampler, which was controlled by a Compaq Prolinea 
4/50 personal computer (software version 5.2). The initial injector temperature 
was 110°C. After 1 min, the temperature was increased by 180°C/min to 
280°C. After 5 min at 280°C, the temperature was decreased to the initial 
temperature by cooling with compressed air. The initial oven temperature was 
110°C. After 1 min, the temperature was increased by 15°C/min to 290°C, 
where it remained constant for 7 min. The interface temperature was 290°C. 
Daughter-ion m/z = 212 was produced at an excitation amplitude of 43V (IP) 
and 46V (CP) (nonresonant) and an excitation RF of 500 dac. By using a high 
background mass (m/z = 95), the unwanted matrix ions were eliminated. 
Consequently background noise is further reduced and the sensitivity is 
improved. Quantification was performed on the daughter ion mass m/z = 212. 
Results and discussion 
MSMS mass spectra of the parent ion mass m/z = 307 of N-trifluoroacetylated 
CP and IP are shown in Fig. 3. High relative intensity was found for daughter 
ion mass m/z = 212 for both compounds. Fig. 4 shows the reconstructed 
(m/z = 307) ion chromatogram of a blank urine sample spiked with CP and IP 
(1 /yg/l urine) obtained by El and a chromatogram of the daughter ion mass 
m/z = 212 of the same sample obtained by MSMS. It is shown that the 
daughter ion mass m/z = 212 obtained by MSMS further increased the 
specificity and the selectivity of the method. Retention times of derivatized IP 
and CP were 8.6 and 9.3 min, respectively. CP and IP were completely 
seperated, and no interference with other compounds was observed. The limit 
of detection is 0.1 ng/ml urine. 
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Fig. 3. MSMS mass spectra of the parent ion mass 
trifluoroacetylated CP and IP (internal standard). 
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Fig. 4. 
1.67* 
Reconstructed (m/z 307) ¡on chromatogram of a blank urine sample 
spiked with CP and IP (1 pg/l urine) and a chromatogram of the 
daughter ion mass m/z = 212 of the same sample obtained by MSMS. 
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Abstract 
Little is known about the exposure of animal keepers to toxic agents during 
the administration of such chemicals to laboratory animals. In this study, we 
have investigated the environmental contamination with cyclophosphamide 
(CP) in an animal laboratory where mice were housed and injected with this 
compound. Also the contamination of gloves, sleeve protectors, and masks 
used for personal protection was studied. The uptake of CP by the animal 
keepers was determined by the analysis of unmetabolized CP in urine. For the 
estimation of CP in the air, air samples were taken and filters of the air-
circulation system were analyzed. On the filters, amounts of CP were detected 
corresponding with < 0.1-1.0 //g/day. Environmental contamination was also 
measured by analysis of wipe samples taken from different spots (objects and 
surfaces). The presence of CP was not only observed in the room where the 
mice were housed and treated with CP but also in adjacent rooms (< 0.02-44 
ng/cm2). The gloves used during the injection of CP were always contaminated 
(2-199 //g/pair). No penetration of the gloves was established. The sleeve 
protectors were incidentally contaminated (<0.3-10 //g) and on the masks no 
CP was found (<0.2 μg). Eighty seven urine samples from four animal keepers 
were analyzed for unmetabolized CP. In one sample CP was detected (0.7 μg). 
The results show that in this particular study animal keepers are exposed to 
CP during their work. 
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Introduction 
In the Netherlands, about 2000 persons are potentially involved in the 
administration of chemicals to laboratory animals for medical, toxicological, or 
other purposes. Although the number of persons is not very large, they may 
be exposed to many different chemical substances. Appropriate methods for 
controlling their exposure to toxic agents are limited. Little is known about 
their exposure to the many different toxic chemicals with which they are 
working. In this study, we describe a particular case in which animal keepers 
were involved in the administration of cyclophosphamide (CP) to mice. 
CP is an agent widely used in hospitals, on one hand, as a cytostatic drug in 
cancer chemotherapy, and, on the other hand, as an immunosuppressant. CP 
is considered to be carcinogenic and mutagenic in humans and in animals.1 
During 1986-1988, the annual use in the Netherlands was about 56 kg.2 
Because of possible hazards due to occupational exposure to antineoplastic 
agents of hospital workers, extensive guidelines and safety precautions have 
been introduced.3,4 Published studies about the occupational exposure to 
antineoplastic agents refer to workers in pharmacies, hospitals and industry.5 
We have studied CP contamination in an animal room where mice were 
housed and treated with CP. Air and spot samples taken from different places, 
and subjects in different rooms in the animal laboratory were investigated for 
the presence of CP. Also contamination of masks, sleeve protectors, and 
gloves, used for protection, was studied. The uptake of CP by the animal 
keepers was measured by the determination of unmetabolized CP in urine. The 
present study is subdivided into two parts. In a first study, a former situation 
was investigated. Thereafter, some additional measures and safety precautions 
were taken that were evaluated in a second study. 
Materials and methods 
Study design 
In the first and the second study, samples were taken during 7 (days 1 -7) and 
9 days (days 8-16), respectively. Three animal keepers (2 male, 1 female) 
were involved in the subcutaneous injection of CP to mice. A fourth animal 
keeper (male) cleaned the cages and the animal rooms. CP administration took 
place in one of the animal rooms where the mice were housed. Details about 
the amounts of CP administered to the mice are presented in Table 1. The 
animal keepers wore protective clothes and latex gloves. Almost always, 
masks and sleeve protectors were used. 
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Going from the central hall of the animal laboratory to the animal rooms, a 
sluice is entered where the animal keepers change their clothes and take other 
personal safety precautions. Thereafter, they enter a corridor that is connected 
with different animal rooms where animals were housed. 
Table 1. Amounts of CP administered to the mice. 
day 
first study 
3 
4 
5 
6 
7 
second study 
9 
10 
11 
12 
13 
14 
15 
16 
keeper 
1 
2* 
3 
4 b 
1 
3 
3 
3 
4 
3 
2 
3 
1 
dose 
3.8 
3.8 
2.5 
-
c 
2.5 
3.7 
2.5 
-
-
3.7 
2.5 
3.7 
2.5 
number of 
mice 
7 
50 
50 
-
100 
30 
30 
30 
-
60 
60 
100 
100 
total 
dose (mg) 
26.6 
190 
125 
-
250 
111 
75 
-
-
222 
150 
370 
250 
animal keeper 2 (female) 
animal keeper 4 was only involved in cleaning of the cages and the animal room 
-, CP was not administered 
Air sampling 
First study 
Once on day 1, two stationary air samples were taken at the same time at 
different places in the animal room. Total airborne particulate matter was 
collected on polytetrafluoroethylene filters with 37-mm diameter and 1.2-μπ\ 
pore size (Sartorius, Göttingen, Germany). In 5 hours, 0.63 m3 of air was 
sampled (sampling rate 2.1 L/minute). 
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Second study 
The air in the animal room was refreshed by an air-circulation system. When 
leaving the animal room, the air was sucked over two filters that were placed 
in the walls. The filters were changed weekly. Seven pair of filters were 
collected and analyzed for CP. 
Wipe sampling 
For the detection of contamination with CP, spot samples were taken before 
and after administration of CP and after cleaning of the cages and the animal 
room. In general, the spots were the same in the first and in the second study. 
Some spots were replaced by new spots. A description is given in Table 2. 
The method of sampling was performed like described previously.6 
First study 
On day 1, wipe samples were taken two times. The first time it was done for 
the estimation of "background" levels of contamination. The second sample 
was collected after cleaning of the animal cages in the animal room. Wipe 
samples were also taken after cleaning of the animal room on day 2 and 
before and after the administration of CP on day 3. 
Second study 
For the estimation of background levels of contamination, wipe samples were 
collected on the first day (day 8) also in this study. Before and after the 
administration of CP, wipe samples were taken during 4 days (days 9, 10, 13 
and 14). This was also done on day 11, although no CP was administered. On 
day 16, wipe samples were only collected after the administration of CP. 
Contamination of gloves, sleeve protectors, and masks 
First study 
During administration of CP and cleaning of the animal room, five pairs of latex 
gloves (Perry X-AM Latex Examination Gloves, Beaded Cuff, Smith & Nephew 
Perry, Massillon, Ohio) and five pairs of sleeve protectors (Tyvek, Hanotex, 
Sneek, The Netherlands) were worn. Surgery masks (Carpex Soft Face Masks, 
Beiersdorf AG, Hamburg, Germany) were used twice by animal keeper 1. After 
the administration of CP and after cleaning of the animal room, both gloves 
and both sleeve protectors were collected. For sample preparation left and 
right ones were put together. For the masks, the same procedure was 
followed. 
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Second study 
Due to the results of the first study, during the injection of CP six double pairs 
of gloves and six pair of sleeve protectors were worn. The outer as well as the 
inner ones were collected separately. Animal keeper 4, who cleaned the 
cages, only used one pair of gloves and no sleeve protectors. All animal 
keepers wore masks except for animal keeper 3 (day 11). 
Table 2. Description of the spots. 
spot description 
1 balance 
2 working table 
3 tap 
4 board above the washstand 
5 latches of the door between the animal room and the corridor 
6 floor in the animal room beneath the cages 
7 floor in the animal room beneath the cages 
8 floor in the animal room in front of the door 
9 floor in the corridor in front of the door of the animal room 
1 0 alcohol bottle 
11 floor in the corridor (central position) 
12 latches of the door between the corridor and the sluice 
1 3 floor in the sluice 
14 floor in the central hall 
15 service hatch 
16 phone 
1 7 plastic foil on the working table 
area 
(cm2) 
520 
7600 
950 
850 
400 
4300 
4300 
3500 
3600 
375 
3300 
300 
3700 
3200 
2400 
280 
2400 
limit of 
detection 
(ng/cm2) 
0.8 
0.02-0.1 
0.09-0.4 
0.5 
1.0 
0.04-0.2 
0.04-0.2 
0.05-0.2 
0.2 
1.1 
0.05 
0.3 
0.05 
0.05 
0.07 
0.3 
0.07 
Urine sampling 
Total urine was collected in several portions during a period of 24 hours after 
the administration of CP or after cleaning of the cages and the animal room. 
They were stored at -20°С until sample preparation. 
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Sample preparation and CP determination 
Sample preparation and CP determination with gas chromatography/mass 
spectrometry (GC/MS) was carried out according to Sessink et al.6 Differences 
in detection limits between the first and the second study are caused by using 
a new GC column and changes in the parameter settings of the GC/MS during 
the second study. 
Results 
Air sampling 
First study 
No CP was found on the two filters of the stationary air samples. The limit of 
detection was approximately 1 /yg/m3. 
Second study 
On three pairs of filters of the air-circulation system, CP was found (Table 3). 
Because it was not possible to measure the amounts of air sampled, the 
amounts of CP per m3 could not be calculated. Therefore, the amounts of CP 
were calculated per day, since all sampling periods were multiples of days and 
the activity of the circulation system could have changed during 24 hours 
(day-night) but not within days. The amounts of CP detected were between 
<0.1-1.0//g/day. 
Table 3. Amounts of CP on the filters of the air-circulation system. 
day samping period (days) μ$ /vg/day 
8 
9 
10 
11 
13 
14 
15 
1 
3 
1 
3 
3 
4 
3 
< 0 4 
0 4 
< 0 4 
< 0 4 
< 0 4 
4 0 
1 7 
< 0 4 
0 1 
< 0 4 
< 0 1 
< 0 1 
1 0 
0 6 
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Wipe sampling 
First study 
On day 1, on almost all spots, background levels of CP were detected (Table 
4). No CP was found on the latches and a part of the floor in the animal room 
beneath the cages. On day 2 and 3, CP was only detected on the balance, the 
working table, and the alcohol bottle. 
Table 4. CP contamination of the working environment during the first study 
(ng/cm2). 
spot day 1 day 2 day 3 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
series 1" 
21 
8 
2 
0.8 
nd 
nd 
0.4 
0.4 
0.7 
4 4 
series 2b 
I 
4 
nde 
nd 
nd 
nd 
nd 
nd 
nd 
-
series 3C 
1 
1 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
-
series 4 series 5" 
2 
nd 
2 
nd 
13 
samples taken for "background" levels 
samples taken after cleaning of the cages 
samples taken after cleaning of the animal room 
samples taken before administration 
samples taken after administration 
-, no sample taken 
nd, not detectable (for limits of detection, see Table 2) 
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Second study 
On day 8, no detectable background levels were found (Table 5). On the other 
days, contamination was measured incidentally before and after the 
administration. The plastic foil on the working table was almost always 
contaminated. The highest amounts of CP per cm2 were found on the tap, on 
the plastic foil on the working table, on the latches of the door between the 
corridor and the sluice, and on the floor in the sluice. No CP was detected on 
the floor in the corridor, on the service-hatch, and on the phone. 
Contamination of gloves, sleeve protectors and masks 
First study 
During the administration of CP to the mice, CP was present on all gloves 
(Table 6). Glove contamination was not found for animal keeper 4 who was 
only involved in cleaning of the animal room. The sleeve protectors were 
contaminated once during the administration of CP. On the masks, no CP was 
detected. 
Second study 
Analysis of the samples of all outer pair of gloves showed the presence of CP 
(Table 6). CP was not found on the inner ones except for day 9 (animal keeper 
3). On half of the sleeve protectors, CP was detected. No CP was found on 
the masks. 
Urine samples 
From the four animal keepers 87 urine samples were analyzed for CP. CP was 
detected in one urine sample of animal keeper 1 (Table 6). A total of 0.7 /yg 
CP (in 205 mL of urine) was excreted over the period of 9-12 hours after CP 
injection. The limit of detection was approximately 1 ng/mL urine. 
Discussion 
In the present study, recently developed methods for the detection of 
environmental contamination with CP and for the measurement of the uptake 
of this compound by the determination of CP in urine were applied in a 
situation where animal keepers were possibly exposed to this chemical 
agent.6,7 As far as we know, no studies, until now, have been published about 
the occupational exposure of animal keepers to CP or other antineoplastic 
agents. In general, little is known about the occupational exposure of this 
group of workers to chemicals, whereas it is known that, in animal 
laboratories, a lot of different chemicals are used. 
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Table 6. CP on the gloves, sleeve protectors, masks, and in the urine of the 
animal keepers (pg). 
day 
first study 
3 
4 
5 
6 
7 
second study 
9 
10 
11 
12 
13 
14 
16 
keeper 
1 
2 
3 
4 
1 
3 
3 
3 
4* 
3 
2 
1 
gloves" 
outer 
23 
75 
19 
< 7 
11 
199 
47 
9 
5 
12 
2 
36 
inner 
77 
< 0.3 
< 0.3 
-
< 0.3 
< 0.3 
< 0.3 
sleeve 
protectors 
< 7 
< 7 
< 7 
< 3d 
10 
< 0.3 
< 0.3 
< 0.3 
-
0.6 
0.3 
0.4 
masks 
< 
< 
< 
< 
< 
< 
< 
< 
3 
_c 
-
-
3 
0.2 
0.2 
-
0.2 
0.2 
0.2 
0.2 
urine 
ndb 
nd 
nd 
nd 
0.7 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
only in the second study double pair of gloves were used 
nd: not detectable (different limits of detection depending on the urine volume) 
-, no sample taken (masks/sleeve protectors were not used) 
only one sleeve protector was collected 
only one pair of gloves was used 
The results of the wipe samples taken in the first part of this study show that 
the animal room was contaminated with CP. Frequent contamination was 
found on the balance, on the working table and on the alcohol bottle. Before 
injection of CP, the mice were weighed on the working table. It is well known 
that mice urinate when they are seized. CP may be present in urine of CP-
treated mice. The cages and the mice could be contaminated from previous CP 
administration, which possibly resulted in contamination of the different 
subjects and surfaces including the gloves. CP contamination was found on 
the alcohol bottle which was used frequently. This contamination could have 
resulted from contact with contaminated gloves. The results of the wipe 
samples also show that CP contamination was not only found in the animal 
room but also in adjacent rooms. In the stationary air samples, no CP was 
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detected, possibly because the volume sucked was too low. Nevertheless, it 
could be possible that small particulates were elevated from the cages that 
could be suspended in the air. Only in one urine sample (animal keeper 1) CP 
was detected. In spite of the use of protective clothes, gloves, sleeve 
protectors and masks, it is not clear whether the uptake occurred via 
inhalation, skin contact, or both. Ingestion is less probable because it was not 
allowed to take food or drinks. 
In the first study, some spread out of CP contamination was found. Therefore, 
it was interesting to know if CP could be measured on other spots eg, in the 
corridor, the sluice, and in the central hall. Therefore, in the second part of the 
study, wipe samples were taken from these places. The results show that, not 
only in the animal room and in the corridor, but also in the sluice and in the 
central hall, CP contamination could be detected. Although the plastic foil on 
the working table became contaminated, the amounts of CP on the working 
table were diminished in comparison with the first observations. It is 
remarkable that the levels of CP in background samples were consistently 
higher. This may be caused by cumulation from the past in combination with 
bad routine cleaning. It may also be expected that, after informing the animal 
keepers about the results of the first study, they became more aware of the 
risks they may face. Therefore, they may have worked more properly during 
the second study, which resulted in lower environmental contamination. To 
check if CP could be measured in the air of the animal room, the filters of the 
air-circulation system were analyzed for CP. From the amounts measured it 
could be concluded that CP was present. Although the amount of air sampled 
could not be calculated, these amounts are supposed to be higher in 
comparison with the amounts of air sucked in the first study. CP 
contamination was found on the outer pair of gloves. The amounts measured 
are comparable with the amounts found in the first study. Except for the first 
sample, it is suggested that CP did not penetrate the outer gloves since no 
contamination was found on the inner ones. Taking the first sample, some 
complications with the collection of the gloves could have resulted in contact 
of the inner gloves with the outer ones. During the administration of CP, half 
of the sleeve protectors became contaminated. In comparison with the first 
study, this might be due to a lower detection limit. Despite the increase in 
sensitivity, CP could not be detected on the masks. 
In the first study, CP was measured in urine of animal keeper 1. It is 
suggested that antineoplastic agents like CP are absorbed by inhalation and 
dermal penetration during preparation and administration of these drugs by 
pharmacy technicians and nurses.810 Although the occupational activities in 
this study differ from the activities of hospital personnel, CP is able to 
penetrate the human skin.9 This could be due to an inefficient protection by 
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gloves.11"14. In general, the degree of permeability appeared to be small, but 
lower permeability was found for gloves with higher thickness. The working 
period of animal keeper 1 was about 1.5 hours. Although the concentration of 
CP in the air was not measured during this working period (day 7), inhalatory 
uptake can be estimated by using the air concentration on day 1 (inhalatory 
uptake = air concentration χ respiratory volume χ working period χ retention 
= < 1.0 pg/m3 χ 10 m3/8 hours χ 1.5 hours χ 100% = < 1.9 //g). The 
amount of CP excreted as percentage of the inhalatory uptake is > 3 7 (0.7 
ug/<1.9 μg). Since a protective mask was used, it is expected that the real 
uptake will be lower. This percentage is much higher in comparison with 
animal studies and in studies with volunteers who received a low dose of CP. 
In animal studies were CP was dosed at 1 mg/kg, an excretion percentage of 5 
was found.1 5 After application of 1 mg on the skin of volunteers, about 1% 
was excreted unchanged in urine. These results do not agree with our 
estimation. When an equal percentage was excreted in our study, the uptake 
should be about 10 times higher. Therefore, we suggest that not inhalation, 
but dermal penetration, is the main exposure route. 
Conclusion 
In this study, it is shown that during the administration of CP to mice, in spite 
of certain safety precautions, CP contamination occurred. CP was found in 
urine of one of the animal keepers. The study demonstrates that animal 
keepers in this particular case are exposed to the chemical with wich they are 
working. Animal keepers may have contact with many different toxic 
chemicals. Knowledge about their possible exposure is lacking because of the 
absence of possibilities to measure exposure. The methods applied in this 
study seem suitable for the control of exposure to CP. 
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Abstract 
In the Netherlands, special guidelines and safety precautions were introduced 
about 10 y ago for preparation and administration of antineoplastic agents. 
However, little is known about the effectiveness of these measures. In this 
study, occupational exposure to antineoplastic agents of nine pharmacy 
technicians who were involved in drug preparation was investigated. 
Cyclophosphamide, 5-fluorouracil and methotrexate accounted for 95% of the 
antineoplastic agents prepared; therefore, the presence of these compounds 
was monitored. During preparation, cyclophosphamide was detected in the air 
of the work environment (<0.04-10.1 //g/m3). Contamination of and 
permeation through the latex gloves used were found for each of the three 
compounds. The uptake of cyclophosphamide was assessed by the 
determination of cyclophosphamide in urine. The drug was found in urine 
samples of six pharmacy technicians, including three persons who were not 
directly involved in the preparation of cyclophosphamide. The amounts 
excreted ranged from 0.2 to 19.4 //g/24h. The results strongly suggest that 
inhalation is of minor importance for internal exposure, compared with other, 
presumably dermal, routes. 
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Introduction 
During the handling of antineoplastic agents, pharmacy technicians and 
nursing personnel may face certain health risks1; therefore, special guidelines 
and extensive safety precautions have been introduced in the Netherlands2,3 If 
the efficiency of these measures is to be studied, it is neccessary to monitor 
exposure levels and the possible uptake of these compounds by workers. 
Recently, we reported studies in which cyclophosphamide (CP), 5-fluorouracil 
(5FU), and methotrexate (MTX) contamination was detected in the work 
environment, and CP and iphosphamide (IP) were found in urine of nurses, 
pharmacy technicians,4,6 and animal keepers.8 
In this follow-up study, we were interested in whether CP, 5FU, and MTX 
were absorbed by inhalation or by dermal penetration. Personal and stationary 
air samples were taken during drug preparation in a hospital pharmacy 
department. Previous studies have shown that gloves used for protection 
during drug preparation become contaminated.4,5 Other studies have 
demonstrated that some antineoplastic agents can permeate different types of 
gloves.7"10 We investigated whether CP, 5FU, and MTX were able to permeate 
latex gloves usually worn during normal occupational activities, particularly 
during the preparation of the drugs. Uptake was determined by analysis of 
unmetabolized CP in urine. 
Materials and methods 
Study design 
Samples were taken on 17 alternate d (Monday, Wednesday, and Friday) 
during 6 wk of drug preparation. Nine pharmacy technicians (eight women and 
one man; 22-35 y of age) were involved in the preparation; eight of these 
technicians had prepared drugs twice during this study. The drugs were 
prepared in a laminar downflow hood. Gloves, hair nets, and special clothes 
were worn for personal protection. Surgical face masks were worn by only 
one technician (no. 1). 
The amounts of CP, 5FU and MTX prepared during this study were 14.55, 
62.8, and 6.16 g, respectively. These compounds accounted for 95% of all 
antineoplastic agents prepared. For CP and MTX, vials with different amounts 
of drug were used. 5FU was packed in standard ampules of 250 mg. 
Air sampling 
During preparation of the drugs, stationary air samples were taken 
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approximately 30 cm from the technician and from the laminar downflow 
hood. Total airborne particulate matter was collected on polytetrafluoro-
ethylene filters with 50-mm diameter and 1.0-//m pore size (Sartorius GmbH, 
Göttingen, Germany). The diameter of the cone was 20 mm, and the suction 
flow of the high volume sampler was about 23.5 l/min. 
Personal air samples were taken with PAS-6. Total airborne particulate matter 
was collected on polytetrafluoroethylene filters that were 37-mm diameter and 
had a pore size of 1.2-/ym. The suction flow was 2.0 l/min. 
Glove contamination 
One pair of white surgical gloves (style 42, Smith and Nephew Medical, Ohio, 
USA) was worn by each technician on each day of drug preparation. On the 
third day, however, one glove worn by one technician was torn and an 
additional one was used. 
The permeation of the latex gloves used during preparation was determined by 
wearing cotton gloves (Laméris, Utrecht, the Netherlands) under the latex 
gloves. Except for technician 2, all technicians wore these cotton gloves on 
one occassion. After preparation of the drugs, the latex and the cotton gloves 
were collected separately. The cotton gloves were extracted and analyzed in 
the same manner as were the latex gloves.5 
Urine sampling 
Total 24-h urine was collected in portions, starting from the beginning of the 
drug preparation. Urine volumes and excretion periods were registered. Urine 
samples were stored at -20°C until sample preparation. Urine from three 
individuals employed in an administrative department served as nonexposed 
controls. The limit of detection was about 0.2 ng/ml urine. 
Sampling procedures, sample preparation, and analysis 
Sampling procedures, sample preparation, and analysis have been described 
elsewhere.4,5 
Statistical analysis 
Statistical analysis was carried out with SAS software version 6.06. 
Correlation was quantified with Spearman's rank correlation coefficient; ρ 
values refer to two-tailed tests. Half of the detection limit was used for 
nondetectable amounts. 
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Results 
Air samples 
No 5FU or MTS was detected on the stationary air sample filters. CP was only 
found on day 1 (Table 1). The limits of detection, depending on the amounts 
of the air sampled, ranged from 0.003 to 0.03 //g/m3 for CP, from 0.2 to 2.2 
//g/m3 for 5FU, and from 0.5 to 5.4 //g/m3 for MTX. 
During personal sampling, CP was found on 4 d (Table 1). On day 8, CP was 
not prepared; 5FU and MTX were absent. The detection limits ranged from 
0.04 to 0.5 //g/m3 for CP, from 2.6 to 35 //g/m3 for 5FU, and from 6.3 to 84 
//g/m3 for MTX. 
Table 1. Stationary and personal air sampling of CP. 
monitor type/day 
stationary 
1 
2-17 
personal 
7 
8 
12 
16 
others 
technician 
7 
1-9 
1 
9 
4 
8 
1-9 
sampli ng time (mm) 
36 
8-80 
64 
9 
49 
37 
6-80 
/ /g/m3 
0.2 
< 0.03 
1.6 
10.1 
1.0 
2.1 
< 0.5 
" 5FU and MTX were not detected 
Glove contamination 
Contamination of the latex and the cotton gloves was found frequently for 
5FU and CP (Table 2). Both compounds were also present on the gloves when 
5FU and CP were not prepared. MTX contamination of the latex gloves was 
found twice. In one case, it was also present on the cotton gloves. MTX was 
prepared during both days. The results show that CP, 5FU, and MTX can 
permeate the latex gloves. There is a correlation between the amounts of 5FU 
(on weight basis and number of ampules) prepared and the total (latex and 
cotton) glove contamination (r = 0.68, p<0.005). No correlation was found for 
CP and MTX. 
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Table 2. Contamination with CP, 5FU, and MTX of gloves used during drug 
preparation fpg/pair). 
CP 5FU MTX 
tech-
day rucian latex cotton latex cotton latex cotton 
1 
2 
3" 
4 
5 
6 
7 
8 
9 
1 0 
11 
12 
1 3 
1 4 
15 
16 
17 
7 
9 
8 
6 
2 
6 
1 
9 
3 
5 
3 
4 
1 
4 
5 
8 
7 
< 
< 
< 
< 
< 
< 
< 
< 
< 
9.6 
5.6 
1.5 
9.4 
0.08 
0.08 
0.08 
0.08 
6.3 
0.08 
0.08 
2.9 
0.08 
0.08 
2.3 
0.08 
2.1 
ns· 
ns 
ns 
ns 
ns 
15 
ns 
< 0.08 
ns 
ns 
< 0.08 
ns 
14 
73 
4 0 
0.5 
< 0.08 
6 9 
< 4.0 
1 9 0 
1 4 0 
21 
< 4.0 
2 0 0 
5 8 
2 6 
7 8 
< 4.0 
2 4 0 
< 4.0 
6 2 0 
9 2 
< 4.0 
< 4.0 
ns 
ns 
ns 
ns 
ns 
< 4.2 
ns 
< 4.2 
ns 
ns 
< 4.2 
ns 
2 9 0 
4 5 0 
7 6 0 
1 3 0 
153 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
2 0 
2 0 
2 0 
2 0 
2 0 
2 0 
2 0 
2 0 
2 0 
2 0 
2 0 
2 0 
2 0 
1900 
2 2 0 
< 
< 
2 0 
2 0 
ns 
ns 
ns 
ns 
ns 
< 11 
ns 
< 11 
ns 
ns 
< 11 
ns 
< 11 
6 3 
< 11 
< 11 
< 11 
* ns: no sampling (cotton gloves were not used) 
ь
 tearing caused individual to use 3 gloves instead of one pair 
CP in urine 
CP was detected in the urine of five technicians (Table 3). The amounts 
excreted ranged from 0.2 to 19.4 pg (median = 0.6 pg). CP was found in the 
urine of technicians who did (n = 4) and who did not (n = 3) prepare CP. CP 
was present in the urine of technicians after the drugs were prepared with 
(n = 3) and without (n = 5) wearing the cotton gloves. No CP was detected in 
the urine of four technicians or the control urine samples. 
Inasmuch as successive urine fractions were collected and analyzed, excretion 
of CP could be measured during the period of 24 h after the beginning of the 
preparation of the drugs. The cumulative CP excretion of the technicians who 
did and who did not prepare CP is presented in Figures 1 and 2, respectively. 
The figures show that for all workers, the excretion of CP started at different 
moments. CP was present mostly in successive fractions. 
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Table 3. Cumulative CP excretion (μς/24 h) in relation to the amounts of 
CP in the air and the amounts of CP prepared. 
С Ρ (μφ 
amount of CP 
day technician prepared (mg) air* urine 
9 
1 
9 
3 
5 
4 
1 
4 
8 
0 
1200 
0 
1350 
0 
650 
2100 
0 
3000 
< 0.07 
2.2 
1.9 
< 0.07 
< 0.07 
1.0 
< 0.07 
< 0.07 
1.6 
1.5 
19.4 
1.5 
0.5 
0.4 
0.3 
0.7 
0.2 
nd" 
• calculated amount of CP "inhaled" during preparation 
ь
 nd: not detected 
Discussion 
In contrast to our previously mentioned studies, CP was detected also in air 
samples. This is surprising because the laminar downflow hood should not 
only protect the drugs prepared, but should also protect the technicians 
against inhalation of aerosols of released drugs. Release of aerosols of CP was 
also demonstrated by the presence of CP on two surgical face masks (4.3 and 
350 μg•, data not shown). 
Sometimes the latex gloves were contaminated with a particular drug even 
though the drug was not prepared. This finding suggests that the 
contamination was already present. CP, 5FU, and MTX can permeate the latex 
gloves because these drugs were detected on the cotton gloves. In the normal 
work situation (without cotton gloves), this could result in dermal penetration, 
which was found to be the case for CP after application on the skin of 
volunteers by Hirst et al.1 1 
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cumulative CP excretion (pg) 
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time (hr) 
Fig. 1 Cumulative CP excretion of technicians preparing antineoplastic agents including CP Time 
was set at 0 when the preparation of the drugs started. (Note technician 1 * • , technician 3 - A, 
and technician 4 - 4 ) 
cumulative CP excretion (pg) 
2 η 
1.5 
0.5 
j · · - - · -
- ¥ Φ Ψ <•%'*" 
0 2 4 6 8 10 12 14 16 18 20 22 24 
time (hr) 
Fig. 2. Cumulative CP excretion of technicians prepanng antineoplastic agents except for CP Time 
was set at 0 when the preparation of the drugs started {Note technician 4 a • , technician s - •, 
and technician 9 - · ) 
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The contamination of the cotton gloves, as percentage of the total 
contamination of both gloves, varied from 0% to 3% for MTX and from 0% to 
100% for 5FU and CP. This suggests a low permeation for MTX and a high, 
but variable permeation for CP and 5FU. A reason for the difference in MTX 
permeation, compared with 5FU and CP might be the higher molecular weight 
and the polarity of MTX, both of which might prevent a quick permeation of 
the glove. 
Another important factor is the time during which the gloves were worn 
because permeation increases with time.8"10 Protection by latex gloves is 
afforded as long as no breakthrough is observed. The breakthrough time is 
defined as the time on which detectable amounts permeated the latex gloves 
and were found on the cotton gloves. With respect to CP, 5FU, and MTX, the 
earliest breakthrough times were 10, 37, and 62 min, respectively. These 
breakthrough times are much shorter than those reported by Colligan et al.1 0 
This might be caused by the lower detection limit of our analytical methods. 
Another reason might be that our model did not resemble the laboratory 
situation. In our study, it remains unknown what the influence of the cotton 
gloves was upon the permeation (rate) because "suction" could influence 
permeation, and flexing and stretching occurred when the latex gloves were 
used in combination with the cotton gloves. Nevertheless, according to 
Colligan et al.,1 1 these effects should be negligible under laboratory conditions. 
It is remarkable that a correlation between the amounts of drugs prepared and 
the contamination of the gloves (latex plus cotton) was found for 5FU only. 
No such correlations were observed for CP and MTX. 5FU was packed in 
ampules, which had to be broken, and every break might have caused the 
release of some drug. The more 5FU prepared, the more (standard) ampules 
were broken, thereby releasing more 5FU. Vials with septa were used for MTX 
and CP, and for every amount used only one action was necessary. 
The amounts of CP excreted in urine were higher, compared with results of 
previous studies.4,5 In one study, no CP was detected.4 In another study, the 
amounts ranged from < 0.01 to 0.5 μg (median = 0.1 //g).5 In the present 
study, CP was present in the urine of technicians who did not prepare CP, 
which suggests environmental sources responsible for the uptake of this 
compound. In the previous studies, only in one or two urine fractions of one 
person was CP detected. In the present study, CP was present in more 
successive fractions or it was measured during different intervals, which 
resulted in higher total amounts excreted. 
It is suggested that during occupational activities, CP is absorbed by inhalation 
or dermal penetration.11"13 A quick excretion is ascribed to inhalation. On the 
other hand, dermal absorption will result in a postponed and slower excretion 
because of the skin barrier. The large differences in excretion patterns of 
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several technicians suggest that both exposure routes contribute to the 
occupational exposure of these workers. Nevertheless, it cannot be excluded 
that interindividual differences in toxicokinetic parameters also play a role. 
The amounts of CP "inhaled" during drug preparation were calculated (Table 
3). In these calculations, the concentration of CP in the air (Table 1) was 
multiplied by the sampling time (Table 1), a respiration volume of 10m3/8 h 
and a retention of 100%. The results show that the amounts of CP inhaled 
were generally lower when compared with the amounts of CP excreted. Also, 
as a result of biotransformation, it is expected that the amounts excreted are 
approximately 1-5% of the applied dose, which was found in CP-treated 
volunteers11 and in CP-treated rats.14 
The results show that the amounts of CP in urine cannot be explained by 
assuming inhalation to be the only exposure route. Instead, the results suggest 
that other exposure routes, in addition to inhalation, are involved. Whether this 
is dermal penetration remains unknown. However, the combination of easy 
permeation of CP through the latex gloves and the possibility of skin 
penetration make it reasonable to assume that dermal uptake is an important 
exposure route. 
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Abstract 
Special guidelines and protective measures have been introduced to protect 
hospital workers during the handling of antineoplastic agents. Nevertheless, it 
was found that they do not prevent the uptake of these toxic compounds. 
Therefore in this Dutch hospital additional protective measures have been 
introduced. The measures included adaptations of the laminar downflow hood, 
the use of special masks and double pairs of gloves by the workers and the 
replacement of ampules in vials. The effects of these additional measures were 
compared with the results of a previous study. As cyclophosphamide (CP), 5-
fluorouracil (5FU), and methotrexate (MTX) comprised 8 1 % of the 
antineoplastic agents prepared, these compounds were monitored again by 
personal air-sampling and the determination of contamination of masks and 
gloves. Biological monitoring was performed by the determination of CP in 
urine of the workers. During preparation, lower concentrations of CP in the air 
were observed in comparison with our previous study. Replacement of 
ampules by vials (5FU) resulted in a significantly diminished contamination of 
the latex gloves with 5FU. CP was detected in urine samples of six of nine 
technicians. The maximum amount excreted over five days was 2.6 μg. The 
mean CP excretion per day was not significantly lower, than in the previous 
study (0.16 μ§ and 1.44 μg respectively). In spite of an intensified hygienic 
regimen, exposure to antineoplastic agents can not be reduced as long as the 
reasons for the exposure are unknown. 
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Introduction 
In The Netherlands new special guidelines and protective measures were 
introduced about 10 years ago to protect hospital workers for the health risks 
of handling of antineoplastic agents.1 Recently, these measures were 
amended.2 Other countries also have protective guidelines.3"6 Nevertheless, 
several studies have shown uptake of antineoplastic agents in hospital workers 
following guidelines.7"15 
Our recent study of the effectiveness of the protective measures showed that 
during preparation, cyclophosphamide (CP) was detected in the air of the 
working environment at concentrations of < 0.04-10.1 //g/m3.7 Contamination 
of, and permeation through latex gloves were found for the three drugs 
studied: CP, 5-fluorouracil (5FU) and methotrexate (MTX). In addition, CP was 
detected in urine samples of some workers. The results showed that although 
protective measures were taken, exposure to these compounds still occurred. 
More strongly, the protective measures were not able to prevent the uptake of 
CP. It was suggested that inhalation was of minor importance for internal 
exposure, compared with other, presumably dermal, routes. 
These results led in this particular hospital to the introduction of additional 
protective measures. The working aperture of the laminar downflow hood was 
reduced by enlargement of the viewing screen. It was also decided that the 
pharmacy technicians should use double pairs of gloves and a special mask. 
Besides, vials with 5FU were used for preparation instead of ampules. In a 
follow-up study, the effects of these additional measures were investigated. 
Personal air-samples were taken and analyzed for the presence of CP, 5FU and 
MTX. Permeation of latex gloves was studied by analyzing the contamination 
of both the inner and the outer gloves. The uptake of CP was determined by 
analysis of unmetabolized CP in urine.16 The results of this study were 
compared with the results of the previous study. 
Materials and methods 
Study design 
Nine pharmacy technicians were involved in drug preparation. Eight of them 
were also involved in the previous study.7 Their codes were the same. The 
drugs were prepared in a laminar downflow hood during five successive days 
(Monday to Friday). For personal protection, latex gloves, hair-nets and special 
clothes were used. In contrast with the previous study, all technicians used a 
double pair of gloves and a special mask. The technicians were aware of the 
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new study design and monitoring. Any possible effect on behaviors is not 
expected because they continued working on the same way. The amounts of 
CP, 5FU and MTX prepared during this study were 24, 195, and 5 g, 
respectively (Table 1). These compounds contributed to 8 1 % of the 
antineoplastic agents prepared. CP, 5FU and MTX were packed in vials. 
Air sampling 
Personal air sampling was performed identical as described before.7 The 
samples were taken during five successive days from all nine technicians. 
Masks 
The masks (Filgif, super sigma 5005-V mask, Groeneveld-Dordrecht B.V., 
Dordrecht, The Netherlands) were collected after drug preparation in such a 
way that no contamination with other materials like for instance the gloves 
was possible. They were packed in aluminum foil until sample preparation. 
Glove contamination 
During all days the technicians wore double pairs of gloves (Ansell Gammex 
latex sterile surgical gloves, Ansell Medical, München, Germany). After 
preparation of the drugs the pairs of gloves were collected separately. 
Urine sampling 
Total urine was collected in portions during five days starting at the beginning 
of the preparation of the drugs. The urine volumes and the excretion periods 
were registered. The urine samples were stored at -20°C until sample 
preparation. 
Sampling procedures, sample preparation and analysis 
Sampling procedures, sample preparation and analysis were described 
elsewhere.B'9,16 The masks were cut in pieces and extracted by sonication 
during 90 min and subsequent shaking during 10 min with 250 ml of a 0.03 M 
sodium hydroxide solution. The extracts were used for direct analysis (5FU 
and MTX) or further clean up (CP). 
Statistical analysis 
Statistical analysis was carried out with SAS software version 6.06. 
Correlation was quantified with Spearman's rank correlation coefficient; ρ 
values refer to two tailed tests. Only ρ values equal to or below 0.05 were 
considered to be significant. Half of the detection limit was used in case of 
non-detectable amounts. 
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Table 1. Amounts of CP, 5FU and MTX prepared (mg)3 
technician day CP 5FU MTX 
10 
Mon 
Tue 
Wed 
Thu 
Fri 
Mon 
Tue 
Wed 
Thu 
Fri 
Mon 
Tue 
Wed 
Thu 
Fri 
Mon 
Tue 
Wed 
Thu 
Fri 
Mon 
Tue 
Wed 
Thu 
Fri 
Mon 
Tue 
Wed 
Thu 
Fri 
Mon 
Tue 
Wed 
Thu 
Fri 
Mon 
Tue 
Wed 
Thu 
Fri 
Mon 
Tue 
Wed 
Thu 
Fri 
900 
6 5 0 
0 
0 
0 
1250 
1000 
500 
0 
0 
600 
600 
0 
600 
0 
1200 
0 
1150 
6 0 0 
0 
1000 
650 
550 
900 
0 
0 
1200 
0 
0 
0 
2 5 0 
9 0 0 
4 0 0 
0 
0 
6 5 0 
3 0 0 0 
0 
4 0 0 
1200 
1000 
350 
1600 
9 0 0 
300 
2600 
1100 
38000 
0 
1000 
1100 
0 
0 
25000 
0 
4500 
0 
1600 
0 
25900 
19900 
4950 
0 
0 
900 
5900 
0 
0 
900 
17900 
4800 
0 
0 
0 
1500 
800 
1100 
0 
0 
500 
800 
900 
0 
25000 
900 
6700 
0 
0 
900 
0 
0 
0 
0 
75 
30 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
30 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
15 
0 
0 
0 
75 
60 
0 
0 
4910 
0 
0 
0 
0 
0 
75 
30 
total 
percentage" 
2 4 3 0 0 
9 
1 9 5 1 5 0 
70 
5 3 0 0 
2 
* as perentage of all antineoplastic drugs prepared 
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Results 
Air samples 
On the filters of the personal air samples no 5FU and MTX were detected. CP 
was found on two days. The air concentrations were calculated to be 0.06 
(technician 2 on Wednesday) and 2.0 μg/π\3 (Technician 8 on Tuesday). On 
both days CP was prepared. The limits of detection, depending on the 
amounts of air sampled, ranged from 0.02-0.15 //g/m3 for CP, 1.6-9,9 ¿ug/m3 
for 5FU and 3.8-24 ¿/g/m3 for MTX. 
Masks 
Ten out of forty five masks were contaminated with CP (Table 2). The 
amounts ranged from <0.2-8.8 /yg. CP was present on two masks whereas it 
was not prepared. The level of contamination was not correlated with the 
amount of drug prepared and the number of vials used. One mask was 
contaminated with 15 μg 5FU while no masks were contaminated with MTX. 
No drugs were detected on masks of five technicians. The limits of detection 
per mask were 0.2 μg for CP, 5 μο, for 5FU and 13 μg for MTX. 
Table 2. Contamination with CP and 5FU of masks used during drug 
preparation3. 
contamination (/yg) 
technician day 
CP 5FU 
Mon 
Tue 
Wed 
Mon 
Thu 
Fri 
Mon 
Tue 
Thu 
Tue 
Fri 
5.5 
2.2 
<0.2 
0.20 
0.28 
8.8 
2.0 
1.8 
1.8 
6.2 
5.7 
< 5 
< 5 
15 
< 5 
< 5 
< 5 
< 5 
< 5 
< 5 
< 5 
< 5 
* only masks with detectable amounts of one of the drugs measured are indicated 
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Glove contamination 
Contamination of the outer pairs of latex gloves was found most frequently for 
CP (twenty six pairs of gloves) and 5FU (nine pairs of gloves) (Table 3). The 
amounts ranged from <0.13-140 μg (median: 1.2 //g) for CP and from <2.0-
450 дд (median: < 2 μ§) for 5FU. One outer pair of gloves was contaminated 
with 94 μg MTX (Technician 9 on Wednesday). 5FU was present on one outer 
pair of gloves when no preparation of 5FU occurred. For CP this was observed 
for three pairs of gloves. The level of contamination of the outer pairs of 
gloves was significantly correlated with the amount of drugs prepared (CP: 
r = 0.60, ρ = 0.0001; 5FU: r = 0.32, ρ = 0.03) and the number of vials used 
(CP: r = 0.63, p = 0.0001; 5FU: r = 0.47, p = 0.001). Contamination of the inner 
pairs of latex gloves was only found for CP (seven pairs of gloves) (Table 3). 
The amounts ranged from <0.13-9.1 //g (median: <0.13 /уд). CP was found 
on one inner pair of gloves when it was not prepared. The level of 
contamination of the inner pairs of gloves was not significantly correlated with 
the amount of drugs prepared and the number of vials used. The 
contamination with 5FU of the inner latex gloves with 5FU could not be 
quantified because of interference of coeluting compounds during analysis of 
the samples. The limits of detection per pair of gloves were 0.13 /yg for CP, 2 
μ§ for 5FU and 10 μg for MTX. 
CP in urine 
CP was detected in urine samples of six technicians (Table 4). The maximum 
amount excreted over five days was 2.6 //g. All technicians prepared CP 
during at least one day (mean: three days). No correlation was found between 
the total amounts excreted over five days and the amounts of CP prepared. 
Even when the amounts of CP prepared were averaged by the number of days 
of preparation. The limit of detection was about 0.25 ng/ml urine. 
Discussion 
In a previous study CP was detected in personal air samples during four out of 
seventeen days.7 The air concentrations ranged from 0.04-10.1 //g/m3. In the 
present study CP was detected once again although less frequently (two out 
of forty five days) and the concentrations were significantly lower (Wilcoxon 
test: ρ = 0.005). Like in the previous study, also in this study no 5FU and no 
MTX was detected in personal air samples. Adaptations of the laminar 
downflow hood may be responsible for the observed decrease in CP air 
concentrations. Obviously, the release of aerosols could not be totally 
prevented which was also demonstrated by the presence of CP on the masks. 
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Table 3. Contamination with CP and 5FU of gloves used during drug 
preparation3. 
CP contamination (//g/pair) 5FU contamination (//g/pair) 
technician day 
outer gloves inner gloves outer gloves 
Mon 
Tue 
Wed 
Mon 
Tue 
Wed 
Mon 
Tue 
Thu 
Fri 
Mon 
Wed 
Thu 
Mon 
Tue 
Thu 
Fri 
Mon 
Tue 
Mon 
Tue 
Wed 
Thu 
Mon 
Tue 
Wed 
Thu 
Fri 
Mon 
Tue 
Wed 
Fri 
4.1 
3.7 
<0.13 
1.9 
<0.13 
0.37 
54 
1.7 
2.1 
<0.13 
83 
11 
5.9 
<0.13 
0.27 
30 
2.6 
<0.13 
2.9 
2.4 
2.3 
1.3 
1.2 
4.5 
70 
3.4 
5.4 
140 
0.73 
<0.13 
1.4 
1.8 
<0.13 
<0.13 
2.4 
<0.13 
<0.13 
<0.13 
<0.13 
<0.13 
<0.13 
<0.13 
1.4 
<0.13 
<0.13 
<0.13 
<0.13 
<0.13 
<0.13 
<0.13 
<0.13 
1.3 
<0.13 
1.5 
<0.13 
<0.13 
<0.13 
<0.13 
3.2 
9.1 
<0.13 
1.3 
<0.13 
<0.13 
14 
< 2 
9. 
< 2 
26 
< 2 
< 2 
< 2 
< 2 
4 5 0 
12 
< 2 
< 2 
38 
< 2 
< 2 
200 
37 
< 2 
< 2 
< 2 
< 2 
< 2 
< 2 
< 2 
< 2 
< 2 
17 
< 2 
< 2 
< 2 
< 2 
' only gloves with detectable amounts of one of the cytostatic drugs measured are indicated 
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Table 4. Cumulative CP excretion in urine of pharmacy technicians and the 
amounts of CP prepared. 
technician CP prepared (mg) CP in urine (/yg/five days) 
1550 
2750 
1800 
2950 
3100 
1200 
1550 
5250 
4150 
24300 
0.6 
nd" 
nd 
2.1 
0.2 
nd 
0.6 
1.1 
2.6 
7.2 
* nd: not detected 
MTX was not detected on the masks whereas the presence of 5FU was 
observed once after the preparation of a large amount of 21000 mg of 5FU. 
In both the present and the previous study contamination with MTX of the 
outer latex gloves was hardly observed. In the present study it was found 
once when a large amount of 4910 mg of MTX was prepared. In the previous 
study contamination with 5FU of the outer latex gloves was found during 
eleven out of seventeen days (range: < 4.0-620 pg) whereas in the present 
study 5FU contamination was observed during nine out of forty five days 
(range: <2.0-450 pg). Both, the frequency of contaminated outer gloves 
(Fisher's exact test ρ = 0.04) and the level of contamination (Wilcoxon test 
ρ = 0.001) were significantly decreased. Whether the diminished contamination 
of the outer gloves with 5FU was due to the use of vials instead of ampules 
needs further investigation. Possibly the breaking of ampules is a cause for the 
release of aerosols resulting in contamination of the gloves.7 
During the previous study contamination with CP of the outer latex gloves was 
found during eight out of seventeen days (range: <0.08-9.6 pg).7 During the 
present study contamination with CP was observed during twenty six out of 
forty five days (range: <0.13-140 pg). No significant differences were found 
between the frequency of contaminated outer gloves and the level of 
contamination in the present and the previous study. Considering an important 
role for the breaking of ampules, this is not surprising because in both studies 
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vials were used for CP preparation. In the previous study cotton gloves were 
worn under the latex gloves to study the permeation through the latex gloves 
for CP, 5FU and MTX. In the present study the cotton gloves were replaced by 
latex gloves identical to those used as outer gloves. Also in the present study, 
permeation through the outer latex gloves was found. In the previous study 
five out of eight pairs of cotton gloves were contaminated with CP (range: 
<0.08-73 //g). From four of these contaminated pairs of cotton gloves the 
corresponding outer pairs of latex gloves were not contaminated with CP 
suggesting 100% permeation of CP. In the present study CP was detected on 
seven out of forty five inner pairs of latex gloves (range: <2-9.1 //g). No CP 
was found on the corresponding outer pairs of latex gloves from two of these 
contaminated pairs of gloves. No correlation was found between the level of 
contamination on the inner latex gloves and the amount of CP prepared or the 
number of vials used. However, the sum of the amounts of CP contaminated 
on the outer and the inner latex gloves was significantly correlated with the 
amount of CP prepared (r = 0.56, ρ = 0.0001) and the number of vials used 
(r = 0.60, ρ = 0.0001). The level of CP contamination on the inner latex gloves 
was significantly diminished in the present study when compared to the 
previous study (Wilcoxon test ρ = 0.02). Because no difference was observed 
between both studies concerning the frequency of contaminated outer gloves 
and the level of contamination with CP, it is plausible to suggest that the 
diminished contamination was caused by the use of latex gloves as inner 
gloves. 
In the previous study in 24 hr urine samples of five out of nine workers CP 
was detected.7 In the present study in urine samples of six out of nine workers 
CP was found, although it should be noticed that these samples were 
collected over a longer period (five days versus one or two days). Mean 
amounts of CP per day were calculated and the results were compared with 
the mean amounts of CP per day calculated from the previous study. A 
decrease from 1.44 to 0.16 //g in mean CP excretion per day was found. 
Although the difference is big, it is not significant (paired Wilcoxon test). 
The results show that the introduced additional protective measures have 
reduced the external exposure to CP and 5FU. MTX was hardly measured 
which is possibly due to a higher detection limit of the analytical method. To 
what extent each of the additional protective measures has reduced this 
decrease, remains unknown. Nevertheless, it is shown that the contamination 
of the latex gloves is reduced possibly due to the use of vials instead of 
ampules. Besides, the results of the filters of the personal air samples show 
that at this moment CP, 5FU and MTX were hardly found in the air of the 
working environment. It is a question whether the use of double pairs of latex 
gloves has diminished the permeation of CP. It is possible that the 
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contamination with CP was decreased due to permeation of CP through the 
inner pairs of latex gloves. This might have resulted in skin contact and hence 
absorption. 
The final aim of this study was to investigate whether these additional 
protective measures have reduced the uptake of CP. It should be noticed that 
a 90% reduction in exposure levels is important even if not significant. There 
might be several reasons for the absence of significancy between both studies 
concerning the amounts of CP in urine. The absence of significance is probably 
caused by large S.D.'s due to large interindividual differences; even the 
individual values of the workers were paired between both studies. Absence of 
significance is probably also a consequence of the small group of workers 
(n = 8). In addition there is no reason to expect high correlations with external 
dose when wide coefficients of variation for low exposure levels are observed. 
Nevertheless, the amounts of CP excreted in urine in this study are more 
comparable with the results of urinary CP excretion in previous published 
studies dealing with other groups hospital pharmacy workers who are working 
under situations with comparable protective measures.917 
The question whether exposure can be reduced by reducing use is a difficult 
one. Normally, it is reasonable to assume a possitive correlation between use 
and exposure. It is a question to what extent diminished use will result in 
diminished exposure because it is not clear at all how exposure takes place. 
The presence of environmental contamination may result in chronic exposure. 
We expect that diminished use will not reduce the environmental 
contamination at that moment present in the working area. The results of this 
study indicate that in spite of efforts in a hygienic regimen exposure to 
antineoplastic agents can not be reduced. Only when we exactly are aware of 
the relationship between sources of exposure, distribution and absorption, we 
may be able to reduce the level of exposure to antineoplastic agents any 
further. 
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Abstract 
The exposure of pharmaceutical plant workers, involved in drug compounding 
and drug production, to 5-fluorouracil (5FU) was studied. 5FU was found by 
the analysis of air and wipe samples. During weighing, 5FU was detected in 
the air (75 ¿/g/m3). 5FU was also present on the filter of the mask of the 
weigher (120 //g). Before drug compounding 5FU was found on the floor 
(range, <1 to 8 ng/cm2; median, 2 ng/cm2). After routine cleaning significant 
higher amounts of 5FU were measured (range, 70 to 630 ng/cm2; median, 150 
/уд/cm2; Ρ = 0.02). The amounts of 5FU present on several objects were lower 
when compared to the amounts on the floor. The gloves used were always 
contaminated (range, 22 to 720 дд/раіг of gloves; median, 141 ¿/g/pair of 
gloves). The uptake of 5FU was established by the determination of σ-fluoro-ß-
alanine (FBAL), the main metabolite of 5FU, in the urine of the workers. Fifty 
micrograms of FBAL were found in urine of the weigher. 
Introduction 
In the Netherlands, 5-fluorouracil (5FU) is the most frequently used 
antineoplastic agent for parenteral administration. Its annual use over 1986 to 
1988 was about 35 kg.1 5FU belongs to the group of the antimetabolites. The 
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results of an animal study for assessing the possible carcinogenicity of 5FU 
were considered to be inadequate.24 Neither chromosome aberrations nor 
sister chromatid exchanges were induced in peripheral blood lymphocytes of 
patients treated with 5FU. 5FU induced micronuclei but not specific locus 
mutations in mice treated in vivo. It induced aneuploidy, chromosomal 
aberrations and sister chromatid exchanges in cultured Chinese hamster cells. 
It did not induce sex-linked recessive lethal mutations in Drosophila, but 
caused genetic crossing-over in fungi. Studies in bacteria were inconclusive. 
5FU is found to be embryotoxic in animals. 
5FU is quickly metabolized in rodents and man.2 After reduction in the liver, 
ring opening resulted in the formation of ammonia, carbon dioxide, urea, σ-
fluoro-ß-alanine (FBAL) and fluoride. In a patient treated with 5FU, about 80% 
of the dose is quickly excreted in urine as FBAL.5 
For measuring occupational exposure to antineoplastic agents different 
methods have been developed in our laboratory which are now validated in 
practice.6"8 In the present study, environmental monitoring was carried out by 
taking air samples followed by the analysis of the samples for the presence of 
5FU. To establish the uptake of 5FU in workers occupational^ exposed to this 
compound, only compound specific detection methods can be used since 5FU 
is not mutagenic and cytogenetic effects are negligible.24 Because it is 
expected that the exposure to 5FU will be low (because of safety precautions) 
and 5FU is quickly metabolized, it is reasonable to assume that the amounts of 
5FU in urine are too low to be detectable. Therefore, a chemical analytical 
procedure for the detection of FBAL in urine was developed. Until now only 
high amounts of FBAL (1 mg/L) could be detected in patients using 19F-nuclear 
magnetic resonance.5 For low amounts this method may not be suitable. 
Therefore a new sensitive method was developed. After derivatization with S-
ethyltrifluorothioacetate and acidified η-butyl alcohol, FBAL was determined 
using gas chromatography/mass spectrometry (GC-MS).10 This GC-MS 
method, in combination with the environmental analysis of 5FU (air and wipe 
samples of possibly contaminated surfaces and objects, contamination of the 
gloves and the filters of the masks), was validated in a pharmaceutical plant 
where workers compound and produce 5FU. 
Materials and methods 
Manufacturing process 
In the pharmaceutical plant, the manufacturing process of 5FU was subdivided 
into two steps: 1) drug compounding and 2) drug production, which took 
place during two successive days in different overpressure rooms. During drug 
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compounding (day 1) about 3.5 kg of 5FU was taken out of a barrel, weighed, 
and mixed in a reactor with water, sodium chloride, and sodium hydroxide. 
After that, the solution was pumped via a filter from the drug compounding 
room to the aseptic production room where the vials were filled (day 2). Two 
workers were involved in drug compounding (day 1): a weigher and a 
controller. The weigher weighed the chemicals, including 5FU, and the 
controller managed the compounding process. During drug compounding, 
special protective clothes were worn. A hair net was used and the shoes were 
covered. Gloves and masks with special filters were worn from the moment 
5FU was weighed. Three workers were involved in drug production (day 2): a 
controller (same person as on day 1 ), an operator, and a packer. The controller 
coupled the barrel with the filtered solution to the production machine which 
filled the vials. The operator runned the production process and cleaned the 
machine when vials were broken. The controller and the packer removed the 
broken vials from the machine. The packer placed the sealed vials in boxes. 
Also during drug production special protective clothes, gloves and boots were 
worn. Except for the eyes, the faces of the workers were totally covered. 
Air sampling 
During drug compounding (about 3 hours), a stationary air sample was taken 
with a high volume sampler which was placed near the balance.11 Total 
airborne particulate matter was collected on a cellulose filter with 47 mm 
diameter and 1.0 μπ\ pore size (type RC 60, Schleicher & Schuell, 's-
Hertogenbosch, The Netherlands). Air (8.9 m3) was sampled (sampling rate, 
50 L/min). The limit of detection was about 0.2 //g/m3. 
During weighing of 5FU (about 1 hour), personal air samples were taken with 
PAS-6.12 Total airborne particulate matter was collected on polytetraethylene 
filters with 37 mm diameter and 1.2 //m pore size (Sartorius GmbH, Göttingen, 
Germany). Air (120 L) was sampled (2.0 L/min, 1.25 m/sec). The limit of 
detection was about 15 ¿fg/m3. 
Wipe sampling 
Wipe samples were taken from the floor of the drug compounding room before 
the beginning of the drug compounding process and after routine cleaning. 
The wipe samples were taken from the floor beneath and in front of the 
balance and in the center and beneath the sink unit. In the corridor, which 
connected the sluice with the drug compounding room, an additional sample 
was taken. 
Wipe samples were also taken from different objects which were placed in the 
drug compounding room like the balance, including the table and the screen, 
the lid of the waste bin, and the latch of the door between the drug 
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compounding room and the sluice. The detection limit for the wipe samples 
was 3.5 pg. 
Gloves and mask filters 
The two filters of the masks worn during drug compounding (about 1 hour) 
were analyzed for contamination with 5FU. The limit of detection was 7 
^g/fi Iter. 
A single pair of gloves (Ansell non-powdered sterile latex hypoallergenic 
surgeon's gloves, Ansell Medical, Munich, Germany) were worn during drug 
compounding and during drug production. During drug compounding, the 
weigher and the controller wore two single pairs of gloves. During drug 
production, the controller used three gloves (because of tearing, an additional 
one was used). The operator and the packer wore two single pairs of gloves. 
Both gloves of each pair were collected together. The limit of detection was 
14 //g/pair of gloves. 
Urine sampling 
Total urine was collected in portions during the period of about 24 hours 
starting from the beginning of the working day. The amounts excreted and the 
excretion periods were registered. The urine samples were stored at -20°C 
until sample preparation. 
Chemicals 
5FU (purity >99%) was obtained from Janssen Chimica (Beerse, Belgium) and 
FBAL (purity >99%) was purchased from Interchim (Montluçon, France). S-
Ethyltrifluorothioacetate (purity >99%) was obtained from Sigma Chemical 
Company (St Louis, MO). All other chemicals were of the highest purity 
obtainable. 
Sampling procedures, sample preparation and HPLC analysis of 5FU 
Sampling procedures, sample preparation and HPLC analysis of 5FU in air- and 
wipe samples and on the gloves were performed according to Sessink et al.6"9 
For the filters of the masks, the same procedures were followed as for the 
gloves. The limit of detection for 5FU was about 65 pg/L extract. 
GC-MS analysis of FBAL in urine 
Sample preparation and derivatization 
One milliter of urine and 100 μΙ of a 5 mol/L sodium hydroxide solution were 
combined in tubes with screw caps. After addition of 150 μ\ of S-
ethyltrifluorothioacetate, the tubes were tightly closed and shaken for 5 hours 
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at room temperature.10 One hundred microliters of concentrated hydrochloric 
acid were added and the solution was mixed. The samples were extracted 
twice with 3 mL of ethylacetate. The combined ethylacetate layers were dried 
under nitrogen at 50°C. After addition of 0.5 mL of freshly prepared acidified 
η-butyl alcohol (250 μ\- of acetylchloride in 5 mL of η-butyl alcohol) and 
subsequent mixing, the tubes were closed for butylation for 1 hour at 90°C. 
The samples were cooled down to room temperature and dried under nitrogen 
at 40°C. After that, 250 /Л. of toluene were added and vials were filled with 
sample and stored at -20°C until analysis. 
GC-MS conditions 
GC-MS analysis was performed on a Varían Saturn GC-MS system controlled 
by a Compaq 386-20e personal computer. The on-column injection mode was 
used (SPI: Septum equipped temperature Programmable Injector). A 30-m DB-
5 column (J & W Scientific, Folsom, CA) was used with 0.25-mm internal 
diameter and 0.25-μητ) film thickness. The column was connected with a 
deactivated fused silica retention gap (Varían, Houten, The Netherlands) with a 
length of 5 m and an internal diameter of 0.53 mm. The initial injector 
temperature was 110°C. After 1 minute the temperature was increased by 
180°C/min to 280°C. After 15 minutes at 280°C the temperature was 
decreased to the initial temperature by cooling with liquid carbon dioxide. The 
initial oven temperature was 110°C. After 1 minute, the temperature was 
increased by 75°C/min to 140°C, and thereafter by 20°C/min to 280°C, 
where it remained constant for 7 minutes. Helium was used as carrier gas 
(column inlet pressure, 14 psi). The interface temperature was 280°C and 
electron impact was used as ionization mode. Identification was carried out by 
the combination of full scan spectra (50-399 atomic mass units) and the 
retention time of derivatized FBAL, which was 5.0 minutes. 
Quantification was performed on the selected ion fragment 186, which was 
abstracted from the full scan spectra. For quantification the peak area of 
derivatized FBAL was calculated. Quantification of the butylated trifluoroacetyl 
derivative of FBAL was carried out by reference to calibration curves 
constructed from the analysis of freshly prepared reference urine samples 
containing FBAL. Linearity was found until at least 50 mg/L (r>.99). The limit 
of detection was about 60 ng/mL urine (signal:noise ratio>4). 
Results 
Sample preparation, derivatization and GC-MS analysis of FBAL 
We have developed an efficient and quick method to carry out the clean-up 
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procedure routinely. FBAL is acetylated with S-ethyltrifluorothioacetate under 
basic conditions.10 After acidification, the dried extracts were derivatized with 
freshly prepared acidified η-butyl alcohol. The described procedure is rather 
simple and suitable for routine analysis. 
The mass spectrum of derivatized FBAL (Fig. 1) is in concordance with the 
mass spectrum of its analog ß-alanine as reported by Leimer et al.13 For 
quantification it was not possible to use the molecule fragment 259 because 
this fragment is not stable under electron impact conditions, consequently, a 
low relative intensity was observed. The high relative intensity in combination 
with a general high specificity for the higher ion fragments resulted in the 
choice of ion fragment 186 for the quantification of FBAL. 
Fig. 1. Mass spectral fragmentation of N-trifluoroacetyl-n-butyl ester of 
FBAL 
1ВВУ. 5 7 
INT 
О о 
Il II 
CFjf С -ΗΝ -СН 2 т CHF - C r 0-гС4Н9 
69 126-
M W = 259 
•186 57 
1Θ6 
2B4 
26β 
•^ т^т^і м- і 
2B1 311327 355 
•IB ¿θ ββ 1ΒΘ 12β 14Β 1Ь8 10Β 2ββ 22β 24β 26Θ 2Ββ Э в Э2В Э4В 36β 3ββ 4ββ 
Development and validation of monitoring methods 109 
Manufacturing process 
5FU was not detected in the stationary air sample (<0.2 //g/m3). In the 
personal sample of the weigher, 5FU was present (75 /;g/m3). In the personal 
sample of the controller, no 5FU was detected (<15 //g/m3). 
Before the beginning of drug compounding, low amounts of 5FU were 
detected on the floor of the drug compounding room (Table 1). It is remarkable 
that the amounts of 5FU after routine cleaning were significantly higher than 
before drug compounding (P = 0.02, Mann-Whitney U test). The highest 
amounts were found beneath the balance. Outside the drug compounding 
room, low amounts of 5FU were detected on the floor in the corridor. The 
different objects studied were also contaminated with 5FU, although the 
amounts were lower when compared to the amounts measured on the floor 
(Table 2). On the filter of the mask of the weigher, 120 /yg 5FU were detected. 
No 5FU was found on the filter of the mask of the controller ( < 7 pg). During 
all activities the gloves of all workers became contaminated with 5FU (Table 
3). 
In one urine fraction of the weigher (780 ml_), 50 pg of FBAL were detected 
that was excreted during the period of 10 to 13.75 hours after the start of 
weighing 5FU (Fig. 2). In the urine fractions of the controller, operator, and 
packer no FBAL was detected ( < 6 0 ng/mL). 
Table 1. Contamination of the floor of the drug compounding room with 
5FU (ng/cm2). 
floor description (cm χ cm) before drug compounding after routine cleaning' 
beneath the balance (70 χ 50) 2 4 9 0 
beneath the balance (80 χ 50) 2 6 3 0 
in front of the balance (80 χ 60) 8 1 1 0 
in front of the balance (80 χ 80) 3 1 5 0 
in the center (1 3 0 χ 30) < 1 7 0 
beneath the sink unit (95 χ 50) 5 0 nsb 
beneath the sink unit (95 χ 50) < 1 ns 
corridor (80 χ 60) 2 < 2 
statistically different from before drug compounding (P = 0 . 0 2 , Mann-Whitney U test) 
ns, no sampling 
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Table 2. Contamination of the objects in the drug compounding room with 
5FU fag). 
object before drug compounding after routine cleaning 
balance table nd* 
inside balancescreen (left) 11 
inside balancescreen (right) nd 
balance ns 
lid of the waste-bin ns 
latch door between compounding room and sluice ns 
22 
ns" 
ns 
5 0 
50 
ns 
" nd, not detected ( < 3.5 /yg) 
'' ns, no sampling 
Table 3. Contamination of the gloves with 5FU (цд/раіг of gloves). 
day worker activit ies glove contamination 
weigher weighing, drug mix ing, room cleaning 3 0 0 
f i l trat ion, room cleaning 22 
controller running drug compounding process, room cleaning 6 4 
f i l t rat ion, room cleaning 141 
controller coupling barrel to the production machine, 
removing broken vials 720° 
removing broken vials nsb 
operator running production machine, machine cleaning 2 5 0 
running production machine, machine cleaning 4 5 
packer packing vials 4 4 
removing broken vials 145 
because of tearing three gloves were used instead of one pair 
the second pair of gloves was not sampled 
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Fig. 2. Total ion chromatogram (M= 186) of the urine sample of the 
weigher containing FBAL. 
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Discussion 
This study shows that the workers were exposed to 5FU during the 
manufacturing process During drug compounding, the workers were mainly 
exposed to 5FU aerosols They were released during the manually unloading of 
the barrel to weigh the drug The release of 5FU was confirmed by the 
presence of 5FU on the filter of the mask, on the gloves, and in the air During 
the drug production process, the workers were potentially exposed to 5FU in 
solution, mainly due to broken vials The release resulted in contamination of 
the latex gloves. Because the latex gloves were regularly rinsed with alcohol 
(disinfection), the amounts detected should be regarded as an 
underestimation. 
Before drug compounding, 5FU was detected on the floor and on several 
objects which were placed in the drug compounding room It is unclear what 
happened during cleaning, it seems as though transposition of 5FU residues 
had occurred 
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The presence of FBAL in one urine fraction of the weigher shows that 5FU 
was really absorbed. How the uptake did happen is not known. The presence 
of 5FU in the air and a non-effectively protective mask could explain the 
inhalatory uptake. However, dermal absorption would also be possible. In 
laboratory studies and in practice, it is shown that most latex gloves do not 
fully protect against skin uptake. Permeation was found for several 
antineoplastic agents including 5FU.9-14"16 Despite the regular contact of the 
gloves wi th 5FU in solution, no FBAL was detected in the urine of the workers 
involved in drug production. 
FBAL was excreted during the period of 10 to 13.75 hours after the beginning 
of weighing of 5FU. FBAL appeared later in urine of the worker when 
compared with a patient to whom 5FU was administered by rapid bolus 
intravenous injection.5 We think that the delayed excretion of FBAL by the 
weigher was due to a slow skin absorption process which was out of order for 
the patient. 
Conclus ion 
In the past, in situations with exposure to 5FU during occupational activities 
ie, drug preparation in hospital pharmacies, only the presence of 5FU in the air 
was established.1718 No methods were available to determine the uptake of 
5FU by the workers. The method for the determination of FBAL in urine seems 
suitable for measuring the uptake of 5FU. 
Appendix 
Introduction 
El ionisation wi th the reconstructed (m/z = 186) ion chromatogram is specific 
for FBAL. However, specificity is increased by using MSMS. Thereto, the 
parent ion mass m/z = 186 is stored in the ion-trap and further split in a so-
called daughter ion wi th m/z = 158 which is very specific for FBAL. This new 
application has resulted in some changes in the method which are briefly 
discussed below. 
Gas chromatographic-mass spectrometric analysis 
The samples were analysed on a Varian Saturn 4D GC/MS/MS ion-trap system 
with a Varian 8200 autosampler, which was controlled by a Compaq Prolinea 
4/50 personal computer (software version 5.2). The initial injector temperature 
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was 110°C. After 1 min, the temperature was increased by 90°C/min to 
280°С After 3 min at 280°C, the temperature was decreased to the initial 
temperature by cooling with compressed air. The initial oven temperature was 
110°C. After 1 min, the temperature was increased by 7.5°C/min to 290°C, 
where it remained constant for 7 min. The interface temperature was 290°C. 
Daughter-ion m/z = 158 was produced at an excitation amplitude of 27V 
(nonresonant) and an excitation RF of 300 dac. Quantification was performed 
on the daughter ion mass т/г = 158. 
Results and discussion 
MSMS mass spectra of the parent ion mass m/z = 186 of derivatized FBAL is 
shown in Fig. 3. High relative intensity was found for daughter ion mass 
m/z = 158. Fig. 4 shows the reconstructed (m/z = 186) ion chromatogram of a 
blank urine sample spiked with FBAL (76.2 μg/\ urine) obtained by El and a 
chromatogram of the daughter ion mass m/z = 158 of the same sample 
obtained by MSMS. It is shown that the daughter ion mass m/z = 158 obtained 
by MSMS further increased the specificity and the selectivity of the method. 
The retention time of derivatized FBAL is 5.5 min. The limit of detection is 
approximately 6 ng/ml urine (signahnoise ratio > 3). 
Fig. 3. MSMS mass spectra of the parent ion mass m/z-186 of 
derivatized FBAL. 
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Reconstructed (m/z 186) ion chromatogram of a blank urine 
sample spiked with FBAL (76.2 цд/І urine! and a chromatogram of 
the daughter ion mass m/z= 158 of the same sample obtained by 
MSMS. 
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Summary 
The exposure of 11 pharmaceutical plant workers to methotrexate (MTX) was 
studied. Personal air samples were taken during the different manufacturing 
processes: drug compounding, vial filling, and tablet preparation. The uptake 
of MTX was established by the determination of MTX in urine. MTX was 
analyzed using the fluorescence polarization immunoassay (FPIA), a method 
that is frequently used for monitoring serum levels in patients treated with 
MTX. The FPIA method was modified in such a way that MTX could be 
measured quickly and efficiently in air and urine samples. MTX was detected 
in air samples of all workers except for those involved in the vial filling process 
(range: 0.8-182 /jg/m3; median: 10 //g/m3). The highest concentrations were 
observed for workers weighing MTX (118 and 182 //g/m3). MTX was detected 
in urine samples of all workers. The mean cumulative MTX excretion over 72-
96 h was 13.4 μ§ MTX-equivalents (range: 6.1-24 μg MTX-equivalents). A 
significantly lower background level of 10.2 //g MTX-equivalents was 
measured in urine of 30 control persons (range: 4.9-21 /yg MTX-equivalents). 
Introduction 
Methotrexate (MTX) has been widely used in oncochemotherapy [1] and in the 
treatment of other nonneoplastic diseases such as psoriasis [5], rheumatoid 
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arthritis [6], and steroid-dependent asthma [9]. MTX primarily inhibits the 
enzyme dihydrofolate reductase. Consequently, DNA and RNA synthesis is 
decreased [1]. MTX is a teratogen and causes a variety of malformations in 
humans and animals [7,8]. Cytogenetic effects like sister chromatid exchanges 
and chromosomal aberrations have been observed in patients. MTX has been 
associated in case reports with a variety of subsequent neoplasms [7,8,11]. 
Toxic side-effects have been observed in patients [1]. In order to avoid or 
control these effects, serum MTX levels have been monitored. 
Several assays for measuring MTX concentrations in biological fluids of 
patients have been reported [16]. Among these assays the enzyme-multiplied 
immunoassay technique (EMIT) and the fluorescence polarization immunoassay 
(FPIA) are the most widely used [10]. Both methods are rapid and sensitive 
and no interference from other matrix compounds is observed. For MTX the 
FPIA method is preferable for levels below 0.2 μΜ because of technical errors 
in the EMIT assay. Monitoring methods for the detection of occupational 
exposure to MTX are not reported in the literature. 
MTX, although metabolized at all doses used in therapy, was almost 
completely excreted in urine [3,12]. In order to measure low levels of MTX in 
urine, which might be expected after occupational exposure, the FPIA method 
was adapted since it was primarily developed for analysis of high MTX levels 
in serum without sample pretreatment [10]. The FPIA method adapted for the 
analysis of MTX in urine was also used for the determination of MTX in air 
samples and was validated in a pharmaceutical plant where workers 
compound and produce MTX in vials and tablets. 
Materials and methods 
Manufacturing process and subjects 
MTX was manufactured by two different processes: (1) drug compounding 
followed by aseptic vial filling and (2) drug compounding followed by tablet 
preparation. The first process took place in two different rooms (the drug 
compounding room and the aseptic production room). The various activities of 
the workers are indicated in Table 1. 
Four workers were involved in drug compounding (weighing and mixing). 
Special protective clothes, a hair-net and sterile latex gloves were worn and 
the shoes were covered. Airstream helmets were only used when MTX was 
weighed. 
Five workers were involved in aseptic vial filling. Special protective clothes, 
sterile latex gloves, and special boots were worn. Except for the eyes, the 
faces of the workers were totally covered. 
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Two workers were involved in drug compounding (weighing, mixing, and 
drying of the granulation mixture) and tablet preparation. Special protective 
clothes, a hair-net, sterile latex gloves, a safety mask, and special shoes were 
worn. 
A group of 30 male and female laboratory technicians were used as 
nonexposed controls. 
Air sampling 
Personal air samples were taken during the period the workers (n = 8) were 
present in the different production rooms and involved in compounding (n = 4), 
vial filling (n = 2) and compounding/tablet preparation (n = 2) of MTX. Except 
for two workers involved in compounding/tablet preparation of MTX, air 
samples were taken from all workers once. The air samples were taken during 
an overall period of 6 days. Total airborne particulate matter was collected on 
polytetraethylene filters (diameter 37 mm, pore size 1.2 μτη, Sartorius GmbH, 
Göttingen, Germany) with samplers (Dupont Alpha-1) that were equipped with 
a cone over the face (diameter 6 mm). In conjunction with a suction flow of 
2.0 I/min, a suction velocity of 1.25 m/s was produced in the face entrance 
[15]. 
Urine sampling 
Total urine was collected in portions during the period of about 72-96 h 
starting from the beginning of the working day. The amounts excreted and the 
excretion periods were registered. As soon as possible after collection, the 
urine samples were stored at -20°C until sample preparation. 
Chemicals 
MTX (Ledertrexate) was obtained from Lederle (Etten-Leur, The Netherlands). 
Reagent kits and calibrators were purchased from Abbott Diagnostics Division 
(Amstelveen, The Netherlands) and were ready for use. Sep-Рак C18 
cartridges packed with C-18 reversed phase liquid chromatography material 
were obtained from Waters (Milford, Mass., USA). All other chemicals were of 
the highest purity obtainable. 
Sample preparation and FPIA analysis of MTX 
The filters of the air samples were sonicated in a 20 ml 0.03 M sodium 
hydroxide solution. 10 ml acetate buffer (0.05 M, pH = 4.0) was added to 10 
ml sample (urine or filter extract) and the pH was set at 3.9-4.0. Sep-Рак C18 
cartridges were prewashed by successive addition of 10 ml methanol and 10 
ml acetate buffer. The cartidges were loaded under low pressure with sample, 
and washed with 10 ml acetate buffer and 10 ml water. MTX was eluted 
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dropwise after addition of 6 ml methanol. After evaporation of the samples 
under nitrogen at 45°C, 2 ml blanc human plasma was added. The samples 
were mixed and incubated at 37°C for 1 h. Finally, they were stored at -20°C 
until analysis. The recovery of MTX in the air samples was about 75%. 
The samples were analyzed on a TDx analyzer (Abbott Diagnostics Division, 
Amstelveen, The Netherlands). The determination of MTX by the FPIA 
procedure was described in the Abbott TDx assays manual. In short: specific 
antibodies are used to isolate the desired analyte. In addition to the 
immunoassay reaction, FPIA incorporates three other concepts into the 
measurement of analytes, namely fluorescence, rotation of molecules in 
solution and polarized light. Methodology and applications of FPIA have been 
reviewed [2]. 
In order to evaluate the intra-assay precision of the assay, blank urine samples 
of five persons were spiked to a final plasma concentration of 0.28 μΜ MTX. 
Four portions of each sample were cleaned up and analyzed separately. The 
intra-assay precision ranged from 0% to 3.4% (mean: 2.2%). The overall 
recovery was 98%. A quick elution with methanol resulted in a lower 
response. In spiked blank urine samples (0.056 μΜ) stored at -20°C for 8 
weeks, no loss of MTX was observed. The analytical limit of detection for 
MTX is 0.01 μΜ. Because background fluorescence levels might be present, 
urine samples of 30 nonexposed control persons were analyzed. The mean 
background level found corresponded with 10.2 //g MTX-equivalents (range: 
4.9-21 MTX-equivalents). In air samples no background levels were observed. 
Statistical analysis 
Statistical analysis was carried out on a personal computer using InStat 1.1 as 
software package. A Ρ value < 0.05 was considered to be of statistical 
significance. 
Results 
Air samples 
MTX was detected in air samples of all workers except for those involved in 
the vial filling process (Table 1). The highest air concentrations were observed 
for the workers who compound MTX, among whom workers 2 and 3 weighed 
MTX and were highly exposed. Lower air concentrations were found for the 
workers involved in the drug compounding/tablet preparation process. The 
limit of detection was about 0.07 /;g/m3. 
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Table 1. Personal air sampling of MTX1. 
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process worker sampling 
time (mm) 
M T X 
l/yg/m3) 
drug compounding 
vial filling 
drug compounding/tablet preparation 
1 
2 
3 
4 
5 
6 
7 
8 
9 
1 0 
11 
210 
306 
135 
205 
ns" 
ns 
ns 
180 
180 
47 
150 
35 
90 
95 
0.8 
182 
117 
46 
ndc 
nd 
13 
1 6 
10 
5.4 
2.6 
* on blank filters M T X was not detected ( < 0 . 0 3 //g) 
ь
 ns, no sampling 
c
 nd, not detected ( < 0 . 0 7 /yg/m3) 
Urine samples 
The results of the urinary MTX excretion of the workers are presented in Table 
2. Because background fluorescence levels might be present in the urine 
samples, the amounts of MTX are expressed in MTX-equivalents. For the 
workers involved in drug compounding, the cumulative excretion over 72 h 
ranged from 6.4-18 pg MTX-equivalents. In urine samples of all workers 
involved in the vial filling process, the cumulative MTX excretion over 72 h 
ranged from 8.7-21 pg MTX-equivalents. The cumulative 96-h excretion was 
6.1 and 24 pg MTX-equivalents for the two workers involved in 
compounding/tablet preparation. The mean urinary MTX excretion of the total 
group was 13.4 pg MTX-equivalents. This was significantly higher than the 
urinary MTX excretion of 10.2 pg MTX-equivalents of 30 control persons (P = 
0.0078, two-tailed t-test). When the three groups were considered separately, 
significantly higher levels of MTX-equivalents were only found for the group of 
four workers involved in drug compounding (P = 0.0207, two-tailed t-test). 
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Table 2. Urinary excretion of MTX. 
process worker MTX-equivalents (//g) 
drug compounding 1 
2 
3 
4 
7.8 
6.4 
13 
18 
vial filling 21 
13 
20 
8.7 
9.5 
drug compounding/tablet preparation 10 
11 
24 
6.1 
Discussion 
The results of the analysis of the air samples show release of MTX during the 
drug compounding and the drug compounding/tablet preparation process. The 
highest air concentrations were observed for the workers weighing MTX. 
Lower air concentrations were detected for the workers involved in drug 
compounding/tablet preparation. During both processes MTX was used as a 
powder. After dissolution in water, no detectable amounts of MTX were 
observed in the air (vial filling process). It was somewhat surprising that only 
low amounts of MTX were found during the drug compounding/tablet 
preparation process because of the expected release of MTX during sifting of 
the granulation mixture. 
Urine analysis shows that, although protective measures were taken, the 
uptake of MTX was significantly higher for the total group of workers when 
compared with the nonexposed controls. When the three groups were 
considered separately, significantly higher MTX levels were only found for the 
group of workers involved in drug compounding. It is striking that these 
workers also showed the highest air concentrations of MTX. 
In addition to the inhalation route, dermal and oral uptake (finger-shunt effect) 
cannot be excluded. Although the workers used protective latex gloves, it is 
known that MTX permeates some of such gloves [4,13,14]. Also the use of 
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several additives like sodium hydroxide and alcohol for cleaning purposes 
could influence permeation and penetration resulting in uptake of MTX by skin. 
In summary, several factors might influence the excretion of MTX observed for 
the workers, The data on excretion of MTX do not permit the development of 
a kinetic model in the case of occupational exposure to this drug. This could 
be helpfull in the development of a simple biomonitoring method. 
Nevertheless, the presented FPIA method may be a feasible tool for the 
detection of MTX in air and urine samples of workers occupationally exposed 
to MTX, but this has to be proven in a larger study. 
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Abstract 
In this study we have compared the results of a method for the detection of 
cyclophosphamide in urine and the results of analysis of chromosomal 
aberrations in peripheral blood lymphocytes of four groups of subjects with 
various exposure statuses. These groups are 17 Dutch and 11 Czech exposed 
workers (mainly hospital nurses and pharmacy technicians) handling 
antineoplastic agents and 35 Dutch and 23 Czech controls (nurses, medical 
doctors, pharmacy and lab technicians) not handling these drugs. The groups 
were subdivided into smokers and non-smokers because of a confounding 
effect of smoking. 
Within the Dutch groups, the percentage of aberrant cells and the number of 
breaks per cell were increased for smokers compared to non-smokers. The 
percentage of aberrant cells was increased in Dutch exposed workers in 
comparison with Dutch control workers. Within the Czech groups the 
percentage of aberrant cells and the number of breaks per cell were increased 
in exposed workers in comparison with control workers. However, both Dutch 
and Czech smokers mainly contributed to the increase. The results suggest an 
additive effect of exposure and smoking in the Dutch subjects and a more than 
additive effect in the Czech subjects. 
In urine samples of three out of 11 Dutch exposed workers cyclophosphamide 
was found in a range of 0.1-0.5 yug/24 h. Higher levels were detected in the 
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urine of eight out of 11 Czech exposed workers, a range of 0.1-2.9 /yg/24 h. 
No correlation was observed between the amounts of cyclophosphamide 
excreted in urine on the one hand and the percentage of aberrant cells and the 
number of breaks per cell on the other hand. 
The present study is the first study showing that hospital workers having an 
increase in chromosome aberrations related to their work are exposed to at 
least one antineoplastic agent. 
Introduction 
Many antineoplastic agents are carcinogenic, mutagenic and teratogenic in 
laboratory animals (IARC, 1981). Some antineoplastic agents are human 
carcinogens since for instance secondary tumors were found in patients 
treated with these drugs (Schmähl and Kaldor, 1986). It is not known whether 
persons occupationally involved in the synthesis, formulation, preparation, and 
administration of these drugs are at risk. Therefore, special guidelines and 
safety precautions were introduced to protect workers from contact with these 
toxic compounds (ASHP, 1990; Integrale Kankercentra, 1992). 
Several biomonitoring methods for the detection of occupational exposure to 
antineoplastic agents have been developed and validated. Methods like the 
determination of mutagenicity and thioethers in urine and cytogenetic methods 
like the analysis of chromosomal aberrations (CA), sister-chromatid exchanges 
and micronuclei in peripheral blood lymphocytes have been used frequently 
(for reviews see Sorsa et al., 1985; Kaijser et al., 1990). Methods for the 
detection of specific antineoplastic agents or their metabolites in urine of 
exposed workers have been developed for cyclophosphamide (CP) (Hirst et al., 
1984; Evelo et al., 1986; Sessink et al., 1992, 1993a,b, 1994b), cis-platinum 
(Venitt et al., 1984), ifosfamide (Sessink et al., 1992b) and 5-fluorouracil 
(Sessink et al., 1994a). 
In this study we have compared the results of a method for the detection of 
CP in urine with the results of analysis of CA in peripheral blood lymphocytes 
for four groups of subjects with various exposure statuses. These groups were 
Dutch and Czech exposed workers handling antineoplastic agents and Dutch 
and Czech controls not handling these drugs. The aim of this study was to 
discuss the usefulness of the two methods with respect to the possibility of 
biomonitoring occupational exposure to antineoplastic agents. 
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Materials and methods 
Subjects 
Four groups were studied: 
-17 Dutch hospital nurses and pharmacy technicians involved in the 
preparation and administration of antineoplastic agents; 
-35 Dutch control pharmacy technicians working in regular pharmacies and not 
handling antineoplastic agents; 
-11 Czech cleaning women, nurses and a lab technician involved in the 
administration and preparation of antineoplastic agents, all working in the 
same department of a hospital; 
-23 Czech control nurses, medical doctors, lab technicians and a cleaning 
woman not handling antineoplastic agents. 
Sex, age, profession, exposure period, smoking habits, alcohol use, diseases, 
medicine use, inoculation and exposure to chemicals and X-rays were 
investigated by means of a questionnaire. The characteristics of the groups are 
shown in Table 1. Most of the workers handling antineoplastic agents wore 
gloves, masks and special clothes. The drugs were prepared in laminar down-
flow hoods. The amounts of the drugs prepared and administered and the 
periods of handling were registered. In addition to CP, ifosfamide, cis-platinum, 
5-fluorouracil, methotrexate, cytarabine, doxorubicin, etoposide, vinblastine 
and vincristine were most frequently prepared and administered. 
Chromosome aberrations in blood lymphocytes 
Peripheral blood samples were taken by venous puncture. The blood was 
collected in vacuum tubes containing heparin. The blood samples were coded, 
cooled at 4-10°C and immediately sent to the laboratory in Prague for the 
determination of CA. Sample preparation has been described elsewhere 
(Pohlová et al., 1986). The culture was incubated at 37°C for 50 h. One 
hundred metaphases were examined for each worker. Chromosome and 
chromatid breaks and exchanges (dicentrics, rings, translocations) were 
counted and the percentage of aberrant cells (%AB.C) and the number of 
breaks per cell (B/C) were calculated. 
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Cyclophosphamide in urine 
Total 24-h urine was collected in portions starting from the end of the 
preparation/administration of the drugs No urine samples were taken from the 
Dutch controls because previous studies had demonstrated that CP could not 
be detected in Dutch persons not exposed to antineoplastic agents. From the 
Czech control group urine samples were taken starting at the end of the 
working day. The amounts of urine excreted and the excretion periods were 
registered. The urine samples were coded and stored at -20°C until sample 
preparation. After preparation by liquid-liquid extraction with diethylether 
anddenvatization with trifluoracetic anhydride, the coded urine samples were 
analyzed using gas chromatography-mass spectrometry. The limit of detection 
was about 0 25 ng/ml urine. Details about sample preparation and analysis 
have been described elsewhere (Sessink et al., 1992b, 1993b). 
Statistical analysis 
Statistical analysis was carried out using SAS software version 6.07. Two-
way analysis of variance (SAS procedure GLM) was used to study influence of 
exposure and smoking. Only P-values equal to or below 0.05 were considered 
to be significant. 
Results 
Chromosome aberrations in blood lymphocytes 
The results of the analysis of CA in the peripheral blood samples are presented 
in Table 2. Only comparisons within the Dutch and within the Czech groups 
were taken into account because it was expected that more or less country-
specific confounders could introduce differences between the groups. The 
groups were subdivided into smokers and non-smokers because confounding 
due to smoking was also expected. 
Within the Dutch groups, the percentage of aberrant cells (%AB C) and the 
number of breaks per cell (В/О were increased for smokers compared to non-
smokers. The %AB.C was increased in Dutch exposed workers in comparison 
with Dutch control workers. Within the Czech groups the %AB.C and the 
number of B/C were increased in exposed workers in comparison with control 
workers. However, both Dutch and Czech smokers mainly contributed to the 
increase. Dutch and Czech exposed smokers showed the highest %AB.C and 
number of B/C in comparison with their corresponding exposed and control 
non-smokers and smoking controls. The results suggest an additive effect of 
exposure and smoking in the Dutch subjects and a more than additive effect in 
the Czech subjects. 
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Cyclophosphamide in urine 
In the Dutch exposed group 79 urine samples were analyzed from 11 out of 
17 workers (Sessink et al., 1992b). In three urine samples from three workers 
CP was detected. The amounts were 0.1 and 0.5 /vg/24 h (non-smokers) and 
0.3jt/g/24 h (smoker). 
The results of the Czech exposed groups are presented in Table 3. Sixty-eight 
urine samples of 11 workers were analyzed. In 35 samples of eight workers 
CP was detected in a range of 0.1-2.9 //g/24 h. CP was found in the urine of 
workers who were (n = 7) and who were not (n = 2) directly involved in the 
preparation or administration of CP. In the urine of smokers (n = 3) and non-
smokers (n = 5) CP was present. Even in the urine of a cleaning woman 
involved in the clearing of cytostatic waste after the administration of these 
drugs, CP was detected. In the Czech control group 147 urine samples were 
analyzed. In one sample obtained from a cleaning woman 0.3 /yg CP was 
found. No correlation was observed between on the one hand the amounts of 
CP excreted in urine and on the other hand the %AB.C and the number of B/C 
in the exposed workers. 
Table 3. Cumulative CP excretion (μς/24 h) of Czech exposed workers in 
relation to profession, smoking habits and handling antineoplastic 
agents. 
worker/profession handling antineoplastic agents (±CP)° smoking habitsb CP in 2 4 h urine 
nurse administration (-CP) 
nurse preparation (-CP) 
nurse preparation and administration ( + CP) 
nurse preparation and administration ( + CP) 
nurse preparation and administration ( + CP) 
nurse preparation and administration ( + CP) 
nurse preparation and administration ( + CP) 
nurse preparation and administration ( + СР) 
lab technician preparation and administration ( + CP) 
cleaning woman waste clearing after administration ( + CP) 
cleaning woman waste clearing after administration ( + СР) 
(-СР), without CP; ( + CP), including CP 
number of cigarettes/day 
nd, not detected 
10 
0 
10 
10 
10 
0 
0 
0 
0 
10 
10 
ndc 
0.3 
nd 
1.4 
2.9 
0.2 
0.9 
2.4 
0.5 
0.1 
nd 
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Discussion 
Cytogenetic methods like the analysis of CA in blood lymphocytes have been 
frequently used for the biological (effect) monitoring of occupational exposure 
to antineoplastic agents. Results of these studies were different in nature. 
Sometimes an increase in CA was found in exposed workers compared to 
controls (Waskvik et al., 1981; Nikula et al., 1984; Pohlová et al., 1986; 
Oestreicher et al., 1990; Milkovic-Kraus and Horvat, 1991; Grummt et al., 
1993). More frequently, no differences between exposed and control workers 
were observed (Kolmodin-Hedman et al., 1983; Stiller et al., 1983; Stucker et 
al., 1986; Benhamou et al., 1988; Sorsa et al., 1988; Krepinsky et al., 1990; 
Sarto et al., 1990; Cooke et al., 1991). The different results might be 
explained by variable levels of exposure, the epidemiological approach and 
technical problems in sample preparation and analysis (Grummt et al., 1993; 
Oestreicher et al., 1990). 
The analysis of CA should be considered only at a group level to indicate 
exposure to genotoxic agents like antineoplastic agents. Matched control 
groups were used because of possible confounders like age, sex, smoking and 
exposure to X-rays and chemicals. When no matched groups were used, the 
groups were subdivided depending on the confounder in question. In some 
studies this was done for smoking. However, no correlation was found 
between smoking habits and CA (Waskvik et al., 1981; Pohlová et al., 1986; 
Grummt et al., 1993) or not enough smokers participated in the study 
(Benhamou et al., 1988). Finally, none of these studies gave exposure data of 
specific antineoplastic agents. 
Our results indicate that the influence of exposure to antineoplastic agents 
was only observed within the Czech group when exposed workers were 
compared to controls (Table 2). However, when the groups were subdivided 
into smokers and non-smokers, an influence of exposure on the %AB.C and 
the number of B/C was only found for smokers. Within the Dutch groups, the 
%AB.C and the number of B/C were increased for smokers compared to non-
smokers and for exposed workers compared to control workers. About the 
mechanism one may speculate. In the past, it has also been described that 
smoking had a synergistic action on the appearance of mutagens in the urine 
after exposure to antineoplastic agents (Bos et al., 1982; Breed et al., 1986). 
In both studies a significant increase in biologically active mutagenic 
metabolites (no bioactivation was needed) was found in urine of smoking 
nurses handling antineoplastic agents in comparison with smoking controls and 
non-smoking nurses. Two possible explanations were given. First, due to 
smoking, induction of enzymes of the mono-oxygenase system involved in the 
biotransformation of CP could be responsible, and, second, differences in 
exposure and working hygiene (a possible finger-shunt effect in smokers 
resulting in an increased oral uptake) might play a role. 
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Our results of the analysis of CP in urine show that when the Czech workers 
were handling CP (and other antineoplastic agents) this particular compound 
was absorbed. No confounding due to smoking was observed, because in 
urine of both, smokers and non-smokers, CP was detected. The presence of 
CP in one urine sample of a control cleaning woman is remarkable. How this 
might have happened is unclear. 
CP belongs to the most abundantly used genotoxic carcinogenic antineoplastic 
agents in The Netherlands. Our results suggest that urinary levels of CP up to 
2.9 //g/24 h may result in biological effects like CA in the long run. Since CA 
are considered to be indicators of an increased genetic risk, these urinary CP 
concentrations may not only show absorption of this particular antineoplastic 
drug but may also indicate a serious risk at these levels after some period of 
working, especially for smokers. 
The determination of CP in urine can be used for the detection of acute 
exposure to CP while the analysis of CA can be used for the detection of long-
term exposure to antineoplastic agents because lymphocytes carrying 
aberrations may persist for months and maybe years. The analysis of CA alone 
is not a reliable indicator of occupational exposure to genotoxic antineoplastic 
agents because many factors do influence the results of this method. 
Measurement of CA must be considered a marker of an early biological 
response. To monitor exposure the use of a sensitive analytical method like 
the determination of CP in urine seems very accurate. The detection limit of 
CP using gas chromatography-mass spectrometry is about 25 pg which makes 
it possible to detect less than nanograms of CP per ml urine (Sessink et al., 
1993b). Since procedures for preparation and administration are almost the 
same for all antineoplastic agents, the combination of the frequent use of CP 
in oncochemotherapy and the availabilty of a sensitive method for the 
determination of CP in urine makes the method suitable for monitoring 
exposure to CP in particular and possibly to antineoplastic agents in general 
(signal function). 
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Abstract 
To study the nephrotoxic effects of occupational exposure to antineoplastic 
agents, the early renal effect parameters retinol-binding protein (RBP) and 
albumin (ALB) were determined in the urine of 11 hospital workers involved in 
the preparation and administration of antineoplastic agents and in 23 hospital 
workers not involved in drug handling, who served as nonexposed controls. 
No significant difference was found between the exposed group and the 
nonexposed control group with respect to the early renal effect parameters 
RBP and ALB. Although it was demonstrated that the hospital workers were 
exposed to cyclophosphamide (CP) and probably other antineoplastic agents, 
the results of the present study show that these exposure levels did not cause 
nephrotoxic effects. 
Introduction 
Urinary proteins such as ß2-microglobulin, albumin (ALB), retinol-binding 
protein (RBP), and the urinary activity of enzymes such as alanine 
aminopeptidase, ß-galactosidase and N-acetyl-ß-D-glucosaminidase are early 
renal effect parameters that have proven useful for the early detection of 
nephrotoxicity. These parameters are widely used in occupational medicine for 
the detection of nephrotoxic effects in workers exposed to chemicals [16,35]. 
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They are also applied clinically to control nephrotoxic side-effects of drugs 
such as aminoglycosides [3] and antineoplastic agents such as cisplatin 
[2,3,6,8,9,12,14,15,19,30,32,33,35]. 
In a number of studies we have demonstrated that workers involved in the 
production, preparation and administration of antineoplastic agents are 
exposed to these drugs [5,22-29]. The uptake was assessed by the 
determination of the parent drug or metabolite in the urine of the workers. 
Large differences were found in urinary excretion of cyclophosphamide (CP) 
between several groups, suggesting variable exposure levels [5,23,24,26,28]. 
The question is whether these exposure levels will cause nephrotoxic effects 
in the workers. 
Recently, we presented the results of a study in which the urinary CP 
excretion was determined together with the analysis of chromosomal 
aberrations in peripheral blood lymphocytes of Dutch and Czech exposed and 
nonexposed hospital workers [26]. It was shown that chromosomal aberration 
frequencies were higher in the groups of exposed hospital workers than in 
their nonexposed controls. The highest amounts of CP were found in the urine 
samples of 11 Czech exposed hospital workers (0.1-2.9 /yg/24 h). For a worst-
case approach, this group and their corresponding nonexposed control group 
(n = 23) were selected for monitoring of early renal effects. Urinary ALB and 
RBP were selected as the most appropriate parameters [35]. 
Materials and methods 
Subjects 
Two groups were studied: 
11 nurses, cleaning women and a lab technician involved in the preparation 
and administration of antineoplastic agents, all working in the same 
department of a hospital; 
23 control nurses, medical doctors, lab technicians and a cleaning woman not 
handling antineoplastic agents. 
Sex, age, profession, exposure period, smoking habits, alcohol use, illnesses, 
medicine use, inoculation and exposure to chemicals and X-rays were investi-
gated by means of a questionnaire. From this, it appearred that the two groups 
were rather comparable. There were no indications that persons involved in 
this study could bring about a confounding effect. Some characteristics of the 
groups are shown in Table 1. Most of the workers handling antineoplastic 
agents used gloves, masks and special clothes. The agents were prepared in 
laminar down-flow cabinets. The amounts of the agents prepared and 
administered and the periods of handling were registered. CP, isophosphamide, 
cisplatin, 5-fluorouracil,' methotrexate, cytarabine, doxorubicin, etoposide, 
vinblastine and vincristine were most frequently prepared and administered. 
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Urine sampling and analysis 
Total 24-h urine was collected in portions starting at the end of the 
preparation/administration of the drugs. The same urine samples were used as 
in a previous study for the determination of CP [26]. Morning urine samples 
were used for analysis of RBP and ALB. Both proteins were determined by 
latex immunoassay [11] and were adjusted for dilution with the urinary 
creatinine (CREAT-U) concentration [35]. All parameters were analyzed within 
one run. The mean concentration and the duplicate precision (between 
brackets) of the determinations of the early renal effect parameters were: RBP 
126.4//g/l (9.6%); ALB 5.9 mg/l (6.4%). 
Statistical analysis 
The nonnormal distributions of the renal effect parameters ALB and RBP were 
transformed logarithmically. Differences in both parameters between the 
exposed group and the nonexposed control group were tested with Student's 
r-test. Correlations were quantified with the Pearson correlation coefficient, л 
Я-values (two-tailed) below 0.05 were considered to be of statistical 
significance. The statistical analysis were carried out on a personal computer 
using the InStat 1.1 software package. 
Results 
The mean concentrations of the renal effect parameters ALB and RBP in the 
exposed group and the nonexposed control group are presented in Table 2. No 
significant difference was observed between the two groups in the 
concentrations of these parameters. No correlation was found between the 
number of years of exposure and the urinary ALB ( r = 0 . 3 1 ; P = 0.50) or RBP 
concentration (r=0.25; P=0.59). In addition, ALB and RBP concentrations 
were not related (л = 0.33; P=0.33). The effect of smoking was also 
investigated. To this end, the exposed group and the nonexposed control 
group were subdivided into smokers and nonsmokers. Two-way analysis of 
variance (SAS General Linear Models procedure, software version 6.07) was 
used to study the influence of smoking and exposure. No significant effect of 
smoking was found upon the urinary ALB and RBP excretion. 
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Table 2. Mean concentrations of the renal effect parameters albumine 
(ALB) and retinol-binding protein (RBP) in the exposed and 
nonexposed group of Czech hospital workers. 
geometric means (range) 
parameter P' 
exposed (n = 11) nonexposed (n = 23) 
ALB (mg/mol CREAT-U) 0 .44 (0.09-2.33) 0 .30 (0.03-0.95) 0.27 
RBP (//g/mol CREAT-U) 7.9 (3.0-18.9) 8.8 (1.2-28.0) 0.71 
" two-tai led f-test 
Discussion 
Urinary renal effect parameters are widely used for the detection of early renal 
dysfunction in workers exposed to nephrotoxic chemicals such as organic 
solvents, heavy metals and silica [16,20]. In patients treated with some 
antineoplastic agents, nephrotoxic side-effects are observed 
[2,3,6,8,9,12,14,15,19,30,32, 33,35). The question is whether nephrotoxic 
effects occur in hospital workers who are occupational^ exposed to 
antineoplastic agents. Up to now, no such data have been published. 
Several studies have shown that groups of hospital workers are exposed to 
antineoplastic agents [4,5,13,17,23,24,26-29,34]. This was found by 
measurement of the parent compound or metabolites in the urine of the 
workers. Pharmacokinetic studies have shown that large amounts of 
antineoplastic agents administered to patients are excreted unchanged in their 
urine [1,7,10,21,31]. These levels are much higher than those found in the 
urine of hospital workers involved in the preparation and administration of 
these agents. However, it remains unclear to what extent chronic exposure to 
low amounts of antineoplastic agents will cause adverse health effects. In a 
previous study, we showed that occupational exposure to these drugs may 
cause genetic effects [26]. It appeared that chromosomal aberration 
frequencies in peripheral blood lymphocytes of hospital workers handling 
antineoplastic agents were increased over those in their controls. The highest 
increase was observed in the exposed smokers, suggesting an additive effect 
of exposure and smoking. Therefore, it is not impossible that these exposure 
levels may cause other health effects, such as nephrotoxicity. In order to 
detect possible nephrotoxic effects at an early stage, the excretion of urinary 
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ALB and RBP was determined. 
Recently, it was found in a large study involving 5670 people that urinary ALB 
concentrations were significantly higher in smokers than in nonsmokers [18]. 
Hence, it is reasonable to assume that smoking is a possible confounder. 
However, in our study no significant effect of smoking on urinary ALB and 
RBP excretion was found. One explanation could be that our study was 
conducted in 34 hospital workers. 
In conclusion, our results show no difference in urinary ALB and RBP excretion 
between the exposed group and the nonexposed control group of hospital 
workers. However, it should be noted that in our (pilot)study rather small 
groups were monitored. No increase in urinary RBP excretion indicates no 
tubular dysfunction. No increase in urinary ALB excretion and urinary RBP 
excretion indicates no tubular and no glomerular renal dysfunction. Although a 
previous study demonstrated that the hospital workers handling antineoplastic 
agents were exposed to one of these drugs, the results of the present study 
indicate that these exposure levels do not result in nephrotoxic effects. 
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Summary 
The urinary excretion of unmetabolized cyclophosphamide (CP) was studied in 
rats after intratracheal, dermal, oral and intravenous administration. Rats were 
given two doses of 1 mg kg'1 CP 48 h apart and urine was collected for 96 h 
after the first treatment. 
With the help of a phosphor-specific filter in a flame photometer attached to a 
gas Chromatograph, low levels of CP were determined after derivatization with 
trifluoroacetic anhydride. 
Cumulative excretion as a percentage of dose ranged from 4.0 to 6.9 after the 
first dose and 2.7 to 5.5 after the second dose. The highest rate of excretion 
after the second administration was observed in rats treated intratracheal^, 
while cumulative excretion was higher (6.9%) after the first than after the 
second (2.7%) intravenous treatment. The most prolonged excretion was 
observed after dermal application. 
Introduction 
During the last decade, much attention has been paid to the determination of 
occupational exposure to cytostatic drugs in hospitals and industry.1,2 Most 
so-called biomonitoring methods are non-selective, which means that the 
parameters measured can be influenced by more than one agent (e.g. urinary 
mutagenicity, chromosome aberrations and sister chromatid exchanges in 
blood lymphocytes).39 
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To follow the uptake of cytostatic drugs at low-level applications requires the 
development of selective and sensitive methods.10,11 This paper deals with the 
estimation of cyclophosphamide (CP), one of the most applied parenteral 
cytostatic drugs in The Netherlands during 1986-1988.12 
Inhalation and absorption through the skin are expected to be the most 
important routes of occupational exposure to cytostatic drugs.1 1 , 1 3 , 1 4 In this 
study, the excretion of unmetabolized CP in rat urine was investigated after 
intratracheal instillation and dermal application. We have investigated whether 
the initial exposure can influence the excretion rate of CP given 48 h later. The 
results found are compared with the results obtained after oral and intravenous 
administration. 
Experimental 
Chemicals 
CP (endoxan; purity >97%) and isophosphamide (IP) (holoxan; purity >97%) 
were purchased from ASTA-Pharma (Bielefeld, FRG). Trifluoroacetic anhydride 
(TFAA; purity >98%) was obtained from Johnson Mattey GmbH (Karlsruhe, 
FRG) and ethyl acetate (purity >99.8%) and n-hexane (purity >95%) were 
bought by Labscan Limited (Dublin, Ireland). Glycerol (purity ±87%) and 
toluene (purity >99.5%) were obtained from Merck (Darmstadt, FRG). 
Animals 
Five groups of three male CPB:WU (Wistar) rats weighing 180-220 g were 
housed individually in stainless-steel metabolism cages for 5 days before 
treatment with CP. Rats had a conventional microbiological status and had free 
access to water and RMH-TM pellets (Hope Farms BV, Woerden, The 
Netherlands). Urine samples and faeces were collected seperately. 
CP was administered to ether-anaesthetized rats at a dose level of 1 mg kg'1 
body weight. For oral, intravenous (penis vene) and intratracheal treatment, a 
saline solution was used. For dermal exposure, a glycerol suspension was 
applied on ca. 2 cm2 of the close-shaven skin of the neck. Control rats 
received no CP. Fourty-eight hours after the first administration, rats received 
a second treatment with the same dose. Eight-hour urine samples were 
collected on ice-water for 4 days after the first administration, adjusted to 10 
ml with distilled water, shaken and stored at -20°C until sample preparation. 
Blank urine samples spiked with CP were prepared immediately after the first 
and the second treatment, and were used as references. 
Sample preparation 
One millilitre of Tris buffer (0.2 M; pH 4.5) and 100 μ\ of internal standard (5 
//g IP ml'1 distilled water) were added to 1 ml of urine sample (in duplicate). 
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The samples were extracted twice with 5 ml of ethyl acetate and the ethyl 
acetate layers were combined in conical tubes with screw caps. Samples were 
dried under nitrogen at 40° С and shaken with 50 μ\ of ethyl acetate until the 
residue was totally dissolved. TFAA (50 //I) was added and, after shaking, the 
tubes were closed for derivatization for 20 min at 70°C.1 0 At room 
temperature the samples were supplemented with 500 μ\ of saturated NaCI 
solution and extracted twice with л-hexane. Hexane extracts were pooled and 
dried under nitrogen at 40°C. Next, 50 μ\ of toluene were added. After 
sonification, the vials were stored at -20°C until analysis. 
GC analysis 
The gas Chromatograph (Carlo Erba 5300) was connected to a flame 
photometer detector (control module type SSD 250; Carlo Erba) with a 
phosphor-specific emission filter (wavelength 526 nm). For peak integration 
(peak area), a Spectra Physics SP 4290 integrator was used. 
The splitless injection mode was used (splitless time 30 s; injector temperature 
250°C; 1 μΐ injection). Carrier and make-up gas flows (He) were 1.0 and 25 ml 
min1, respectively. A 10 m SE-54-DF fused-silica column (Permabond 
Macherey-Nagel, Düren, FRG) was used, with 0.32 mm internal diameter and 
0.5 μπ\ film thickness. The detection temperature was 250°C and the 
excitation dial was set on 7.0. Air and hydrogen flows were 110 and 100 ml 
min 1, respectively. The initial temperature was 75°C. After 1 min, the 
temperature was raised to 250°C (20°C min1). After 5 min at 250°C, the 
temperature was raised at the same rate to 275°C, where it remained 
constant for 10 min. 
Quantitation of the trifluoroacetyl derivatives was carried out by reference to 
calibration curves constructed from the analysis of reference urine samples. 
Results 
A typical chromatogram of a urinary sample containing 10 ng of IP and 1 ng of 
CP is shown in Fig. 1. The TFAA derivatives of IP and CP were separated 
completely and no interference with other compounds was found. Retention 
times of derivatized IP and CP were ca. 12.6 and 13.9 min, respectively. All 
reference urine curves used in this study were linear (range 4-2000 ng ml"1 
urine). The limit of detection (signal-to-noise ratio of 3:1) was ± 6 ng ml"1 
urine. All urine samples were prepared in duplicate and gave a coefficient of 
variation of 7.9 % (n = 59). 
Figure 2 shows the excretion of unmetabolized CP in urine of rats as a 
percentage of the dose after intratracheal, dermal, oral and intravenous 
administration. 
No CP was present in urine samples of rats 24 h after intravenous treatment, 
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32 h after intratracheal and oral treatment and 40 h after dermal application. In 
control urine samples, no CP was found. 
Intravenous injection (first treatment) and intratracheal instillation (second 
treatment) gave the highest excretion rate and dermal application gave the 
lowest (both treatments). 
Table 1 shows the cumulative CP excretion in the first 32 h after treatment. 
The percentage excretion declined in the following order: intravenous injection, 
dermal, intratracheal and oral treatment. The order of excretion after the 
second dose was: intratracheal, dermal, oral and intravenous treatment. 
Fig. 1. Gas chromatograph-flame photometer detector chromatogram of a rat 
urine sample containing 10 ng of IP and 1 ng of CP. 
CP 
1 0 1 5 2 0 m i n 
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Fig. 2. Excretion in 8-h periods of unmetabolized CP in rat urine as a 
percentage of the dose (1 mg kg'1 body weight) after intratracheal 
(A), dermal (B), oral (C) and intravenous (D) administration (mean of 
three rats ± S.D.). The second treatment was 48 h after the first 
treatment. Determinations were performed in duplicate. 
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Table 1. Cumulative excretion of CP in urine of rats in the first 32 h after 
intratracheal, dermal, oral and intravenous treatment with CP". 
route of 
administration 
intratracheal 
dermal 
oral 
intravenous 
first treatment 
excretion 
№ 
11.9 ± 2.5 
13.6 ± 0.3 
8.4 ± 3.7 
14.9 ± 2.8 b 
% dose 
5.2 ± 1.0 
5.6 ± 0.4 
4 . 0 ± 2.0 
6.9 ± 1 . 1 b 
second treatment 
excretion 
12.5 + 3.4 
11.2 ± 4.7 
7.6 ± 2.4 
6.1 ± 3.3 
% dose 
5.5 ± 1.6 
4.5 ± 1.6 
3.6 + 1.2 
2.7 ± 1.5 
mean of groups of three rats ± S.D. 
only two rats, because of loss of one urine sample 
Discussion 
Some investigators have found that the cumulative excretion of CP in urine of 
CP-treated rats ranged from 11 to 35% of the dose after intraperitoneal 
administration of therapeutic amounts. 1 5 , i e The cumulative CP excretion 
appeared to increase with dose but the rate of excretion seemed to be 
independent of dose.After treatment with 1 mg kg"1 body weight, the 
cumulative excretion was below 7% (Table 1). The lowest cumulative 
excretion was observed after oral administration, probably because of a first 
pass effect. Such an effect has been found in patients when oral treatment 
was compared with intravenous injection.17 
Cumulative excretion showed some difference between the first and a second 
intravenous treatment. The first treatment resulted either in an inhibition of 
excretion or an induction of biotransformation. Some human studies suggested 
induction by repeated treatments with CP,1B, ia while in other studies no such 
effect was observed.20,21 
Our results, along with those of Hirst et al.1 1 in dermal-treated volunteers, 
demonstrate that CP easily penetrates the skin. Therefore, dermal exposure 
must be considered as a possible exposure route for CP. 
Hirst et al. also found a higher rate of excretion of CP in urine of nurses after 
handling CP in comparison with dermal-treated volunteers.11 Their results 
suggested that the route of exposure of nurses may differ from that of the 
volunteers. The velocity with which CP appeared in urine implied that it was 
absorbed soon after its ' preparation and it was likely that CP entered the 
Toxicokinetics on cyclophosphamide 155 
circulation following inhalation. Our results show that after intratracheal 
administration, CP must be absorbed easily because it appeared in urine rather 
quickly. Although the experimental conditions were different, our results are in 
agreement with those of Hirst et al.11 
In conclusion, the results show little difference in excretion rate and 
cumulative urinary excretion of CP in rats after the first or after the second 
intratracheal, dermal, oral or intravenous treatment. Excretion was rapid and 
almost complete within 8-16 h after treatment, except that excretion was 
delayed after dermal application. These results suggest that intake of CP by 
inhalation and absorption via the skin, which are expected to be the most 
important routes of occupational exposure to cytostatic drugs, are possible 
and can be determined by the measurement of CP in urine. 
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Abstract 
Sensitive methods for the determination of the cyclophosphamide metabolites 
nornitrogen mustard, 4-ketocyclophosphamide and carboxyphosphamide are 
presented. After liquid-liquid extraction and derivatization, the metabolites are 
determined by gas chromatography and thermionic specific detection. The 
methods were used to study the in vitro biotransformation of 
cyclophosphamide with S-9 liver fractions of human donors. The results show 
large interindividual differences in the formation of nornitrogen mustard and 
carboxyphosphamide. 4-Ketocyclophosphamide was not detected. 
Introduction 
Cyclophosphamide (CP) is an alkylating antineoplastic agent with activity 
against a variety of human tumours [1]. CP is also used in the treatment of 
autoimmune diseases and during renal and bone marrow transplantations [1]. 
The activity of CP is caused by its metabolites [1]. During bioactivation by 
hepatic cytochrome P-450, 4-hydroxycyclophosphamide is formed which is in 
equilibrium with its ring-opened tautomer aldophosphamide (Fig.1). Both 
metabolites are detoxified by isoenzymes of the NAD-linked aldehyde 
dehydrogenase and aldehyde oxidase resulting in the formation of 
carboxyphosphamide (CAR) and 4-ketocyclophosphamide (KCP), respectively. 
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ß-Elimination of acrolein from aldophosphamide yields phosphoramide mustard, 
a directly active alkylating species which reacts with DNA Cleavage of 
phosphoramide mustard results in the formation of nornitrogen mustard 
(NNM) Acrolein binds covalently to proteins. Most CP metabolites are 
ultimately eliminated by renal excretion 
In recently published studies, we have determined non-metabolised CP in urine 
samples of occupationally exposed hospital workers handling antineoplastic 
agents [2-5] For the determination of low concentrations in urine a sensitive 
gaschromatographic-mass spectrometnc method was developed [6] In urine 
samples of many hospital workers CP was found However, little is known 
about intenndividual differences in biotransformation of this agent Therefore, 
the in vitro biotransformation of CP was studied using (non)mduced S-9 liver 
fractions. The rate of formation of the toxic metabolite NNM and the non-toxic 
metabolites KCP and CAR were measured We were especially interested in 
the balance between toxification (NNM formation) and detoxification 
(KCP + CAR formation) which is expressed by the toxic/non-toxic metabolites 
ratio NNM/IKCP + CAR) 
The number of chromatographic methods available for the monitoring of CP 
metabolites is limited [7] Therefore, new methods for the determination of 
KCP, CAR and NNM in incubation mixtures are developed. After liquid-liquid 
extraction and denvatization, the metabolites are determined with gas 
chromatography and thermionic specific detection NNM was determined after 
denvatization with benzenesulphonyl chloride KCP and CAR were determined 
after denvatization with Ν,Ν-dimethylformamide dimethyl acetal 
Experimental 
Chemicals 
CP, 4-hydroxyperoxycyclophosphamide, throphosphamide (TRO), CAR and 
KCP were gifts from ASTA-Medica (Frankfurt am Main, Germany). Glucose-6-
phosphate, sucrose and aniline were purchased from Sigma (St. Louis, MO, 
USA). 7-Ethoxy- and 7-pentoxyresorufm were from Boehnnger (Mannheim, 
Germany). Nornitrogen mustard HCl (NNM) and resorufin were from Aldnch 
(Milwaukee, Wl, USA) and benzenesulphonyl chloride, EDTA and 4-
morpholinepropanesulphonic acid (MOPS), were obtained from Janssen 
Chimica (Beerse, Belgium) Ν,Ν-dimethylformamide dimethyl acetal was 
purchased from Chrompack (Middelburg, Netherlands) NADP was from USB 
(Cleveland, OH, USA) All other chemicals were of the highest purity 
obtainable. 
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Fig. 1. Schematic presentation of the biotransformation of cyclophosphamide 
showing the most important reactions and metabolites (after Sladek 
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Human livers 
Pieces of human donor livers were used. They were kindly obtained from Dr. 
W.H.M. Peters, Division of Gastrointestinal and Liver Diseases, University of 
Nijmegen, Netherlands. Donor livers were made available anonymously. 
Consequently, limited information on the age and sex and no information 
about smoking and drinking habits was available. Their characteristics are 
presented in Table 1 . 
Preparation of the S-9 liver fractions 
Liver homogenates were prepared (20%, w/v) in SETH-buffer (0.25 M 
sucrose, 2 mM EDTA and 10 mM Tris-HCI, pH = 7.4) with a Teflon-glass 
homogenizer. After centrifugation at 9000 g for 20 min, the floating fat layer 
was removed. The S-9 liver fraction was divided into a number of samples, 
frozen in liquid nitrogen and stored at -80°C until use. 
In vitro incubations 
The frozen S-9 liver fractions were thawed quickly at 37°C immediately prior 
to use and kept on ice. The incubation mixture contained 44 mM MOPS buffer 
pH = 7.4, 2 mM NADP, 5 mM MgCI2.6H20, 2 mM glucose-6-phosphate, 1 mM 
EDTA, and an amount of S-9 liver fraction based on 3.5 mg protein. After a 
preincubation of 5 min at 37°C, the incubation was started by adding 1.5 
//mol СР. The final incubation volume was 1 ml. The mixture was mildly 
shaken during the (pre)incubation at 150 rpm. The incubation was stopped 
after 30 min by the addition of 75 μ\ of a 6 M HCl solution. The reaction 
mixture was immediately cooled on ice-water. All incubations were carried out 
double in triplicate. One series in triplicate was used for the determination of 
CAR and KCP. The other was used for the determination of NNM. 
Enzyme measurements 
Total cytochrome P-450 was determined from the dithionite-difference 
spectrum according to Rutten et al. [8]. Protein concentrations were measured 
with the method of Bradford using crystalline bovine serum albumin as 
standard [9]. 7-Ethoxyresorufin-O-deethylase (EROD) activity was determined 
according to Burke et al. [10] and 4-aniline-hydroxylase (AH) was measured 
according to Ishidate et al. [11]. Enzyme and total cytochrome P-450 
measurements were performed in duplicate and protein concentrations were 
measured in triplicate. 
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Sample preparation and gas chromatographic analysis of the cyclophos­
phamide metabolites 
CAR and KCP 
After the incubation was stopped, 45 μΐ 10 M NaOH and 100 μ\ 1 M MOPS 
buffer pH = 8.0 were added. Excess of CP was removed by 4 extractions with 
7 ml of diethyl ether by shaking for 5 min to avoid interference during the 
analysis. The ether layers were discarded and 200 μ\ 6 M HCl was added. The 
mixture was extracted twice with 4.5 ml ethyl acetate by shaking during 5 
min. The ethyl acetate layers were combined in conical tubes with screw caps 
and dried under nitrogen at 40°C. After addition of 700 μ\ toluene, 25 μ\ Ν,Ν-
dimethylformamide dimethyl acetal and subsequently mixing, the tubes were 
closed for derivatization for 35 min at 115°C. The samples were cooled to 
room temperature and dried again under nitrogen at 50°C. Thereafter 200 μ\ 
toluene, containing 1 ^g TRO (internal standard for controlling the sensitivity 
of the detector) was added, followed by sonification for 5 min. Α 1-μΙ sample 
was injected. 
Gas chromatography with thermionic specific detection was performed on a 
Varian 3400 GC that was controlled by a Varían GC Star Workstation on a 
Grid 386 personal computer. Samples were injected spiitless. A 1 5-m DB-5 
column (J&W, Folsom, CA, USA) was used with 0.32 mm internal diameter 
and 0.25 //m film thickness. The injector temperature was 320°C. The initial 
oven temperature was 85°C. After 1 min, the temperature was increased to 
280°C following 4 segments (85-170°C, 20°C/min; 170-190°C, 5°C/min; 
190-210°C, 10°C/min; 210-280°C, 20°C/min) where it remained constant 
for 6 min. Helium was used as carrier gas [column inlet pressure 12 p.s.i. (ca. 
8.2-102 Pa)]. The thermionic specific detector was set at 300°C. For 
quantification the peak area ratios CAR/TRO and KCP/TRO were calculated. 
Quantification of the CAR and KCP derivatives was carried out by reference to 
calibration curves constructed from the analysis of freshly prepared reference 
samples containing CAR (0, 5, 10, 20, and 25 nmol) and KCP (0, 13, 26, 38, 
and 51 nmol) dissolved in a blank incubation mixture. The reference samples 
containing CAR and KCP underwent the whole sample preparation procedure. 
NNM 
The incubation was stopped after 15 s, and 45 μΙ 10 M NaOH and 100 μΙ 1 M 
MOPS buffer pH = 8.0 were added. After 22 h at 37°C, 4.5 ml diethyl ether 
and 5 μ\ benzenesulphonylchloride were added successively and the mixture 
was shaken during 90 min, and centrifuged during 5 min at 2500 rpm (1500 
g). The ether layers were removed and dried under nitrogen at 30°C. After 
addition of 1 ml water, the solution was extracted twice with 2 ml л-hexane. 
The hexane layers were removed and dried under nitrogen at 40°C. Finally, 
the extract was dissolved in 200 μ\ toluene containing 1 μg TRO (internal 
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standard for controlling the sensitivity of the detector). A 1 μ\ sample was 
injected. 
For the analysis of NNM the same equipment and conditions were used as for 
the analysis of CAR and KCP, except for the oven programme. The initial oven 
temperature was 8 5 ° С After 1 min, the temperature was increased by 
15°C/min to 280°C, where it remained constant for 6 min. For quantification 
the peak area ratio NNM/TRO was calculated. Quantification of the derivatized 
NNM and TRO was carried out by reference to calibration curves constructed 
from the analysis of freshly prepared reference samples containing 4-
hydroxyperoxycyclophosphamide (0, 25, 50, 100, and 200 nmol) dissolved in 
blank incubation mixtures. For the determination of NNM we were not able to 
use calibration curves constructed from the analysis of freshly prepared 
reference samples containing NNM itself. It appearred that NNM was not 
formed within the incubation period but in a later stage out of metabolites 
generated during the incubation (Fig. 1). Therefore, the incubation mixture was 
put at 37°C during 22 h and 4-hydroxyperoxycyclophosphamide, which was 
completely converted to NNM, was preferred for the construction of the 
calibration curve instead of NNM itself. 
Statistical analysis 
Statistical analysis was carried out on a personal computer using InStat 1.1 as 
software package. Correlations were quantified with the Pearson correlation 
coefficient r. P-values (two-tailed) below 0.05 were considered to be of 
statistical significance. 
Results and discussion 
We have developed methods for the determination of the CP metabolites KCP, 
CAR and NNM in incubation mixtures. Prior to analysis, KCP and CAR were 
extracted from the incubation mixture with ethyl acetate and methylated with 
Ν,Ν-dimethylformamide dimethyl acetal. Fig. 2 shows typical chromatograms 
of derivatized extracts of a blank incubation mixture spiked with KCP, CAR 
and TRO (internal standard) (A); a blank incubation mixture spiked with TRO 
(В); and an incubation mixture containing a S-9 fraction of a human donor liver 
(C). The retention times of KCP, CP, CAR, and TRO were 6.8, 6.9, 7.2 and 
8.9 min, respectively. The C.V. of the retention times was below 0.7%. In 
order to quantify the amount of KCP exactly, it was necessary to remove 
excess of CP. This was done by four extractions with diethyl ether prior to the 
extraction of the acidified incubation mixture with ethyl acetate. Finally, KCP 
and CP were completely separated and no interference with other compounds 
was observed. NNM was derivatized with benzenesulphonylchloride in diethyl 
ether according to the so-called Hinsberg-test resulting in the formation of a 
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sulfonamide [12]. Fig. 3 shows typical chromatograms of derivatized extracts 
of a blank incubation mixture spiked with NNM (in situ formed out of 4-
hydroxyperoxycyclophosphamide) and TRO (internal standard) (A); a blank 
incubation mixture spiked with TRO (В); and an incubation mixture containing 
a S-9 fraction of a human donor liver (C). The retention times of NNM, CP, and 
TRO were 7.6, 7.8 and 9.0 min, respectively. The C.V. of the retention times 
was below 0.2%). No interference of NNM, CP and TRO with other 
compounds was observed. All calibration curves were linear, with a coefficient 
of correlation of a least 0.99. The limits of detection for CAR, KCP and NNM 
were 0.5, 0.5 and 0.1 nmol/ml incubation mixture (2.5, 2.5 and 0.5 pmol on 
column). The intra-assay precision (mean relative standard deviation of all 
triplicate incubations) was about 9% for NNM and 16% for CAR. The recovery 
of the extraction procedures is almost 100%. 
Fig. 2. Chromatograms of ethyl acetate extracts of incubation mixtures after derivatization with 
Ν,Ν-dimethylformamide dimethyl acetal. Peaks (retention timet: KCP=4-ketocyclophospha-
mide 16.8 mini; CP = cyclophosphamide (6.9 mini; CAR = carboxyphosphamide (7.2 mini; 
TRO = trophosphamide (internal standard) (8.9 min). (Al Blank incubation mixture spiked 
with KCP (26 nmol/ml incubation mixture!, CAR (10 nmol/ml incubation mixture) and TRO 
(15 nmol/ml toluene!. (B) Blank incubation mixture spiked with TRO (15 nmol/ml toluene). 
(C) Incubation mixture containing S-9 liver fractions of liver 4. 
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Fig. 3. Chromatograms of diethyl ether extracts of incubation mixtures after derivatization with 
benzenesulphonylchloride. Peaks (retention time): NNM=nornitrogen mustard (7.6 min); 
CP= cyclophosphamide (7.8 min); TRO = trophosphamide (internal standard) (9.0 min). (A) 
Blank incubation mixture spiked with NNM (WO nmol/ml incubation mixture) and TRO (15 
nmol/ml toluene). (B) Blank incubation mixture spiked with TRO (15 nmol/ml toluene). (C) 
Incubation mixture containing S-9 liver fractions of liver 7. 
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Large differences in total P-450 content and EROD and AH activities were 
observed among the liver fractions of the donors (Table 1). Total P-450 
content ranged from 0.08 to 0.22 nmol/mg protein. EROD and AH activity 
ranged from 2.7 to 12.9 and from 0.06 to 0.32 pmol/min per mg protein, 
respectively. Large differences were also found in NNM, CAR and total 
metabolite formation and NNM/CAR ratio after incubation of CP with human S-
9 liver fractions (Table 2). In none of the incubation mixtures KCP was 
detected. The highest amount of NNM was formed by liver 1. The NNM 
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formation rate was eight times higher when compared to liver 7 having the 
lowest NNM formation rate. Liver 4 showed the highest CAR formation rate. 
This was fifteen times higher when compared to liver 6, having the lowest 
rate. Liver 4 also showed the highest NNM + CAR formation rate. This was 
eight times higher when compared to liver 6 with the lowest NNM + CAR 
formation. Liver 1 showed the highest NNM/CAR ratio. This was four times 
higher when compared to liver 4, the lowest one. It should be mentioned that 
the livers 1 and 4 with the highest NNM + CAR formation differed substantially 
in NNM/CAR ratio. Comparable results were found for the livers 6 and 7 with 
the lowest NNM + CAR formation. 
Table 1. Total P-450 content, EROD and AH activities in human S-9 liver 
fractions. 
liver sex age total P-450 EROD" AHb 
(nmol mg ' protein) (pmol mm ' mg ' protein) (pmol min 'mg ' protein) 
1 ic 
2 male 
3 •> 
4 ? 
5 male 
6 » 
7 > 
Mean ± S.D. 
? 
16 
7 
20 
47 
? 
? 
0.09 
0.11 
0.09 
0.22 
0.09 
0.12 
0.08 
0.11 ±0.05 
4.7 
3.6 
3.7 
4.0 
8.0 
12.9 
2.7 
5.6±3.6 
0.17 
0.18 
0.13 
0.32 
0.15 
0.19 
0.06 
0.17±0.08 
" 7-ethoxyresorufin-O-deethylase 
ь
 4-aniline-hydroxylase 
c
 sex and age are not known 
The results show large differences in the biotransformation of CP. Comparable 
results were found by Chang et al. although microsomes of human donor livers 
were used instead of S-9 liver fractions as was done in our study [13]. 
Besides, they studied CP 4-hydroxylase activity fluorometrically while we have 
determined CP metabolites with gas chromatography. They found that P-
4501A1, 1A2 and 2E1 did not contribute to the hydroxylation of CP. In our 
study, we did not find a correlation between EROD (P-4501A1) activity and 
NNM, CAR, total metabolite formation and the NNM/CAR ratio. On the con-
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trary, we found a correlation between CAR and total metabolite formation and 
AH (P-4502E1) activity (/-=0.8373, Я=0.0187 and /-=0.7954, P=0.0325, 
respectively). NNM formation and the NNM/CAR ratio were not correlated. 
Unfortunately, it is not possible to establish the causal factor of the large 
differences in EROD and AH activity between the individual human S-9 liver 
preparations since no more data of the donors was available. Enhanced 
activity of EROD and AH do not per se reflect the induction of specific 
enzymes caused, for instance, by the life style factors smoking or alcohol. 
Genetic factors may also be of importance with respect to P-450 isoenzyme 
activities involved in the biotransformation of CP. 
Table 2. Formation of NNM and CAR after incubation of cyclophosphamide 
with human S-9 liver fractions'. 
liver NNM CAR NNM + CAR NNM/CAR ratio 
89 
40 
18 
69 
22 
15 
11 
38±31 
39 
21 
14 
117 
23 (n = 2) 
8(n = 2) 
14 
34 ±38 
128 
61 
32 
186 
45 
23 
25 
71 ±61 
2.3 
1.9 
1.3 
0.6 
1.0 
1.9 
0.8 
1.4±0.7 
" values of NNM and CAR formation are means ± S.D. of duplicate (n = 2) or triplicate 
incubations (pmol/min per mg protein) 
The large interindividual differences in especially the formation of NNM and 
CAR and the NNM/CAR ratio between the liver S-9 samples suggest large 
interindividual differences in the toxicity of CP due to differences in 
biotransformation. A high NNM/CAR ratio may be predictive for a relatively 
high level of DNA-alkylating metabolites in vivo. Otherwise a low NNM/CAR 
ratio may be predictive for the formation of detoxified metabolites. 
We may assume that comparable differences in biotransformation will occur in 
man in vivo, for instance in treated patients and in occupational^ exposed 
workers. This means that it is not possible to estimate the exact individual 
dose of CP in occupationally exposed workers on basis of their individual 
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urinary excretion of CP. Therefore, we have applied the developed methods for 
the determination of KCP, CAR and NNM in urine of hospital workers. 
Unfortunately, the methods were not appropriate because we were not able to 
extract the metabolites and to derivatize them. Hence, only the method for the 
determination of CP in urine of hospital workers can be used to establish 
occupational exposure to CP and to estimate a group based exposure level. 
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Abstract 
The aim of the present study is to investigate the influence of the 
environmental factors, smoking and alcohol, on the biotransformation of 
cyclophosphamide (CP) in the rat in vivo and in vitro with S9 liver fractions. 
The biotransformation of CP was studied by the determination of the CP-
metabolites, nor-nitrogen mustard (NNM), 4-ketocyclophosphamide (KCP), and 
carboxyphosphamide (CAR). The effect of the environmental factors, smoking 
and alcohol consumption, on the biotransformation enzymes was mimicked by 
pretreatment of rats with ß-naphthoflavone and ethanol, respectively. Rats 
treated with olive oil and water served as controls and rats pretreated with 
Aroclor 1254 and phénobarbital were used as positive controls. The influence 
of sex and supplementation with NAD and GSH, mimicking a biological 
variation in NAD and GSH levels in rat and human liver, was also studied. 
Pretreatment of rats with Aroclor 1254 decreased the excretion of 
unmetabolized CP in urine, most likely due to an enhanced biotransformation. 
The in vitro hepatic biotransformation of CP in rats was strongly influenced by 
sex, by supplementation with NAD and GSH, and by pretreatment with the 
enzyme-inducers, phénobarbital and Aroclor 1254. No influence of 
pretreatment with the enzyme-inducers, ß-naphthoflavone and ethanol, was 
found. The results suggest that the influence of the environmental factors, 
alcohol consumption and smoking, on the biotransformation of CP in man will 
be negligible. 
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Introduction 
Cyclophosphamide (CP) is an important antineoplastic drug used in the 
chemotherapy of cancer and autoimmune diseases. The activity of CP is 
caused by its metabolites (Sladek, 1988). During bioactivation by hepatic 
cytochrome P450, 4-hydroxycyclophosphamide is formed which is in 
equilibrium with its ring-opened tautomer aldophosphamide (Fig. 1). Both 
metabolites are detoxified by isoenzymes of the NAD-linked aldehyde oxidase 
and aldehyde dehydrogenase resulting in the formation of 4-
ketocyclophosphamide (KCP) and carboxyphosphamide (CAR), respectively. 
Toxification occurs after ß-elimination of acrolein from aldophosphamide to 
yield phosphoramide mustard which is further converted to nor-nitrogen 
mustard (NNM). Phosphoramide mustard is responsible for the DNA-alkylating 
activity resulting in the cytotoxic effect of CP. Acrolein binds covalently to 
proteins. Most CP(metabolites) are ultimately eliminated by renal excretion. 
In several recently published studies we have investigated the exposure of 
hospital workers to CP (Sessink et al., 1992a,b; 1994a,b; 1995b). It was 
found that during drug handling the workers were exposed to this compound. 
Despite the introduced guidelines and protective measures, we were able to 
detect CP in their urine. It was concluded that uptake of CP due to 
occupational exposure did happen. The question is to what extent the 
amounts of CP excreted in urine are a measure for the uptake of the drug. 
More precisely, what is the relationship between uptake and urinary excretion 
of CP. Several processes such as the biotransformation, resulting in 
transformation of the parent compound in metabolites, are involved. 
Differences in biotransformation are genetically determined but are also 
influenced by chemical exposure from the environment among which so-called 
life style factors, that may cause induction or inhibition of enzymes involved in 
the biotransformation of toxic compounds such as CP (Fournier and Thomas, 
1986). 
In the present study the in vitro biotransformation of CP was investigated 
using S9 liver fractions of pretreated and control rats. The biotransformation of 
CP was studied by the determination of the CP-metabolites, nor-nitrogen 
mustard (NNM), 4-ketyocyclophosphamide (KCP), and carboxyphosphamide 
(CAR). The effects of the environmental factors, smoking and alcohol, on 
biotransformation enzymes were mimicked by pretreatment of rats with ß-
naphthoflavone and ethanol, respectively (Pelkonen et al., 1986; Sesardic et 
al, 1987). The results were compared with the results obtained from control 
rats (olive oil and water pretreatment, respectively) and from rats pretreated 
with Aroclor 1254 and phénobarbital, respectively (positive controls). The 
influence of sex and supplementation with NAD and GSH, mimicking a 
biological variation in NAD and GSH levels in rat and human liver, was also 
studied. We were especially interested in the balance between toxication and 
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detoxication which is expressed by the toxic/non-toxic metabolites ratio 
NNM/(KCP + CAR). 
Fig. 1. Abridged scheme of the biotransformation of CP showing only the 
currently recognized biologically important reactions and metabolites 
(after Sladek, 1988). 
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Several investigators have studied the in vitro hepatic biotransformation of CP 
in rats after pretreatment with phénobarbital, Aroclor 1254, ß-naphtoflavone 
and 3-methylcholanthrene (Sladek, 1988; Clarke and Waxman, 1989; LeBlanc 
and Waxman, 1989). In our study, we were able to detect specific CP 
metabolites using recently developed gas chromatographic methods after the 
incubation of CP with S9 liver fractions instead of microsomes or purified 
cytochrome P450 (iso)enzymes (Sessink et al., 1995a). 
The biotransformation of CP was also studied in vivo by determination of 
unmetabolized CP in urine of rats pretreated with Aroclor 1254. CP was 
administered by intravenous injection. In addition, dermal application was 
chosen to mimic the possible dermal uptake as expected during occupational 
activities of hospital workers (Hirst et al., 1984; Sessink et al., 1994a). 
Methods 
Animal pretreatment for the determination of CP in urine 
Four Groups of three male random-bred Wistar rats (Cpb:WU (SPF), body wt 
about 215 g) were housed individually in stainless-steel metabolism cages and 
had free access to tap water and RMH food pellets (Hope Farms BV, Woerden, 
The Netherlands). Urine samples and faeces were collected separately. Two 
groups of rats were pretreated with Aroclor 1254 (Alltech, Deerfield, IL, USA) 
in olive oil (i.p., 500 mg/kg body wt, 5 days before CP administration) or olive 
oil as control (i.p., 2 ml/kg body wt). CP (ASTA-Medica, Frankfurt am Main, 
Germany) was administered by dermal application or intravenous injection 
(penis vene) to a group of Aroclor 1254-pretreated rats and to a group of 
control rats (1 mg/kg body wt). For dermal application, a glycerol suspension 
was applied on about 2 cm2 of the close-shaven skin of the neck. Urine 
samples were collected on ice water for 24 h. A dose of 1 mg CP/kg body wt 
is about 10000 times higher when compared to the occupational exposure of 
hospital workers to CP (3.6-18 μg CP/day) (Sessink et al., 1 995b). 
Animal pretreatment for the in vitro incubations 
Six Groups of three male and six groups of three female random bred Wistar 
rats (Cpb:WU (SPF), body wt about 190 g) were used. The animals were 
housed per group. They had free access to tap water and RMH food pellets 
(Hope Farms BV, Woerden, The Netherlands). Groups of male and female rats 
were pretreated with Aroclor 1254 in olive oil (i.p., 500 mg/kg body wt, 5 
days before preparation of the S9 liver fraction), phénobarbital (OPG, Utrecht, 
The Netherlands) in saline (i.p., male rats: 75 mg/kg body wt, female rats: 50 
mg/kg body wt, during 4 days before preparation of the S9 liver fraction), ß-
naphthoflavone (Janssen, Beerse, Belgium) in olive oil (¡.p., 40 mg/kg body wt, 
during 3 days before preparation of the S9 liver fraction) and olive oil as 
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control (i.p., 2 ml/kg body wt). Groups of ethanol pretreated male and female 
rats were obtained by giving tap water containing 15% ethanol for 6 weeks 
The corresponding control rats received tap water without ethanol (van de 
Wiel et al., 1990) The rats were anaesthetized with pentobarbital and finally 
killed by cervical dislocation. 
Preparation of the S9 liver fractions 
After cervical dislocation, the livers were perfused in situ with 0.9% NaCI 
(w/w), completely removed, weighed and immediately cooled in ice-cold SETH 
buffer (0.25 M sucrose, 2 mM EDTA and 10 mM Tns-HCI, pH 7 4) Liver 
homogenates were prepared (20%, w/v) in SETH buffer with a teflon-glass 
homogenizer After centrifugation at 9000 χ g for 20 mm, the floating fat layer 
was removed. The S9 liver fraction was divided in a number of samples, 
frozen in liquid N2 and stored at -80°C until use 
In vitro incubations 
The frozen S9 liver fractions were thawed quickly at 37°С immediately prior 
to use and kept on ice. The incubation mixture contained 44 mM MOPS buffer 
pH 7.4, 2 mM NADP, 5 mM MgCI2-6H20, 2 mM glucose-6-phosphate, 1 mM 
EDTA, 4 mM NAD, 5 mM GSH, and an amount of S9 liver fraction based on 
0 35 nmol P450 After a preincubation of 5 mm at 37°C, the incubation was 
started by adding 1.5 ¿/mol СР. The final incubation volume was 1 ml The 
mixture was mildly shaken during the (pre)incubation at 150 rev /mm The 
incubation was stopped after 30 mm by the addition of 75 μΙ of a 6 M HCl 
solution. The reaction mixture was immediately cooled on ice-water All 
incubations were carried out double in triplicate One series in triplicate was 
used for the determination of CAR and KCP. The other was used for the 
determination of NNM (Sessmk et al , 1995a). 
Enzyme measurements 
Total cytochrome P450 was determined from the dithionite-difference 
spectrum according to Rutten et al. (Rutten et a l , 1987) Protein 
concentrations were measured by the Bradford method using crystalline bovine 
serum albumine as standard (Bradford, 1976) 7-Ethoxyresorufm-O-deethylase 
(EROD) and 7-pentoxyresorufm-O-deethylase (PROD) activities were 
determined according to Burke et al. and anilme-hydroxylase (AH) activity was 
measured according to Ishidate et al (Burke et al., 1985, Ishidate et al., 
1978). Enzyme and total cytochrome P450 measurements were performed in 
duplicate. Protein concentrations were measured in triplicate 
174 Chapter 4 
Sample preparation and gas chromatographic analysis of CP in urine 
After liquid-liquid extraction and denvatization wi th trifluoroacetic anhydride, 
CP was determined with gas chromatography/mass spectrometry (Sessink et 
al., 1 9 9 1 , 1992b). 
Sample preparation and gas chromatographic analysis of the CP metabolites in 
the incubation mixture 
After liquid-liquid extraction and denvatization, the metabolites are determined 
wi th gas chromatography and thermionic specific detection. NNM was 
determined after denvatization wi th benzenesulphonyl chloride. KCP and CAR 
were determined after denvatization with Λ/,/V-dimethylformamide dimethyl 
acetal (Sessink et al., 1995a). 
Statistical analysis 
Two-way analysis of variance (SAS procedure GLM) was used to study 
influence of pretreatment and administration route for the in vivo experiments. 
These data were analyzed using Statistical Analysis System version 6.08 (SAS 
Institute Inc., Cary, NC, USA). Unpaired two-tailed 7"-tests were used t o study 
influence of pretreatment, sex, and supplementation wi th NAD and GSH for 
the in vitro incubations (Tables 2 and 3). Log-transformed data were used. 
InStat 1.1 was used as the software package. P-values below 0.05 were 
considered to be significant 
Results 
Effect of Aroclor 1254 pretreatment and administration route on the urinary 
excretion of unmetabolized CP 
CP was excreted in urine of control rats within 16-20 h after intravenous and 
dermal administration. After pretreatment with Aroclor 1254, CP excretion 
was completed at 4-8 h after administration. The cumulative CP excretion as 
percentage of the dose administered ( ± S.D.) was lower in the Aroclor 1254-
pretreated rats (intravenous administration: 1 4 ± 0 . 4 , dermal application: 
0 6 ± 0 . 1 ) compared to the olive oil-pretreated control rats (intravenous 
administration. 7 6 + 1.2, dermal application: 5 . 8 ± 1 . 1 ) (/ D <0.0001). The 
cumulative CP excretion was also lower after dermal application (Aroclor 
1254-pretreated rats: 0.6 ± 0 . 1 ; olive oil control rats. 5.8 ± 1 . 1 ) compared to 
intravenous administration (Aroclor 1254-pretreated rats: 1.4 ± 0 4; olive oil 
control rats: 7.6 ± 1 . 2 ) (Я = 0.026). It is concluded that pretreatment wi th 
Aroclor 1254 decreased the excretion of unmetabolized CP in urine of rats 
most likely due to an enhanced biotransformation of CP in vivo. The influence 
of the administration route was of minor importance indicating almost 
complete dermal absorption. 
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Effect of pretreatment with cytochrome P450 enzyme-inducers on enzyme 
activities 
As was expected, EROD activity was substantially increased in both male and 
female rats after Aroclor 1254 pretreatment and to a lesser extent after ß-
naphthoflavone pretreatment in comparison with the olive oil control rats 
(Table 1). EROD activity was slightly increased in male rats after phénobarbital 
pretreatment. PROD activity was slightly increased in male and female rats 
after phénobarbital and Aroclor 1254 pretreatment and in female rats after ß-
naphtoflavone pretreatment. AH activity was slightly enhanced in male and 
female rats after Aroclor 1254 and ethanol pretreatment and in male rats after 
phénobarbital pretreatment. 
Effect of pretreatment with cytochrome P450 enzyme-inducers on the 
biotransformation of CP 
The rates of formation of NNM and CAR after incubation of CP with S9 liver 
fractions pretreated and control male and female rats, and the influence of 
supplementation with NAD and GSH are shown in Table 2 (Aroclor 1254, ß-
naphthoflavone, and olive oil control) and Table 3 (phénobarbital, ethanol, and 
water control). In none of the incubation mixtures KCP was detected (<0.5 
nmol/ml incubation mixture). Consequently, the formulas for the calculation of 
the total metabolite formation rate and the toxic/non-toxic metabolites ratio are 
simplified in NNM + CAR and NNM/CAR, respectively. 
Without supplementation with NAD and GSH 
The results show that Aroclor 1254 and phénobarbital pretreatment increased 
the formation rate of NNM in male rats and the formation rate of CAR in male 
and female rats compared to their corresponding controls. The formation rate 
of NNM and CAR was not affected after ß-naphthoflavone and ethanol 
pretreatment. The formation rate of especially NNM and to a lesser extent CAR 
is higher in male than in female rats for all pretreatments and controls. 
Consequently, the total metabolite formation rate NNM + CAR and the 
NNM/CAR ratio is higher in male than in female rats. 
Supplementation with NAD 
Supplementation of the S9 incubation mixtures with NAD decreased the NNM 
formation rate in ß-naphtoflavone pretreated and in female olive oil-treated 
control rats. The NNM formation rate was not affected by the other 
pretreatments and in the water control group. On the contrary, the CAR 
formation rate was increased in male rats for all pretreatments and their 
corresponding control groups more or less compensating the decrease of the 
NNM formation rate. Consequently, the total metabolite formation rate 
NNM + CAR was not changed and the NNM/CAR ratio was decreased (except 
for female water control rats). 
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In addition, Aroclor 1254 pretreatment increased the formation rate of NNM in 
female rats and the formation rate of CAR in male rats compared to their 
corresponding controls. The formation rate of CAR was decreased after ß-
naphtoflavone pretreatment in female rats. Phénobarbital pretreatment 
increased the formation rate of NNM in male rats and the formation rate of 
CAR in male and female rats compared to their corresponding controls. The 
formation rate of NNM and CAR was not affected after ethanol pretreatment. 
The formation rate of NNM and CAR is higher in male rats than in female rats 
for all pretreatments and the control groups (except the NNM formation rate in 
the water control group). 
Supplementation with NAD and GSH 
Supplementation of the S9 incubation mixtures with NAD and GSH decreased 
the NNM formation rate compared to NAD supplementation alone. The CAR 
formation rate was not affected. Consequently, the NNM/CAR ratio was 
decreased. The total metabolite formation rate NNM + CAR was only decreased 
in the male rats. This is due to the large reduction in the NNM formation rate 
in the male rats compared to the female rats. These results were not 
influenced by the pretreatment. Once again, the formation rate of NNM and 
CAR was higher in male rats than in female rats within each pretreatment. 
In addition, Aroclor 1254 and phénobarbital pretreatment increased the 
formation rate of CAR compared to their corresponding controls. Phénobarbital 
pretreatment also increased the formation rate of NNM in female rats. 
Discussion 
The cumulative urinary CP excretion (24 h) was significantly decreased in 
Aroclor 1254-pretreated rats when compared to control rats. An enhanced in 
vivo biotransformation of CP is suggested and is confirmed by the results of 
the incubations in vitro which demonstrate an increase in total CP metabolite 
formation after pretreatment with Aroclor 1254. These results suggest the 
influence of external (chemical) factors on CP biotransformation in vivo. The 
cumulative CP excretion was lower after dermal application compared to 
intravenous administration. This suggests a higher biotransformation activity 
after dermal application than intravenous administration. Consequently more 
metabolites could be formed after dermal application than after intravenous 
administration. However, it is unknown whether this will result in more toxic 
or non-toxic metabolites. 
Several investigators have studied the in vitro hepatic biotransformation of CP 
in rats after pretreatment with phénobarbital, Aroclor 1254, ß-naphtoflavone 
and 3-methylcholanthrene (Sladek, 1988; Clarke and Waxman, 1989; LeBlanc 
and Waxman, 1989). The experiments were carried out with microsomes or 
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purified cytochrome P450 (iso)enzymes The biotransformation of CP was 
measured by application of several methods. However, no data about specific 
CP metabolite formation were presented It was shown that after 
phénobarbital pretreatment especially cytochrome P4502B1, contributed to the 
biotransformation of CP in the rat, whereas cytochromes P4502C6 and 2C11 
were responsible for the biotransformation of CP in control rat liver (Clarke and 
Waxman, 1989, LeBlanc and Waxman, 1989) Recently, it was demonstrated 
that CP hydroxylation in man was preferentially catalyzed by liver microsomal 
cytochrome P4502B (Chang et al., 1993) It is suggested that induction of 
enzymes involved in CP biotransformation results in an increased therapeutic 
effect since more of the DNA-alkylating metabolite phosphoramide mustard is 
formed However, the absence of NAD-hnked aldehyde dehydrogenase and 
aldehyde oxidase in incubations with microsomes and purified P450 systems 
might overestimate the formation of phosphoramide mustard because 
metabolites such as CAR and KCP could not be formed It was our aim to 
study the effect of enzyme induction and sex on the formation of toxic (NNM) 
and non-toxic (CAR and KCP) CP metabolites in rat liver S9 fractions. 
In common wi th other investigators, we also found that the biotransformation 
of CP was increased after Aroclor 1254 and phénobarbital pretreatment 
(Sladek, 1988, Clarke and Waxman, 1989; LeBlanc and Waxman, 1989) 
However, the NNM/CAR ratio was slightly changed after Aroclor 1254 
pretreatment but increased after phénobarbital pretreatment This is possibly 
caused by a higher increase in CAR formation due to induction of aldehyde 
dehydrogenase (Lindahl, 1992). 
The effects of smoking and alcohol on biotransformation enzymes in the rat 
were mimicked by pretreatment of the rats wi th ß-naphthoflavone and ethanol, 
respectively These so-called life-style factors may cause induction or inhibition 
of enzymes involved in the biotransformation of toxic compounds such as CP 
(Fourmer and Thomas, 1986) In the present study, no differences in the 
biotransformation of CP were observed after ß-naphthoflavone pretreatment 
(P4501A1 induction) and after ethanol pretreatment (P4502E1 induction) 
From these results it could be concluded that pretreatment of rats wi th ß-
naphthoflavone and ethanol did not increase CP hydroxylation. Comparable 
results were found in in vitro experiments wi th microsomes of human donor 
livers which showed that P4501A1 , 1A2 and 2E1 did not contribute to the 
hydroxylation of CP (Chang et al., 1993). In addition, we did not f ind a 
correlation between EROD activity and NNM, CAR, total metabolite formation 
and the NNM/CAR ratio in a human liver incubation study (Sessink et al , 
1995a) On the contrary, we found a correlation between CAR and total 
metabolite formation and AH activity while NNM formation and the NNM/CAR 
ratio were not correlated 
The formation rate of NNM and CAR will differ depending on the biological 
variation in NAD and GSH levels in rat and human liver This variation. 
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mimicked by supplementation with NAD necessary for the formation of CAR, 
increased the formation of this metabolite and decreased the formation of 
NNM as expected. In a corresponding way, NNM formation was decreased 
after supplementation with GSH. This is explained by conjugation of the 
electrophiles NNM and phosphoramide mustard. 
We have found that the in vitro biotransformation of CP was strongly 
influenced by sex, and also by supplementation with NAD and GSH. It is 
concluded that pretreatment with the enzyme-inducers, ethanol and ß-
naphtoflavone, did not influence the biotransformation of CP in the rat. Hence, 
it is tempting to conclude that alcohol consumption and smoking, mimicked by 
pretreatment of rats with ethanol and ß-naphthoflavone, respectively, will not 
affect CP biotransformation in man. 
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Abstract 
In the present study a cancer risk assessment of occupational exposure to 
cyclophosphamide (CP), a genotoxic carcinogenic antineoplastic agent, was 
carried out following two approaches based on (1) data from an animal study 
and (2) data on primary and secondary tumors in CP-treated patients. Data on 
the urinary excretion of CP in health care workers were used to estimate the 
uptake of CP, which ranged from 3.6 to 18 //g/day. Based on data of an 
animal study, cancer risks were calculated for a health care worker with a 
body weight of 70 kg and a working period of 40 years, 200 days a year 
(linear extrapolation). The lifetime risks (70 years) of urinary bladder cancer in 
men and leukemias in men and women were found to be nearly the same and 
ranged from 95 to 600 per million. Based on the patient studies, cancer risks 
were calculated by multiplication of the 10-year cumulative incidence per gram 
of CP in patients by the estimated mean total uptake in health care workers 
over 10 years, 200 days a year. The risk of leukemias in women over 10 years 
ranged from 17 to 100 per million using the secondary tumor data (linear 
extrapolation). Comparable results were obtained for the risk of urinary bladder 
tumors and leukemias in men and women when primary tumor data were 
used. Thus, on an annual basis, cancer risks obtained from both the animal 
and the patient study were nearly the same and ranged from about 1.4 to 10 
per million. In The Netherlands it is proposed that for workers, a cancer risk 
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per compound of one extra cancer case per million a year should be striven for 
("target risk") and that no risk higher than 100 per million a year ("prohibitory 
risk") should be tolerated. From the animal and the patient study it appears 
that the target risk is exceeded but that the risk is still below the prohibitory 
risk. 
Introduction 
Antineoplastic agents are widely used in the treatment of cancer and some 
non-neoplastic diseases [5,6]. Depending on their mechanism of action, these 
drugs are subdivided into several categories, e.g., alkylating agents, 
antimetabolites, mitotic inhibitors, and antibiotics. The alkylating agents 
express their cytotoxicity by interaction with the DNA of tumor cells. Because 
the desired cytotoxicity is not specific for cancer cells, normal cells may also 
be damaged, resulting in toxic side-effects. Carcinogenicity of a number of 
antineoplastic agents has been observed in animal studies and primary and 
secondary tumors have been found in patients treated with these drugs 
[4,10,11,13-17,21]. Cyclophosphamide (CP) is one of the most frequently 
used alkylating antineoplastic agents for different types of tumors [5,31]. 
According to the International Agency for Research on Cancer, there is 
sufficient evidence of carcinogenicity in humans and animals [13,14]. Due to 
its reactivity with DNA and mutagenicity in various short-term tests, CP is 
classified as a genotoxic carcinogen. 
Because of the carcinogenic potency of CP and other antineoplastic agents, 
health care workers involved in the preparation and administration of these 
drugs may be at risk [30]. Therefore exposure to these compounds should be 
avoided, and safety guidelines and protective measures such as wearing 
masks, gloves, gowns, and special clothes and using laminar air-flow safety 
hoods have been introduced to protect workers when handling these drugs 
[1,29]. Nevertheless, in several studies it has been shown that uptake of CP 
does occur during occupational activities [24,25,27,28]. With a sensitive gas 
chromatographic-mass spectrometric method CP has been detected in the 
urine of health care workers handling antineoplastic drugs [26]. 
The risk of exposure to CP and other antineoplastic agents has been discussed 
in many studies [7,9,32]. However, a quantitative risk assessment could not 
be made because of the lack of the necessary exposure data. In this study we 
used data on the urinary excretion of CP in health care workers to estimate the 
uptake of CP. Next, a cancer risk assessment was carried out following two 
approaches based on (1) data from an animal study and (2) data on primary 
and secondary tumors in CP-treated patients. 
Although we realize that risk assessment of occupational exposure to 
carcinogens is a complex matter, we think that such data are necessary to set 
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priorities in the protection of workers against genotoxic carcinogens In this 
paper we present an anitial approach to cancer risk estimation for health care 
workers exposed to CP The pitfalls are discussed 
Materials and methods 
Carcinogenicity studies in animals 
The carcinogenicity of CP has been observed in several animal studies 
[13,14,21] For cancer risk assessment, studies are needed in which the 
animals are chronically exposed to at least two doses, preferably giving a clear 
dose-response relationship Only the study of Schmahl and Habs appears to 
satisfy this requirement [20] In this study male and female Sprague-Dawley 
rats were treated with CP in drinking water The treatment started when the 
rats were 100 days old Doses of 0, 0 31 , 0 63, 1 25 and 2 5 mg/kg body 
weight were administered, 5 times a week, during their lifetime Forty rats 
were used for each sex and dose After a lifetime observation period, tumors 
of the urinary bladder and of the lymphoid and hematopoietic tissues 
(leukemias) were most frequently found and a dose-response relationship was 
obtained (Table 1) A statistically significant increase in leukemias was 
observed in males and females combined Only in males was a statistically 
significant increase in tumors of the urinary bladder found 
Epidemiological studies in patients 
Many cases of cancer have been reported after therapeutic treatment with CP 
[4,10,11,13,14,16,17,21] Among the various types of cancer, leukemias and 
tumors of the urinary bladder have been found most frequently not only as 
secondary tumors following cancer treatment but also as primary tumors after 
treatment for other non-neoplastic diseases In some of these studies the 
doses of CP were known and consequently the relative risks could be 
calculated [11,17] The results of these studies showed a dose-dependent 
increase in the relative risk of developing leukemias after treatment with CP for 
breast and ovarian cancer For cancer risk assessment only data can be used 
from studies in which, in addition to the dose of CP administered, the tumor 
incidence is given Both kinds of data were available, from two studies and 
these are briefly described below [4,10] 
In five clinical trials the development of secondary leukemias was studied in 
333 ovarian cancer patients treated with CP [10] For the total group, a 10 
year cumulative incidence of 5 4% was calculated When the total group was 
subdivided into three dose groups, only in the highest dose group were 
leukemias observed, with a 10-year cumulative incidence of 11 1% For 1657 
ovarian cancer patients not treated with CP a 10-year cumulative incidence of 
0 1 % was found 
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Table 1. Urinary bladder tumors and /eukemias from oral cyclophosphamide 
treatment in male and female Sprague-Dawley rats3. 
dose 5 t imes a 
week (mg/kg 
body weight) 
0 
0.31 
0.63 
1.26 
2.5 
number of urinary bladder tumors 
males 
0/38 
2/34 
2/36 
5/35 c 
7/31° 
» f rom Schmahl and Habs |20] 
l
' Fischer exact test : 
c
 Fischer exact test : 
d
 Fischer exact test: 
" Fischer exact test : 
' Fischer exact test : 
Я = 
P = 
P = 
P = 
P = 
= 0.015 
= 0 . 0 2 2 
= 0.011 
= 0 . 0 0 2 4 
0 . 0 3 7 
females 
0/34 
0/37 
0/37 
0/33 
1/27 
number of leukemias 
males and females 
0/72 
3/71 
6/73 b 
6/68" 
4/58' 
The development of tumors was also studied in patients with rheumatoid 
arthritis treated with CP as an immunosuppressive agent [4]. A total of 119 
patients (76 women) were treated with a mean CP dose of 52.9 g while 119 
matched controls received no CP. Tumors were observed in 24.4% of the CP-
treated patients during an observation period of 10.8 year. A tumor incidence 
of 13.4% was observed in the matched controls during an observation period 
of 11.8 year. An increased incidence was observed for urinary bladder tumors 
(6 vs 0), skin cancer (8 vs 0) and leukemias (5 vs 1). The proportion of 
patients with tumors was significantly higher among men than women in the 
CP-treated group and in the control group. The increase in tumors between the 
control group and the CP-treated group was the same for men and women. 
Unfortunately, no information was available upon sex-specific tumor types. 
Estimation of the daily uptake 
Despite the introduction of safety guidelines and protective measures, in 
several studies it has been shown that (health care) workers involved in the 
preparation and administration of antineoplastic agents like CP are exposed to 
this particular compound, since uptake was established by detection of CP in 
urine (Table 2) [8,12,24,25,27,28]. In order to avoid the use of unreliable data 
obtained from urinary CP excretion after a rather short period of only a few 
days, urine of eight hospital pharmacy workers was collected during two to 
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four periods of 4 successive days. A total of 476 urine samples were 
analysed. CP was detected in one or more urine samples of each worker. The 
mean daily excretion was 0.18 //g (range: 0.01-0.53 pg). These urinary excre­
tion levels are the basis for the estimation of the exposure. In urine samples 
with undetectable amounts of CP the amounts excreted were set at zero. 
Table 2. Range of cyclophosphamide in urine of (health care) workers exposed 
to antineoplastic agents. 
group 
health care workers 
nurses 
pharmacy technicians 
pharmacy technicians 
animal caretakers 
pharmacy technicians'1 
pharmacy technicians" 
nurses 
pharmacy technicians 
cleaning w o m e n 
nurses 
pharmacy technicians 
no. of 
workers 
2 0 
2 
2 
25 
4 
9 
9 
8 
1 
2 
7 
8 
period of urine 
sampling (days) 
4 
57" 
2 
1-2 
2-5 
1-2 
5 
1 
2-4 
8-16 
mean amount* (range) 
of CP in urine (//g/day) 
0.39 (0-2.5) 
0.47 (0.43-0.51)° 
0 
0.05 (0-0.5) 
0.05 (0-0.2) 
1.36 (0-10.05) 
0.16 (0-0.51) 
0.79 (0-2.9I 
0 . 8 0 (0-4.2) 
0.18 (0 01-0.53) 
reference 
Evelo et al. |8| 
Hirst et al. 112] 
Sessink et al. !231 
Sessink et al. 124] 
Sessink et al. [ 2 5 ] 
Sessink et al. |27| 
unpublished 
Sessink et al. 128] 
unpublished 
this study 
amounts below the detect ion l imits were set at zero 
in both nurses urine sampling was performed over a total of 57 days 
mean and range were calculated by assuming a mean sampling period of 28 Уз days 
the same persons 
It is supposed that during occupational activities antineoplastic agents like CP 
are absorbed by inhalation and via dermal penetration [2,12,18,27]. Suchlike 
exposure conditions were imitated in rats by intratracheal instillation and 
dermal application of a single CP dose of 1 mg/kg body weight [22]. For both 
treatments a total of about 5% of the applied dose was excreted unchanged in 
urine, all within 24 h. Application of 1 mg CP on the skin of volunteers 
revealed an urinary excretion of about 1 % [12]. The mean uptake of CP was 
calculated by multiplication of the mean daily urinary CP excretion of 0.18 pg 
by 20 (5% excretion after dermal and intratracheal treatment of rats) or 100 
( 1 % excretion after dermal application in volunteers). Hence, it was estimated 
that the mean daily uptake of CP will range from 3.6 to 18 pg. 
190 Chapter 5 
Cancer risk assessment based on the animal study 
Cancer risks were estimated using linear extrapolation and assuming that the 
time dependence of tumor development is more likely related to the cumulative 
dose of CP than to life span and the rate of aging [19]. The model is based on 
intersection of a straight line between zero dose and the lowest dose in the 
animal experiment at which a significant increase in tumors is observed (Table 
1). From the results of the study of Schmahl and Habs, the median survival 
periods of the rats at the different doses were obtained [20]. To calculate the 
exposure periods, the survival periods were reduced by 100 days (at the start 
of the experiment the rats were 100 days old) and multiplied with 5/7 (the rats 
were administered CP 5 times a week) The total cumulative CP doses were 
calculated by multiplication of the doses by the exposure periods. The cancer 
risks per mg CP were calculated by dividing the tumor incidences by the total 
cumulative CP doses. Finally, lifetime cancer risks for health care workers 
were calculated by multiplication of the cancer risks per mg CP in rats by the 
total cumulative CP uptake of the health care workers over a working 
(exposure) period of 40 years (range: 28 8-144 mg) and the results were 
divided by body weight. An overview of the calculated data is given in Table 
3 
Cancer risk assessment based on the epidemiological studies 
From the study of Greene et al., the 10-year cumulative cancer risk per gram 
was calculated by using the median dose of 19.5 g among the total group and 
the corresponding 10-year cumulative cancer incidence of 5.4% [10]. A linear 
dose-response curve was constructed, using the 10-year cumulative cancer 
risk of 0.1 % which was observed in the control group of patients without CP 
treatment. Finally, a 10-year cumulative cancer incidence of 0.27% per gram 
was calculated. A 10-year cumulative cancer incidence of 0.24% per gram 
was calculated by using the data of the highest dose group of 46.35 g and the 
corresponding 10-year cumulative cancer incidence of 11 1 %. 
The same procedure was followed for the results of the study by Baker et al. 
[4] The 10-year cumulative cancer risk difference between CP-treated patients 
and control patients was calculated by linear extrapolation from the measured 
10.8 year observation period to a 10 year period. The mean dose was 52.9 g, 
resulting in a 10-year cumulative cancer incidence of 0.21 % per g. 
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Results 
Cancer risk assessment based on the animal study 
Cancer risks were calculated for a health care worker of 70 kg body weight 
and a working (exposure) period of 40 years, 200 days a year. Within the 
range of the estimated mean daily CP uptake of 3.6-18 pg (total cumulative CP 
uptake over 40 years: 28.8-144 mg), the calculated lifetime risks of urinary 
bladder cancer in men and leukemias in men and women were nearly the same 
and range from 120 to 600 per million and 95 to 475 per million, respectively 
(Table 3). 
Table 3. Cancer risk calculations for health care workers obtained by linear 
extrapolation using incidence of tumor of the urinary bladder in male 
rats and leukemias in male and female ratsa. 
parameter urinary bladder tumors leukemias 
rat 
lowest dose w i t h significant 1.25 0.63 
increase in t u m o r s ' 
(mg CP/kg body weight per day) 
tumor incidence11 (%) 14.3 8.2 
median survival period (days) 6 4 6 8 8 9 
exposure period (days) (646-1001x5/7 = 3 9 0 (889-100)x5/7 = 5 6 4 
total cumulated dose 1.25x390 = 4 8 7 . 5 0 . 6 3 x 5 6 4 = 355 
(mg CP/kg body weight) 
cancer risk per mg CP 0.143/487.5 = 2 9 3 x 1 0 6 0 .082/355 = 2 3 3 x 1 0 " 
(kg body weight/mg CP) 
health care worker 
l i fetime cancer nsk c 1/70x293x(28.8-144) = 1 2 0 - 6 0 0 1/70x233x128.8-144) = 95-475 
(per million) 
' f rom Schmahl and Habs 120] 
ь
 f r o m Table 1 
c
 70 kg body weight; total cumulative CP uptake over 4 0 years: 2 8 . 8 - 1 4 4 m g 
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Cancer risk assessment based on epidemiological studies 
Cancer risks were calculated by multiplication of the 10-year cumulative 
incidence per gram CP in patients by the estimated mean total CP uptake in 
health care workers over 10 years, 200 days a year, based on the estimated 
mean daily uptake of 3.6-18 //g (total cumulative CP uptake over 10 years: 
7.2-36 mg). No differences were found in the study on secondary tumors by 
Greene et al. between the results based on calculations with the median dose 
of the total group of 19.5 g and the highest dose group of 46.35 g (Table 4) 
[10]. In both cases cancer risk ranged from about 17 to 100 per million. A 
marginally lower cancer risk of 15 to 76 per million was obtained when 
primary tumor data from the study by Baker et al. were used (Table 4) [4]. 
Table 4. Cancer risks for health care workers obtained from tumor incidence 
data of patients. 
patients" exposed workers ' reference 
CP dose (g) cancer risk (per million) cancer risk (per million) 
leukemias in women 
19.5C 5 4 0 0 0 20-100 Greene et al. 1101 
46 .35 " 111000 17-86 
0" 1000 
urinary bladder tumors and leukemias in men and women 
52.9 ' 1 1 2 0 0 0 15-76 Baker at al. | 4 | 
' 10-year observation period 
b
 10-year exposure period (total cumulative CP uptake over 10 years: 7.2-36 mg) 
' median dose 
d
 highest dose group 
" control group wi thout CP treatment 
' mean dose 
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Discussion 
In the present study a cancer risk assessment of occupational exposure to CP 
was carried out following two approaches based on (1) data from an animal 
study and (2) data based on primary and secondary tumors in CP-treated 
patients During this operation several assumptions were made, and these are 
discussed below 
Tumor type 
The same tumor types, namely urinary bladder tumors and leukemias, were 
found in the animals and in the patients It is remarkable that urinary bladder 
tumors only appeared in male rats while leukemias were observed equally in 
male and female rats Unfortunately, no information is available from the 
patient study of Baker et al with respect to the sex-specific induction of 
urinary bladder tumors [4] Consequently it is assumed that no sex differences 
were present Because the study of Greene et al only included women, it 
remains impossible to establish whether leukemias were induced in a sex-
specific manner [10] For extrapolation of the results of the animal study and 
patient studies this means that (1) the animal study may only be used for risk 
assessment of urinary bladder tumors in men and leukemias in men and 
women, (2) extrapolation from the patientstudy of Greene et al is restricted to 
risk assessment of leukemias in women, and (3) it is assumed that the patient 
study of Baker et al is suitable for the risk assessment of urinary bladder 
tumors and leukemias in men and women [4,10] 
Estimation of the daily uptake 
For the estimation of the mean daily CP uptake, the excretion of 
unmetabolized CP in urine was investigated In order to obtain accurate 
information about the daily CP excretion in urine, urine samples were collected 
from several persons over two to four periods of 4 successive days In this 
way incidentally extremely high levels were averaged and overestimation was 
minimized Nevertheless, a large intenndividual difference in CP excretion was 
obtained, undoubtedly due to intenndividual differences in uptake and/or 
biotransformation of CP In order to compare the results of the different 
studies in a proper way, undetectable amounts of CP were set at zero This 
results in an underestimation of the cancer risk For the estimation of the 
uptake, we used results of studies in which relatively low amounts of CP were 
administered to rats and volunteers Data of patients were not used because 
the amounts of CP administered were much higher than would be expected 
after occupational exposure 
The results of the animal study showed that a total of about 5% of a single CP 
dose of 1 mg/kg body weight was excreted in urine, all within 24 h, 
irrespective of the route of exposure (intratracheal, dermal, oral, intravenous) 
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[22] Lowering of the dermally applied dose to 0.1 and 0 01 mg/kg body 
weight resulted in excretion percentages of 8 3% ± 2 1 % and 5 1 % ± 2.9%, 
respectively (mean ± S D., л = 5); these figures are not significantly different 
from one another (unpublished results) Therefore the excretion of 
unmetabohzed CP is estimated to be about 5% of the administered dose It is 
unclear why the percentage recovery of CP m urine in the volunteer study was 
only about 1 % [12]. This may, of course, have been due to interspecies 
differences, but on the other hand it may also have been the result of 
incomplete absorption by the human skin. This latter possibility, which seems 
quite reasonable, would lead to an overestimation of both mean daily uptake 
and cancer risk if 1 % excretion is taken as a starting point. Nevertheless, this 
is the only study in which volunteers have been treated with a relatively low 
CP dose. It should also be pointed out that the influence of chronic low-dose 
exposures by different exposure routes on the excretion percentage remains 
unknown. 
Extrapolation 
The data from the animal study showed a linear dose response curve between 
daily CP dose and cancer risk Consequently, linear extrapolation was used for 
cancer risk assessment It should be noted that cancer risk is not primarily 
caused by the amount of CP absorbed but depends on the amount of 
phosphoramide mustard formed after biotransformation [31]. The formation of 
phosphoramide mustard results in the alkylation of target DNA and cancer risk 
is expected to correlate better with the amount of phosphoramide mustard 
able to bind to target tissue. On the basis of the linear dose-response 
relationship in the animal study between CP dose and cancer risk we assume 
that the amount of phosphoramide mustard increases linearly with the CP 
dose. Since biotransformation of CP in man and rat are similar, it is also 
reasonable to assume that in patients the amount of phosphoramide mustard 
will increase linearly with the dose [13,31] This explains our choice of the 
linear extrapolation when using the patient data 
Cancer risk 
The results of the animal study showed a lifetime risk (70 years) of urinary 
bladder tumors in men and of leukemias in men and women of 95-600 per 
million after a period of CP exposure of 40 years, 200 days a year. 
Comparable cancer risks of 1.5-10 per million a year were estimated from the 
patient studies. It should be noted that in the animal study the number of 
lifetime cases was indicated while the cancer risk in patients was estimated on 
an observation period of 10 years. Since it is unclear how the dose-response 
curve will be after the 10-year observation period, it is not possible to show 
what the consequences will be for lifetime cancer risks Therefore the 
calculated risks most probably are underestimates. It should also be noted that 
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in the patient study of Greene et al. a possible predisposition of the patients 
under consideration may have resulted in higher cancer incidences upon 
treatment wi th genotoxic carcinogens [10]. It should be emphasized that in the 
study of Baker et al. the total cancer risk was assessed [4] . Not only urinary 
bladder tumors and leukemias were considered but also other types of cancer, 
especially skin cancer. This may partly explain the lower cancer risk calculated 
from the animal study as only urinary bladder tumors and leukemias could be 
taken into account here. Risks based on animal data should be calculated from 
the number of tumor-bearing animals, i.e., the sum of the number of animals 
having tumors at sites that show a statistically increased incidence as 
compared to controls. Unfortunately, the data of Schmähl and Habs do not 
allow such an approach, which might have resulted in higher estimated cancer 
risks [20]. 
Cancer risk and legislation 
In the United States, Sweden, Germany, and the European Union, treshold 
limit values or comparable maximum exposure levels have been introduced for 
some (genotoxic) carcinogens in order to protect workers [3] . In The 
Netherlands it is proposed that, for workers, a cancer risk for each compound 
of 1 extra cancer case per million a year should be striven for ("target risk") 
and that no risk higher than 100 per million a year ("prohibitory risk") should 
be accepted [3]. From the animal and the patient study it appeared that the 
target risk is exceeded but that the risk is still below the prohibitory risk. 
Nevertheless, it should be noted that in some studies groups of workers have 
excreted higher amounts of CP than the mean daily CP excretion of 0.18 jug in 
the present study, consequently resulting in higher cancer risks (Table 2). 
It should be emphasized that this risk assessment was based on exposure to 
one single antineoplastic agent while it is known that more antineoplastic 
agents are used for which no exposure data are available. However, it is 
reasonable to assume that exposure to all antineoplastic agents will occur in a 
similar manner because the drugs are mostly handled in a comparable way. In 
fact, this means that the cancer risk might be higher than assessed in the 
present study, supposing that no antagonistic interaction takes place. 
However, this is not of influence in possible surpassing of target and 
prohibitory risk levels because these are based on single compounds. 
In conclusion: The calculated cancer risk due to occupational exposure to CP 
was based on available dose-response data and on the indirect assessment of 
CP exposure by measuring CP excretion in urine. Although the presented 
cancer risk assessment due to exposure to CP has its limitations, the cancer 
risks calculated from CP exposure of health care workers indicate that these 
workers still have higher risks for cancer due to the handling of CP and/or 
other antineoplastic agents in spite of the protective measures that have been 
taken. 
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Chapter 6 
General discussion and summary 
The aim of the research studies presented in this thesis was the development 
and validation of methods for monitoring of occupational exposure to 
antineoplastic drugs. After evaluation of the methods used hitherto, it was 
concluded that there is a need for sensitive and compound-specific methods 
for EM and BM. Data about the use of parenterally administered antineoplastic 
drugs in the Netherlands over 1986-1988 showed that CP, IP, and 5FU were 
most frequently used. During the validation studies, it was observed that in 
addition to these drugs, MTX was also often administered. Therefore, CP, IP, 
5FU, and MTX were selected for monitoring. 
Development and validation of methods for environmental and 
biological monitoring of antineoplastic agents 
Environmental monitoring 
Methods for the determination of CP, IP, 5FU and MTX in environmental 
samples were developed and applied in several studies to measure the release 
and the spread out of these drugs during several occupational activities. In 
principle, the EM methods were developed to validate the BM methods. 
For the determination of CP and IP in air- and wipe samples a sensitive GC-MS 
method was developed. 5FU and MTX were determined using HPLC methods. 
In general the drugs are extracted from the air- and wipe samples with a 
sodium hydroxide solution. In the case of 5FU and MTX, the extracts can 
almost directly be analysed. For the determination of CP and IP, the same 
extracts are further cleaned up by extraction with an organic solvent. The 
organic solvent is evaporated and the extract is derivatised with trifluoroacetic 
anhydride. The limit of detection for 5FU ranges from 7 to 65 ng/ml extract. 
For CP, IP and MTX, the limits of detection are 0.25, 0.25, and 0.60 ng/ml 
extract, respectively. 
Exposure to CP, 5FU, and MTX was measured by the analysis of these 
compounds in air samples and wipe samples from possibly contaminated 
surfaces and objects. 
During preparation of the drugs, stationary air samples were taken in front of 
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the laminar air-flow hoods. CP (0.2 //g/m3) and MTX (0.3 //g/m3) were 
detected once. Personal air samples were also taken. The CP concentration 
ranged up to 10.1 //g/m3. Contamination of the work environment was found. 
On the working trays of the laminar air-flow hoods CP, 5FU, and MTX were 
present (CP: to 160 ng/cm2; 5FU: to 62 ng/cm2; MTX: to 633 ng/cm2). Even 
after cleaning of the laminar air-flow hood, it remained contaminated (CP: to 
14 ng/cm2; 5FU: to 27 ng/cm2; MTX: to 293 ng/cm2). On the floors in front of 
and beneath the laminar air-flow hoods (CP: to 2.6 /yg/m2; 5FU: to 236 /yg/m2) 
and on the floors of the adjacent rooms (5FU: to 107 /jg/m2) the presence of 
CP and 5FU was established. The gloves used during preparation of the drugs 
(CP: to 149 /jg/pair of gloves; 5FU: to 1070 /yg/pair of gloves; MTX to 1963 
//g/pair of gloves) and used during cleaning of the hoods (CP: to 11 /уд/pair of 
gloves; 5FU: to 59 //g/pair of gloves; MTX: to 49 //g/pair of gloves) were 
frequently contaminated. Incidentally on vials (CP: 0.06 //g; MTX: 15 //g) used 
for the preparation of the drugs and on packings of prepared drugs (CP: 2.1 
¿ig; 5FU: to 6.2 /yg) CP, 5FU and MTX were detected. 
The floors in the administration rooms, the floors in adjacent rooms (CP: 0.9 
ng/cm2; MTX: to 5.9 ng/cm2) and the floors around the beds of the patients 
were contaminated with CP (median: 4.5 /уд/cm2) and 5FU (median: 1.8 
ng/cm2). Incidentally CP and 5FU were found on other objects such as tables 
(CP: to 4.5 /jg; 5FU: to 22 /yg) and cleaned urinals (CP: 8.3 /yg). 
Comparable results were found in a situation where animal keepers were 
involved in the injection of CP to laboratory animals. CP was detected on 
filters of the air-circulation system (to 1.0 /уд/day) suggesting contamination of 
the environmental air although on the masks of the workers no CP was found. 
CP was detected in wipe samples taken from the floor (to 0.4 ng/cm2), several 
objects and surfaces (to 44 ng/cm2). CP was also detected in adjacent rooms 
(to 6.9 ng/cm2). The gloves (to 199 /yg) and sleeve protectors (to 10 μg) used 
during the injection were also contaminated with CP. 
Although special guidelines and protective measures have been introduced to 
protect hospital workers during the handling of antineoplastic agents, it was 
found that they do not prevent the presence of these toxic compounds in the 
work environment. The introduction of additional protective measures such as 
adaptations of the laminar downflow hood, the use of special masks and 
double pairs of gloves by the workers and the replacement of 5FU ampules in 
5FU vials resulted in a decrease of the concentrations of CP in the air during 
preparation of the drugs. It is suggested that replacement of 5FU ampules by 
5FU vials is probably responsible for the diminished contamination of the latex 
gloves with 5FU. Possibly the breaking of ampules is a cause for the release of 
aerosols resulting in the contamination of the gloves. The results suggest that 
the introduced additional protective measures have reduced the external 
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exposure to CP and 5FU To what extent each of the additional protective 
measures has reduced the exposure, remains unknown 
Environmental exposure to 5FU and MTX was measured in a pharmaceutical 
plant where workers were involved in the production of these drugs 
5FU was found by the analysis of air and wipe samples During weighing, 5FU 
was detected in the air (75 ^g/m3) 5FU was also measured on the filter of the 
mask of the worker involved in weighing the drug (120 μg) Before drug 
compounding, 5FU was found on the floor (up to 8 ng/cm2) After routine 
cleaning significantly higher amounts of 5FU were measured (70-630 ng/cm2) 
suggesting ineffective cleaning procedures The gloves used were always 
contaminated (22-720 /ug/pair of gloves) 
MTX was detected in air samples of all workers except for those involved in 
the vial filling process (0 8-182 //g/m3) The highest concentrations were 
observed for workers weighing MTX (118 and 1 82 pg/m3) 
The results presented above show that the methods developed and used are 
applicable to measure the release and the spread out of CP, 5FU, and MTX 
after several occupational activities 
Biological monitoring 
A sensitive GC-MS method was developed for the determination of CP and IP 
in urine Sample preparation (liquid-liquid extraction) followed by denvatisation 
with tnfluoroacetic anhydride makes the method appropriate for routine 
analysis and enables to measure the uptake of these drugs during the 
preparation and administration. The limit of detection is approximately 0 25 
ng/ml urine. 
In several studies presented in this thesis, the method was validated. The 
uptake of CP and IP was measured by determination of these drugs in the 
urine of workers such as pharmacists and pharmacy technicians involved in 
drug preparation, nurses involved in drug administration and animal keepers 
involved in the injection of chemicals to laboratory animals The highest CP 
excretion rate observed was about 10 //g/day (Table 1) However, it is shown 
that there were large differences between the groups It should be noted that 
the most reliable information about the magnitude of the urinary excretion rate 
of CP is obtained by analysing urine samples of a large group of workers for a 
long period. CP and IP were found not only in the urine of pharmacy 
technicians, nurses and an animal keeper actively handling these compounds 
but also in the urine of pharmacy technicians and nurses not directly involved 
in the preparation and administration of these drugs CP and IP were excreted 
during different periods after the beginning of the working period, suggesting 
different times of exposure, different exposure routes, and/or intenndividual 
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differences in biotransformation and excretion rate for these compounds. 
Table 1. Overview of several studies concerning the measurement of excretion 
rates of CP in urine in (health care) workers exposed to antineoplastic 
agents 
group 
nurses 
health care workers 
pharmacy technicians 
pharmacy technicians/nurses 
animal keepers 
pharmacy technicians" 
pharmacy technicians" 
nurses 
pharmacy technicians 
cleaning w o m e n 
nurses 
pharmacy personnel/nurses 
pharmacy technicians 
number of 
workers 
2 
2 0 
2 
18 
4 
9 
9 
8 
1 
2 
7 
21 
8 
period of 
sampling 
in urine 
5 7 b 
4 
2 
1-2 
2-5 
1-2 
5 
1 
2-4 
1-5 
8-16 
urine 
(days) 
mean excretion rate* 
(range) of CP 
(//g/day) 
0.47 (0.43-0.511° 
0.39 (0-2.5) 
0 
0.05 (0-0.5) 
0.05 (0-0.2) 
1.44 (0-10) 
0 . 1 6 (0-0.51) 
0 . 7 9 (0-2.9) 
0 . 8 0 (0-4.2) 
5.2 (0-38) 
0.18 (0.01-0.53) 
reference 
11] 
121 
chapter 2.1 
chapter 2.2 
chapter 2.4 
chapter 2.5 
chapter 2.6 
chapter 3.1 
[31 
chapter 5.1 
* the excretion rates calculated for amounts below the detection l imits were set zero 
ь
 both nurses sampled urine over a total of 57 days 
c
 mean and range were calculated by assuming a mean sampling period of 28'/2 days 
" the same persons 
| 1 | Evelo СТА, Bos RP, Peters JGP, Henderson PTh. Urinary cyclophosphamide assay as a method 
for biological monitoring of occupational exposure to cyclophosphamide. Int Arch Occup 
Environ Health (1986) 5 8 : 1 5 1 - 1 5 5 . 
I2] Hirst M, Tse S, Mil ls DG, Levin L. Occupational exposure to cyclophosphamide. The Lancet 
( 1 9 8 4 ) : 1 8 6 - 1 8 8 . 
13] Ensslin AS, Stoll Y, Pethran A, Pfaller A, Rommelt H, Fruhmann G. Biological monitoring of 
cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to 
cytostat ic drugs. Occup Environ Med (1994b) 5 1 : 2 2 9 - 2 3 3 . 
Although special guidelines and protective measures have been introduced to 
protect hospital workers during the handling of antineoplastic agents, it was 
found that they do not prevent the uptake of these toxic compounds. 
Therefore, in one study additional protective measures were introduced to 
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investigate whether the developed methods could be used in intervention 
studies The measures included adaptations of the laminar downflow hood, the 
use of special masks and double pairs of gloves by the workers and the 
replacement of 5FU ampules by vials The effects of these additional measures 
were compared with the results of a previous study It was shown that the 
introduced additional protective measures reduced the external exposure to 
CP The mean CP excretion rate before and after the intervention was 1 44 
and 0 16 /ug/day, respectively The difference was not statistically different 
For the determination of MTX in urine after occupational exposure, a FPIA 
method was developed FPIA, is frequently used for monitoring serum levels in 
patients treated with MTX The FPIA method was modified in such a way that 
MTX could be measured quickly and efficiently in urine samples of exposed 
workers The urine samples are purified using solid phase extraction 
Concentrations of at least 1 equivalent MTX/ml urine could be detected 
A GC-MS method was developed for the determination of FBAL, a main 
metabolite of 5FU in urine of exposed workers Before analysis, FBAL is 
denvatized with S-ethyltrifluorothioacetate and acidified η-butyl alcohol The 
detection limit is about 60 ng/ml urine 
The methods developed for biological monitoring of exposure to 5FU and MTX 
have been validated in a pharmaceutical plant where workers are involved in 
the production of 5FU and MTX Fifty micrograms of FBAL were found in one 
urine sample of a worker weighing 5FU The excretion rate of MTX over 72-
96h was higher for the exposed groups of workers (mean 4 2 цд MTX-
equivalents/24 h, range 1 5-7 0 цд MTX-equivalents/24 h) compared to their 
controls (mean· 3 2 //g MTX-equivalents/24 h, range 1 5-6 6 pg MTX-
equivalents/24 h) 
The developed methods have been proven to be appropriate for biological 
monitoring of occupational exposure to CP, IP, 5FU and MTX The methods 
have been applied in several studies It appeared that the methods were 
appropriate for the measurement of the uptake of the compounds in the body 
of the workers The results of several studies described here have shown that 
during the preparation and administration of antineoplastic agents, among 
which CP, the workers were internally exposed to CP Uptake of CP was even 
found in pharmacy technicians involved in the preparation of antineoplastic 
drugs other than CP The exact exposure routes could not be identified 
although it was indicated that inhalation was probably not the only one 
Especially the results of hospital workers, with CP in their urine, not preparing 
or administering CP, shows the surplus value of this BM method 
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Biological effects in workers exposed to antineoplastic agents 
To study a possible relationship between uptake and an early biological 
response in hospital workers, the excretion of CP in urine and the presence of 
chromosomal aberrations in peripheral blood lymphocytes was determined in 
four groups of subjects with various exposure statuses (17 Dutch and 11 
Czech exposed hospital workers handling antineoplastic agents and 35 Dutch 
and 23 Czech control hospital workers not handling these drugs) The groups 
were subdivided into smokers and non-smokers. 
Within the Dutch groups, the percentage of aberrant cells (3 2 versus 2 0) and 
the number of breaks per eel (0 042 versus 0 023) were increased for smokers 
compared to non-smokers The percentage of aberrant cells was increased in 
Dutch exposed workers in comparison with Dutch control workers (2 6 versus 
2 1) Within the Czech groups the percentage of aberrant cells (2 7 versus 
1 8) and the number of breaks per eel (0 034 versus 0 020) were increased in 
exposed workers in comparison with control workers However, both Dutch 
and Czech smokers mainly contributed to the increase The results suggest an 
additive effect of exposure and smoking in the Dutch subjects and a more than 
additive effect in the Czech subjects 
In the urine samples of 3 out of 11 Dutch exposed workers the CP excretion 
rate ranged from 0 1 to 0 5 /vg/24 h Higher excretion rates were found for 8 
out of 11 Czech exposed workers, ranging from 0 1 to 2 9 //g/24 h No 
correlation was observed between the amounts of CP excreted in urine on the 
one hand and the percentage of aberrant cells and the number of breaks per 
cell on the other hand 
The results suggest that urinary levels of CP up to 2 9 //g/24 h may result in 
biological effects like chromosomal aberrations in the long run Since 
chromosomal aberrations are considered to be indicators of an increased 
genetic risk, these urinary CP concentrations may not only demonstrate 
absorption of CP but may also indicate a serious risk, especially for smokers 
In order to study nephrotoxic effects due to occupational exposure to 
antineoplastic agents, the early renal effect parameters retinol-binding protein 
(RBP) and albumin (ALB) in urine have been determined in 11 hospital workers 
involved in the preparation and administration of antineoplastic agents A 
group of 23 hospital workers not involved in drug handling served as non-
exposed controls No difference was found between the exposed group and 
the non-exposed control group with respect to RBP (7 9 //g/mol CREAT-U 
versus 8 8 /yg/mol CREAT-U) and ALB (0 44 mg/mol CREAT-U versus 0 30 
mg/mol CREAT-U) Although it was demonstrated that the hospital workers 
were exposed to CP, measured by the urinary CP excretion rate (0 1-2 9 
/>g/24 h), the results of the present study show that these exposure levels did 
not cause any defined nephrotoxic effects 
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Toxicokinetic studies on cyclophosphamide (uptake, biotransfor-
mation, and excretion) 
Inhalation and absorption through the skin are supposed to be the most 
important routes of occupational exposure to cytostatic drugs. In a study, the 
excretion rate of unmetabolized CP in rat urine was investigated after 
intratracheal instillation and dermal application, mimicking possible 
occupational exposure routes. The results show that the total amount of CP 
excreted (about 5% of the dose was excreted unchanged) was independent of 
the exposure route. The lowest excretion rate was observed after dermal 
application. 
Our results in rats, along with those of Hirst et al. in dermal-treated 
volunteers, demonstrate that CP easily penetrates rat and human skin [1]. 
Therefore, dermal exposure must be considered as a possible exposure route 
for CP. 
The in vitro biotransformation of CP was studied with S-9 liver fractions of 
human donors. Thereto, sensitive methods for the determination of the CP 
metabolites NNM, KCP and CAR were developed. After liquid-liquid extraction 
and derivatization, the metabolites are determined using gas chromatography 
and thermionic specific detection. The results show large interindividual 
differences in the formation of NNM and CAR. KCP was not detected. 
The biotransformation of CP was also investigated in the rat in vitro with S9 
liver fractions. The aim was to investigate a possible influence of the 
environmental factors smoking and alcohol consumption on the 
biotransformation of CP. The effects were mimicked by pretreatment of rats 
with ß-naphthoflavone and ethanol, respectively. The influence of sex and 
supplementation of the incubates with NAD and GSH was also studied. The in 
vitro hepatic biotransformation of CP in rat was strongly influenced by sex and 
by supplementation with NAD and GSH. No influence of pretreatment with ß-
naphthoflavone and ethanol was observed. The results suggest that the 
influence of the environmental factors smoking and alcohol consumption on 
the biotransformation of CP in man will be negligible. 
Risk assessment of occupational exposure to cyclophosphamide 
A cancer risk assessment of occupational exposure to the genotoxic 
carcinogenic antineoplastic agent CP was carried out following two 
approaches (1) based on data from an animal study, and (2) based on data of 
primary and secondary tumors in CP-treated patients. The uptake of CP was 
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estimated based on the urinary excretion of CP in several workers exposed to 
antineoplastic agents such as CP The uptake varies from 3 6-18 //g per day 
Cancer risk was estimated on the basis of dose-response data from an animal 
study and data from patient studies Several assumptions were made Cancer 
risk based on the animal study was calculated for a 70 kg worker and an 
exposure period of 40 years, 200 days a year Lifetime risk of bladder cancer 
in men and leukemias in women were approximately the same and vary from 
100-600 per million at a daily dose of 3 6-18 //g Cancer risk based on the 
patient study was calculated by multiplication of the 10 year cumulative 
incidence per g CP wi th the mean daily uptake over 10 years, 200 days a year 
ranging from 7 2 to 36 mg Based on secondary tumor data the risk of 
leukemias in women was calculated to be 17-100 per million over 10 years A 
marginally lower risk for bladder cancer and leukemias in men and women of 
1 5-76 was found when primary tumor data were used Thus, on an annual 
basis, cancer risks obtained from both the animal and the patient study were 
nearly the same and ranged from about 1 4 to 10 per million 
In The Netherlands it is proposed that, for workers, a cancer risk for each 
compound of 1 extra cancer case per million a year should be striven for 
("target risk") and that no risk higher than 100 per million a year ("prohibitory 
risk") should be accepted From the animal and the patient study it appeared 
that the target risk is exceeded but that the risk is still below the prohibitory 
risk Nevertheless, it should be noted that in some studies groups of workers 
have higher CP excretion rates than the mean daily CP excretion rate of 0 1 8 
/vg used for the present cancer risk assessment (Table 1) For example, in a 
comparable study wi th 7 nurses a mean excretion rate of 0 80 /vg/day was 
found Consequently, this about 5 times higher CP excretion rate may result in 
a correspondingly higher cancer risk It should be noted that the present risk 
assessment only concerns cancer 
Despite the introduction of "target risk" and "prohibitory risk" levels, it should 
be emphasized that it is the task of employees, employers, and authorities to 
avoid every case of cancer due to occupational exposure to CP and other 
antineoplastic drugs 
In conclusion 
The methods described in this thesis may offer an important contribution to 
trace occupational exposure to antineoplastic agents and consequently to 
reduce the possible health-risks of the workers involved in handling these 
drugs 
Samenvatting 
Het doel van het onderzoek dat ¡n dit proefschrift getiteld Monitoring van 
beroepsmatige blootstelling aan cytostatica wordt beschreven, is het 
ontwikkelen en valideren van methoden voor het meten van beroepsmatige 
blootstelling aan cytostatica. Uit de beoordeling van de methoden die tot het 
begin van het in dit proefschrift beschreven onderzoek in gebruik waren bleek 
dat gevoelige en specifieke methoden voor omgevingsmonitoring en voor 
biologische monitoring van beroepsmatige blootstelling aan cytostatica in feite 
niet voorhanden waren. Uit gegevens over het gebruik van parenteraal 
toegediende cytostatica in de Nederlandse ziekenhuizen gedurende 1986-1988 
bleek dat cyclofosfamide (CP), ¡fosfamide (IP) en 5-fluorouracil (5FU) het 
meest frequent werden gebruikt. Tijdens het onderzoek bleek dat methotrexaat 
(MTX) eveneens veelvuldig werd toegediend. Om deze reden zijn CP, IP, 5FU 
en MTX geselecteerd als modelstoffen voor het ontwikkelen van 
monitoringsmethoden. 
Ontwikkeling en validering van methoden voor omgevingsmonito-
ring en biologische monitoring van cytostatica 
Omgevingsmonitoring 
Methoden voor het bepalen van CP, IP, 5FU en MTX in omgevingsmonsters 
zijn ontwikkeld en in verschillende studies toegepast, met als doel het 
vrijkomen en de verspreiding van deze stoffen gedurende verschillende 
beroepsmatige activiteiten te kunnen meten. De methoden voor omgevings-
monitoring zijn vooral ontwikkeld om de methoden voor biologische monitoring 
te kunnen valideren. 
Voor het bepalen van CP en IP in lucht- en veegmonsters is een gevoelige GC-
MS methode ontwikkeld. 5FU en MTX worden geanalyseerd met behulp van 
HPLC. Allereerst worden de stoffen uit de lucht- en veegmonsters met een 
basische oplossing geëxtraheerd. Voor het bepalen van 5FU en MTX worden 
de extracten vervolgens geanalyseerd. Voor het bepalen van CP en IP worden 
dezelfde extracten verder opgewerkt door een extractie met een organisch 
oplosmiddel. Het oplosmiddel wordt ingedampt waarna het extract wordt 
gederivatiseerd met trifluorazijnzuuranhydride. De detectiegrens varieert van 7 
tot 65 ng/ml extract voor 5FU. Voor CP, IP en MTX zijn de detectiegrenzen 
achtereenvolgens 0,25, 0,25, en 0,60 ng/ml extract. 
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De blootstelling aan CP, 5FU en MTX werd gemeten door het analyseren van 
deze stoffen in lucht- en veegmonsters van mogelijk gecontamineerde 
oppervlakken en voorwerpen. 
Gedurende de bereiding van de cytostatica in de apotheek van een ziekenhuis 
zijn stationaire luchtmonsters genomen voor de laminar airflow (laf)-kast. CP 
(0,2 //g/m3) en MTX (0,3 //g/m3) zijn éénmaal gedetecteerd. Daarnaast werden 
persoonsgebonden luchtmonsters verzameld. De CP concentratie bedroeg 
maximaal 10,1 / /g/m3 . Contaminatie van de werkomgeving werd eveneens 
waargenomen. Op het werkblad van de laf-kast werden CP, 5FU en MTX 
aangetoond (CP: maximaal 160 ng/cm2 , 5FU: maximaal 62 ng/cm2 ; MTX: 
maximaal 633 ng/cm2). Zelfs na het schoonmaken van de laf-kast bleef de 
contaminatie aanwezig (CP· maximaal 14 ng/cm2 , 5FU: maximaal 27 ng/cm2 ; 
MTX. maximaal 293 ng/cm2). Op de vloeren voor en onder de laf-kast (CP1 
maximaal 2,6 / /g/m2 ; 5FU: maximaal 236 //g/m2) en op de vloeren van de 
aanliggende ruimten (5FU· maximaal 107 //g/m2) werden CP en 5FU 
aangetoond De handschoenen die tijdens de bereiding van de cytostatica (CP: 
maximaal 149 //g/paar handschoenen; 5FU· maximaal 1070 //g/paar 
handschoenen; MTX maximaal 1963 //g/paar handschoenen) en gedurende het 
schoonmaken van de laf-kasten (CP- maximaal 11 //g/paar handschoenen; 
5FU maximaal 59 //g/paar handschoenen; MTX: maximaal 49 //g/paar 
handschoenen) werden gebruikt, waren meestal gecontamineerd. Af en toe 
werd contaminatie van de buitenzijde van de flacons, die werden gebruikt voor 
de bereiding van de cytostatica, aangetoond (CP: 0,06 / /g ; MTX: 15 //g) 
evenals contaminatie van de verpakking van de bereide cytostatica (CP· 2,1 
/ /g, 5FU: maximaal 6,2 //g) 
De vloeren van de toedieningsruimten en de aanliggende ruimten (CP: 0,9 
ng/cm2 , MTX maximaal 5,9 ng/cm2) en rondom de bedden van de patiënten 
waren eveneens gecontamineerd met CP (mediaan: 4,5 //g/cm2) en 5FU 
(mediaan: 1,8 ng/cm2). Af en toe werd CP en 5FU op andere voorwerpen 
aangetoond zoals tafels (CP: maximaal 4,5 / /g ; 5FU: maximaal 22 //g) en 
omgespoelde urinalen (CP: 8,3/ /g) . 
Vergelijkbare resultaten werden geconstateerd in een situatie van proefdier-
verzorgers die betrokken waren bij het injecteren van CP bij proefdieren. CP 
werd gedetecteerd op de filters van het luchtventilatiesysteem (maximaal 1,0 
//g/dag) dat contaminatie van de omgevingslucht suggereerde alhoewel op het 
mondmasker van de proefdierverzorgers geen CP werd gevonden. CP werd 
ook gedetecteerd in veegmonsters, die van de vloer zijn genomen (maximaal 
0,4 ng/cm2), evenals van verschillende voorwerpen en oppervlakken (maximaal 
44 ng/cm2) CP werd ook gedetecteerd in de aanliggende ruimten (maximaal 
6,9 ng/cm2) De handschoenen (maximaal 199 //g) en mouwbeschermers 
(maximaal 10 μg) die tijdens de injecties werden gedragen, bleken ook 
gecontamineerd met CP te zijn. 
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Alhoewel speciale richtlijnen en beschermende maatregelen voor het omgaan 
van ziekenhuispersoneel met cytostatica zijn geïntroduceerd, is aangetoond dat 
deze de aanwezigheid van dergelijke toxische stoffen in de werkomgeving niet 
uitsluiten De introductie van aanvullende beschermende maatregelen zoals 
aanpassingen aan de laf-kast, het gebruik van speciale maskers, het dragen 
van twee paar handschoenen over elkaar en het vervangen van 5FU in 
ampullen door 5FU in flacons resulteerde in een afname van de CP 
concentratie in de lucht tijdens de bereiding van de cytostatica Verondersteld 
wordt dat de vervanging van ampullen met 5FU door flacons met 5FU 
waarschijnlijk de reden is voor de verminderde contaminatie van latex 
handschoenen met 5FU Mogelijk is het breken van ampullen de oorzaak van 
het vrijkomen van aerosolen dat resulteert in contaminatie van de 
handschoenen De resultaten suggereren dat de aanvullende beschermende 
maatregelen de externe blootstelling aan CP en 5FU hebben gereduceerd In 
welke mate de aanvullende beschermende maatregelen elk afzonderlijk de 
blootstelling hebben beïnvloed, blijft onbekend. 
De blootstelling aan 5FU en MTX werd gemeten in een farmaceutisch bedrijf 
waar werknemers betrokken waren bij de formulering van deze cytostatica 
(wegen, mengen, filtreren en afvullen) 
5FU werd aangetoond in lucht- en veegmonsters 5FU werd gedurende het 
afwegen in een luchtmonster gedetecteerd (75 /jg/m3) 5FU is eveneens 
aangetoond op het filter van het masker van de medewerker die betrokken 
was bij het afwegen van de stof (120 /yg) Voorafgaand aan het 
produktieproces werd 5FU op de vloer van de werkruimte aangetoond 
(maximaal 8 ng/cm2) Na de routinematige schoonmaak van de ruimte werden 
significant grotere hoeveelheden gemeten (70-630 ng/cm2) De resultaten 
suggereren een ineffectieve schoonmaakprocedure De handschoenen waren 
altijd gecontamineerd (22-720 /jg/paar handschoenen). 
MTX is gedetecteerd in luchtmonsters in de ademzone van alle medewerkers 
met uitzondering van diegenen die betrokken waren bij het vullen van de 
flacons bij de afvulmachine (0,8-182 /yg/m3) De hoogste concentraties werden 
waargenomen bij de medewerkers die MTX afwogen (118 and 182 /jg/m3) 
Bovenstaande resultaten tonen aan dat de ontwikkelde methoden bruikbaar 
zijn om het vrijkomen en de verspreiding van CP, 5FU en MTX bij verschillende 
beroepsmatige activiteiten te meten 
Biologische monitoring 
Er werd een gevoelige GC-MS methode ontwikkeld voor het bepalen van CP en 
IP in urine De monstervoorbereiding (vloeistof-vloeistof extractie) gevolgd 
door denvatisering met tnfluorazijnzuuranhydride maakt de methode geschikt 
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voor routinematige analyse en maakt het mogelijk de uitscheiding van deze 
cytostatica in de urine van ziekenhuispersoneel betrokken bij de bereiding en 
de toediening van cytostatica te meten De detectiegrens is ongeveer 0,25 
ng/ml urine en kan worden verlaagd tot 0,1 ng/ml door gebruik te maken van 
GC-MSMS 
In verschillende studies die in dit proefschrift worden beschreven is de 
methode gevalideerd De opname van CP en IP is gemeten door het bepalen 
van deze cytostatica in de urine van de medewerkers zoals apothekers 
(assistenten) betrokken bij de bereiding van de cytostatica, verpleegkundigen 
betrokken bij de toediening van de cytostatica en proefdierverzorgers 
betrokken bij de toediening van CP aan proefdieren De hoogste CP 
uitscheidingssnelheid bedroeg ongeveer 10 //g/dag (Tabel 1) Er werd echter 
aangetoond dat er grote verschillen waren tussen de groepen Hierbij dient te 
worden opgemerkt dat de meest betrouwbare informatie over de grootte van 
de uitscheidingssnelheid van CP in de urine wordt verkregen door 
urinemonsters van een grote groep personen verzameld over een lange periode 
te analyseren CP en IP werden niet alleen aangetoond in de urine van 
apothekersassistenten, verpleegkundigen en proefdierverzorgers die 
daadwerkelijk met de CP en IP omgingen, maar ook in de urine van 
apothekersassistenten en verpleegkundigen die niet betrokken waren bij de 
bereiding en de toediening van deze stoffen CP en IP werden uitgescheiden 
over verschillende perioden vanaf het begin van de werkzaamheden Dit kan 
duiden op verschillende blootstellingsmomenten, verschillende opnameroutes 
en/of intenndividuele verschillen in de biotransformatie en uitscheidmgs-
snelheden van deze stoffen 
Alhoewel speciale richtlijnen en beschermende maatregelen zijn geïntroduceerd 
om het ziekenhuispersoneel te beschermen tijdens het omgaan met cytostatica 
blijkt dat dit de opname van deze stoffen niet voorkomt Vandaar dat in één 
studie aanvullende beschermende maatregelen zijn genomen om te 
onderzoeken in hoeverre de ontwikkelde methoden in interventiestudies 
konden worden gebruikt De maatregelen hadden betrekking op het aanpassen 
van de laf-kast, het gebruik van speciale maskers, het gebruik van twee paar 
handschoenen over elkaar en het vervangen van 5FU in ampullen door 5FU in 
flacons Het effect van deze aanvullende maatregelen is vergeleken met de 
resultaten uit de voorafgaande studie waarin deze maatregelen nog niet waren 
ingevoerd De resultaten tonen aan dat de aanvullende beschermende 
maatregelen de uitwendige blootstelling aan CP hebben verminderd De 
gemiddelde CP excretiesnelheid voor en na de interventie bedroeg 
respectievelijk 1,44 en 0,16 /yg per dag Het verschil was niet statistisch 
significant 
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Tabel 1. Een overzicht van verschillende studies waarbij de uitscheidings-
snelheid van CP in de urine van {ziekenhuis)personeel dat werd 
blootgesteld aan cytostatica is bepaald 
groep aantal periode van gemiddelde (range) referentie 
personen urine verzamelen uitscheidingssnelheid' 
(dagen) CP in urine (¿/g/dag) 
verpleegkundigen 
ziekenhuispersoneel 
apothekersassistenten 
apothekersassistenten/ 
verpleegkundigen 
proef dierverzorgers 
apothekersassistenten'1 
apothekersassistenten'' 
verpleegkundigen 
apothekersassistenten 
schoonmaaksters 
verpleegkundigen 
apotheekpersoneel/ 
verpleegkundigen 
apothekersassistenten 
2 
20 
2 
18 
4 
9 
9 
8 
1 
2 
7 
21 
8 
57" 
4 
2 
1-2 
2-5 
1-2 
5 
1 
2-4 
1-5 
8-16 
0,47 (0,43-0,51 Ϋ 
0,39 (0-2,5) 
0 
0,05 (0-0,5) 
0,05 (0-0,2) 
1,44 (0 10) 
0,16 (0-0,51) 
0,79 (0-2,9) 
0 , 8 0 (0-4,2) 
5,2 (0-38) 
0,18 (0,01-0,53) 
Hl 
[2] 
hoofdstuk 2.1 
hoofdstuk 2.2 
hoofdstuk 2.4 
hoofdstuk 2.5 
hoofdstuk 2.6 
hoofdstuk 3.1 
I3] 
hoofdstuk 5.1 
' de uitscheidingssnelheid voor niet detekteerbare hoeveelheden is op 0 gesteld 
'' beide verpleegkundigen hebben urine verzameld over een totale periode van 5 7 dagen 
c
 gemiddelde en range zijn berekend door van een gemiddelde over 28 !4 dagen uit te gaan 
" dezelfde personen 
11J Evelo СТА, Bos RP, Peters JGP, Henderson PTh. Urinary cyclophosphamide assay as a method 
for biological monitor ing of occupational exposure to cyclophosphamide. Int Arch Occup 
Environ Health (1986) 5 8 : 1 5 1 - 1 5 5 . 
[ 2 | Hirst M, Tse S, Mills DG, Levin L. Occupational exposure to cyclophosphamide. The Lancet 
(19841:186-188. 
I3| Ensslin AS, Stoll Y, Pethran A, Pfaller A, Rommelt H, Fruhmann G. Biological monitor ing of 
cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to 
cytotoxic drugs. Occup Environ Med (1994) 5 1 : 2 2 9 - 2 3 3 . 
Voor het bepalen van MTX ¡η urine van beroepsmatig blootgestelde personen 
is een fluorescentie polarisatie immunoassay (FPIA) methode ontwikkeld. FPIA 
wordt frequent gebruikt voor het monitoren van MTX in serum van patiënten. 
De FPIA methode is op een zodanige wijze gemodificeerd dat MTX snel en 
efficiënt in urinemonsters van blootgestelde personen kon worden gemeten. 
De urinemonsters worden gezuiverd met solid-phase extractie. Concentraties 
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van minimaal 1 equivalent MTX/ml urine konden worden gedetecteerd 
Er werd een GC-MS methode ontwikkeld voor het bepalen van σ-fluoro-ß-
alanine (FBAL), de hoofdmetaboliet van 5FU, in urine van beroepsmatig 
blootgestelde personen Hiertoe wordt FBAL gedenvatiseerd met S-
ethyltnfluorothioacetate en aangezuurd n-butanol De detectiegrens is 
ongeveer 60 ng/ml urine doch kan nog verder worden verlaagd tot 6 ng/ml 
door gebruik te maken van GC-MSMS 
De ontwikkelde methoden voor biologische monitoring van blootstelling aan 
5FU en MTX zijn gevalideerd in een farmaceutisch bedrijf waar werknemers 
betrokken waren bij de formulering van deze stoffen (afwegen, mengen, 
filtreren, en afvullen) Vijftig microgram FBAL werd aangetoond in een 
urinemonster van een medewerker die betrokken was bij het afwegen van 
5FU De uitscheidingssnelheid van MTX over 72-96 uur was hoger voor de 
blootgestelde groep (gem 4,2 //g MTX-equivalenten/24 uur, range 1,5-7,0 //g 
MTX-equivalenten/24 uur) dan voor de controle groep (gem 3,2 //g MTX-
equivalenten/24 uur, range 1,5-6,6/yg MTX-equivalenten/24 uur) 
De ontwikkelde methoden zijn in de praktijk geschikt gebleken voor biologische 
monitoring van beroepsmatige blootstelling aan CP, IP, 5FU and MTX De 
methoden werden toegepast in verschillende studies Hierbij is gebleken dat de 
methoden geschikt waren voor het meten van de opname van deze stoffen in 
het lichaam van de betrokken personen De resultaten van de verschillende 
studies hebben aangetoond dat gedurende de bereiding en de toediening van 
cytostatica, waaronder CP, het personeel inwendig werd blootgesteld aan CP 
Opname van CP werd zelfs gevonden bij apothekersassistenten die cytostatica 
hebben bereid met uitzondering van CP Een eenduidige blootstelhngsroute kon 
niet worden aangegeven alhoewel er sterke aanwijzingen waren dat inhalatie 
met de enigste blootstellingsroute was Vooral de resultaten waarbij CP in de 
urine van ziekenhuispersoneel werd aangetoond terwijl deze geen CP hadden 
bereid en/of toegediend, toont de meerwaarde van deze biologische 
monitoringsmethode aan 
Biologische effecten in werknemers blootgesteld aan cytostatica 
De uitscheiding van CP in de urine en de aanwezigheid van chromosoomaf-
wijkingen in perifere lymphocyten werden bepaald in 4 groepen ziekenhuis-
personeel met verschillende blootstelling Het doel van deze studie was na te 
gaan of er een mogelijk verband zou bestaan tussen de opname van CP en een 
vroege biologische respons in de vorm van genetische schade De 4 groepen 
waren. 17 Nederlandse en 11 Tjechische blootgestelde ziekenhuismede-
werkers, die beroepsmatig handelingen met cytostatica uitvoerden, en 35 
Nederlandse en 23 Tjechische controle personen werkzaam in dezelfde 
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ziekenhuizen, doch niet betrokken bij de bereiding en de toediening van 
cytostatica. De groepen werden onderverdeeld in rokers en niet-rokers. 
Binnen de Nederlandse groepen was het percentage afwijkende cellen (3,2 
versus 2,0) en het aantal breuken per cel (0,042 versus 0,023) verhoogd voor 
rokers in vergelijking met niet-rokers. Het percentage afwijkende cellen was 
hoger in de Nederlandse blootgestelde groep dan in de Nederlandse controle 
groep (2,6 versus 2,1). Binnen de Tjechische groepen was het percentage 
afwijkende cellen (2,7 versus 1,8) en het aantal breuken per cel (0,034 versus 
0,020) hoger in de blootgestelde groep dan in de controle groep. Dit werd 
met name veroorzaakt door de Nederlandse en de Tjechische rokers. De 
resultaten wezen op een additief effect van blootstelling en roken in de 
Nederlandse groepen en een meer dan additief effect in de Tjechische groepen. 
In de urine van 3 van de 11 Nederlandse blootgestelde medewerkers varieerde 
de uitscheidingssnelheid van CP in de urine van 0,1 tot 0,5 />g/24 uur. Hogere 
uitscheidingssnelheden werden gevonden bij 8 van de 11 Tjechische 
medewerkers variërend van 0,1 tot 2,9 //g/24 uur. Er is geen correlatie 
aangetoond tussen de hoeveelheden CP die met de urine werden uit-
gescheiden en het percentage afwijkende cellen en het aantal breuken per cel. 
De resultaten suggereren dat uitscheidingsnelheden van CP in de urine tot 
maximaal 2,9 /yg/24 uur op de lange termijn zouden kunnen resulteren in 
biologische effecten zoals chromosoomafwijkingen. Aangezien chromosoomaf-
wijkingen als indicatoren van genetische schade worden beschouwd, tonen 
deze uitscheidingssnelheden niet alleen opname van CP aan, maar kunnen ze 
ook wijzen op een ernstig gezondheidsrisico, met name voor rokers. 
Om de mogelijke nefrotoxische effecten als gevolg van de beroepsmatige 
blootstelling aan cytostatica te onderzoeken, werden de vroege effect-
parameters retinol-bindend eiwit (RBP) en albumine (ALB) bepaald in de urine 
van 11 ziekenhuismedewerkers die betrokken waren bij de bereiding en 
toediening van cytostatica. . Een groep van 23 ziekenhuismedewerkers niet 
betrokken bij de bereiding en toediening van cytostatica diende als controle 
groep. Er werd geen verschil tussen de blootgestelde en de controle groep 
aangetoond met betrekking tot RBP (7,9 //g/mol CREAT-U versus 8,8 /vg/mol 
CREAT-U) en ALB (0,44 mg/mol CREAT-U versus 0,30 mg/mol CREAT-U). 
Alhoewel werd aangetoond dat het ziekenhuispersoneel was blootgesteld aan 
CP, (excretiesnelheid van CP in de urine varieerde van 0,1-2,9 //g/24 uur), 
toonden de resultaten van deze studie aan dat deze blootstellingsniveaus geen 
meetbare nefrotoxische effecten tot gevolg hadden. 
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Toxicokinetische studies met cyclofosfamide (opname, biotrans-
formatie en excretie) 
Inhalatie en huidopname worden verondersteld de belangrijkste opnameroutes 
van beroepsmatige blootstelling aan cytostatica te zijn. In een studie werden 
de uitscheidingssnelheden van onveranderd CP in de urine van ratten bepaald 
na intratracheale toediening en dermale applicatie. Deze blootstellingroutes 
werden gekozen om de mogelijke beroepsmatige blootstellingsroutes na te 
bootsen. De resultaten tonen aan dat de maximale uitgescheiden hoeveelheid 
CP (ongeveer 5% van de dosis werd onveranderd uitgescheiden) onafhankelijk 
was van de blootstellingsroute. De laagste uitscheidingssnelheid werd 
gevonden na dermale applicatie. 
Deze resultaten en die van Hirst et al. (1984) in dermaal behandelde 
vrijwilligers, tonen aan dat CP gemakkelijk de huid van ratten en de mens 
passeert [1]. Om deze reden wordt dermale blootstelling als een mogelijke 
blootstellings- en opnameroute voor CP beschouwd. 
De in vitro biotransformatie van CP werd onderzocht met S-9 leverfracties van 
humane donoren. Daartoe werd een methode ontwikkeld waarmee de CP 
metabolieten norstikstof mosterd (NNM), 4-ketocyclofosfamide (KCP) en 
carboxyfosfamide (CAR) in ¡ncubatiemengsels konden worden bepaald. Na 
vloeistof-vloeistof extractie en derivatisering, werden de metabolieten gemeten 
met GC-TSD. De resultaten tonen grote interindividuele verschillen in de 
vorming van NNM en CAR aan. KCP kon niet worden gedetecteerd. 
De biotransformatie van CP is ook onderzocht in vitro met S9 rattelever 
fracties. Het doel was na te gaan of er een mogelijke invloed van de 
omgevingsfactoren roken en alcoholgebruik op de biotransformatie van CP zou 
bestaan. De effecten zijn nagebootst door ratten te behandelen met 
respectievelijk ß-nafthoflavon en ethanol. De invloed van geslacht en suppletie 
met NAD en GSH werd eveneens onderzocht. De resultaten tonen aan dat de 
in vitro biotransformatie van CP in de rat sterk wordt beïnvloed door het 
geslacht en de suppletie met NAD en GSH. Voorbehandeling met ß-
nafthoflavon en ethanol beïnvloedde de biotransformatie niet. De resultaten 
suggereren dat de omgevingsfactoren roken en alcoholgebruik een 
verwaarloosbare invloed hebben op de biotransformatie van CP in de mens. 
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Risicoschatting van beroepsmatige blootstelling aan cyclofos-
famide 
Er werd een kankerrisicoschatting als gevolg van beroepsmatige blootstelling 
aan het genotoxisch carcinogene cytostaticum CP uitgevoerd waarbij 2 
benaderingen werden gevolgd. In het ene geval werd uitgegaan van gegevens 
van een carcinogeniteitsstudie bij proefdieren. In het andere geval werd 
uitgegaan van gegevens over de ontwikkeling van primaire en secundaire 
tumoren bij patiënten behandeld met CP. In beide studies werden met name 
blaastumoren en leukemiën gevonden. De opname van CP in de 
beroepssituatie werd geschat op basis van de uitscheiding van CP in de urine 
van verschillende groepen werknemers die blootgesteld waren aan cytostatica 
waaronder CP. De opname varieerde van 3,6-18 //g per dag. Het kankerrisico 
werd bepaald op basis van de dosis-respons gegevens van de proefdierstudie 
en de patiëntenstudies. Hierbij zijn verschillende aannames gedaan. Het 
kankerrisico gebaseerd op de proefdierstudie is berekend voor een persoon van 
70 kg met een blootstellingsperiode van 40 jaar, 200 dagen per jaar. Het 
"lifetime" risico op blaaskanker in mannen en leukemiën in mannen en 
vrouwen was vergelijkbaar en varieert van 100-600 per miljoen bij een 
dagelijkse dosis van 3,6-18 /vg. Het kankerrisico gebaseerd op de 
patiëntengegevens werd berekend door de 10-jaars cumulatieve incidentie per 
g CP te vermenigvuldigen met de gemiddelde opname over 10 jaar, 200 dagen 
per jaar variërend van 7,2 tot 36 mg. Op basis van secundaire tumordata is 
het risico op leukemiën in vrouwen berekend op 17-100 per miljoen over 10 
jaar. Een marginaal lager risico voor blaaskanker en leukemiën in mannen en 
vrouwen van 15-76 werd gevonden wanneer primaire tumor data werden 
gebruikt. Omgerekend betekent dit dat het kankerrisico verkregen op basis van 
zowel de proefdiergegevens als de patiëntengegevens overeenkomt met 
ongeveer 1,4 tot 10 per miljoen per jaar. 
In Nederland wordt voorgesteld bij beroepsmatige blootstelling aan 
kankerverwekkende stoffen te streven naar een kankerrisico per stof van 1 
extra kankergeval per miljoen per jaar (streefrisiconiveau) en geen hoger risico 
dan 100 per miljoen per jaar (verbodsrisiconiveau). Uit de risicoschatting op 
basis van de proefdiergegevens en de patiëntengegevens blijkt dat het 
streefrisiconiveau wordt overschreden, maar dat het risico nog onder het 
verbodsrisiconiveau blijft. Wel dient te worden opgemerkt dat in enkele 
onderzochte groepen hogere uitscheidingssnelheden voor CP zijn gevonden 
dan de gemiddelde CP uitscheidingssnelheid van 0,18 /;g waarop deze 
risicoschatting is gebaseerd (Tabel 1). Een voorbeeld hiervan is een studie met 
7 verpleegkundigen waarbij een ongeveer 5 keer zo hoge gemiddelde 
excretiesnelheid van 0.80 /yg/dag werd gevonden. Dit betekent een 
overeenkomstig 5 keer hoger kankerrisico. Van belang is nogmaals op te 
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merken dat deze risicoschatting uitsluitend betrekking heeft op kanker. 
Ondanks de introductie van streef- en verbodsrisiconiveaus dient te worden 
benadrukt dat het de taak van werkgevers, werknemers en de overheid is 
ervoor te zorgen dat elke vorm van beroepskanker als gevolg van blootstelling 
aan cytostatica (en andere kankerverwekkende stoffen) moet worden 
voorkomen. 
Tot slot 
De methoden die in het kader van het hier beschreven onderzoek zijn 
ontwikkeld en gevalideerd, kunnen een belangrijke bijdrage leveren aan het 
opsporen van beroepsmatige blootstelling aan cytostatica en daarmee aan het 
reduceren van de mogelijk hiermee gepaard gaande risico's voor de gezondheid 
van betrokkenen. 
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De moeilijke periode die mijn ouders tijdens het promotieonderzoek met hun 
gezondheid hebben doorgemaakt, heeft enerzijds voor mij een sterk 
relativerende werking gehad op het belang van (dit) promotieonderzoek als 
basis voor een succesvolle carrière Anderzijds heeft het me gesteund gezien 
het belang van preventie van beroepsziekten zoals kanker 
Tot slot dank ik Ingrid en Tom voor de tijd die ZIJ mij hebben gegeven om dit 
proefschrift af te ronden Veel gezamenlijke vrije tijd is hiervoor gebruikt 
Ingrid, hopelijk wordt het beter maar je weet hoe ik ben 
Exposure Control 
is een adviesbureau gespecialiseerd op het gebied van 
monitor ing van beroepsmatige blootstelling aan cytostatica 
Exposure Control concentreert haar diensten op: 
- inventarisatie van blootstelling aan cytostatica 
- het opstellen en uitvoeren van meetprogramma's (omgevings- en 
biologische monitoring) 
- het verlenen van advies omtrent te nemen beheersmaatregelen 
Tot de overige diensten die Exposure Control aanbiedt behoren: 
- het beoordelen van de toxiciteit van stoffen en Produkten 
- het verlenen van advies inzake risico's van beroepsmatige 
blootstelling aan chemische stoffen 
Tot de klanten van Exposure Control behoren: 
- ziekenhuizen 
- chemische industrieën 
- farmaceutische industrieën 
- ARBO-diensten 
Exposure Control vertegenwoordigt in Nederland Carmel Pharma uit 
Göteborg (Zweden) met betrekking tot de verkoop van PhaSeal®, een 
infuussysteem waarmee cytostatica in gesloten vorm kunnen worden 
bereid en toegediend. Hierdoor wordt blootstelling aan deze stoffen 
voorkomen. 
Voor nadere informatie kunt u contact opnemen met: 
Exposure Control 
t.a.v. P.J.M. Sessink 
Postbus 467 
6600 AL Wijchen 
Tel/fax: 024 -6411838 
/УГ Шиг fa/efa / 
PhaSeaf 
the system for sealed handling of 
chemotherapeutic agents 
carmel. 
Carmel Pharma ab 

Stellingen behorende bij het proefschrift: 
Monitoring of Occupational Exposure to Antineoplastic Agents 
1. De beschreven methoden voor omgevings- en biologische monitoring 
van cyclofosfamide, ifosfamide, 5-fluorouracil en methotrexaat zijn bij 
de huidige expositieniveau's bruikbaar voor het opsporen van 
contaminatie van de werkomgeving en voor het vaststellen van de 
opname van deze cytostatica in het lichaam van personen die 
beroepsmatig met deze stoffen in aanraking kunnen komen. 
Dit proefschrift. 
2. Beroepsmatige blootstelling aan cyclofosfamide kan het beste worden 
vastgesteld met behulp van biologische monitoring. 
Dit proefschrift. 
3. Ondanks de uitgebreide arbeidshygiënische maatregelen en 
voorzieningen die in Nederland momenteel worden toegepast, worden 
apothekersassistenten en oncologieverpleegkundigen blootgesteld aan 
cytostatica. 
Dit proefschrift. 
4. De relatief grote hoeveelheden cyclofosfamide in de urine in de studie 
van Ensslin et al. in vergelijking met de resultaten in dit proefschrift en 
de vele, in verband met matrixpoblemen niet geanalyseerde monsters, 
doet vermoeden dat er sprake is geweest van een identificatie 
probleem. Deze problemen zouden kunnen worden voorkomen door 
gebruik te maken van GC-MS(MS). 
Ensslin et al.. Occupational and Environmental Medicine 1994;51:229-
233. 
5. De Europese gedachte is nog ver te zoeken als het gaat om uniformiteit 
in het opstellen van een richtlijn met betrekking tot het beroepsmatig 
omgaan van ziekenhuismedewerkers met cytostatica. 
6. Gezien het ontbreken van duidelijke gegevens met betrekking tot 
gezondheidsrisico's bij zwangeren als gevolg van blootstelling aan 
cytostatica verdient het aanbeveling apotheekmedewerkers en 
oncologieverpleegkundigen met een kinderwens vrij te stellen van 
handelingen met cytostatica. 
7. Voor de genotoxisch carcinogene stof cyclofosfamide dient het 
verbods- en streef-risiconivo van een extra kans op kanker van 
respectievelijk 4 per 1000 en 4 per 10.000 personen per jaar te 
worden vastgesteld op basis van de uitscheiding van cyclofosfamide 
in de urine en niet op basis van concentraties cyclofosfamide in de 
omgevingslucht. 
Berekening van het risico op kanker door beroepsmatige 
blootstelling aan genotoxisch carcinogene stoffen. Advies van de 
Commissie WGD van de Gezondheidsraad (1995/06WGD). 
8. Alhoewel het ontwikkelen van methoden voor biologische-effect 
monitoring ongetwijfeld wetenschappelijk interessant is, is het de 
vraag in welke mate een aantal hiervan in de arbozorg zullen/kunnen 
worden toegepast met name vanwege de moeilijke interpretatie van 
de data en de hoge kosten van deze methoden. Dit in tegenstelling 
tot methoden van biologische monitoring. 
9. Het onderwerken van bermmaaisel in de landbouw is uit 
milieuoogpunt ongewenst omdat dit gepaard gaat met het gebruik 
van meer bestrijdingsmiddelen. 
10. Een hogere opkomst bij verkiezingen kan worden gerealiseerd door 
burgers voor het uitbrengen van hun stem met air miles te 
"belonen". 
Paul Sessink. 
Nijmegen, 4 november 1996. 




